{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2013/legemiddelstatistikk-20132-pdf.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Houston 911 Acknowledgement:Julie 2011: Legemiddelstatistikk Legemiddelstatistikk 2013:2 Folkehelseinstituttet 7The use of drugs in the population is increasing. An important goal of the health policies regarding pharmaceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parliament decided to establish a national prescription database in Norway (NorPD). The task of building up the register was given to the Norwegian Institute of Public Health (NIPH). Since 1st January 2004, the institute has received monthly data on prescriptions from all Norwegian pharmacies. This report is the sixth edition of the annual statistics from NorPD. General information about NorPD, drug statistics, classification of drug and measurement methods is included in part 1 of the report. Part 2 contains some key figures from NorPD and the main tables with informa-tion about the number of individuals who had prescriptions dispensed from pharmacies in Norway during the latest five years period (2008-2012). The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. For 2012, information about age, gender and costs are included in the tables. The ATC/ DDD version of January 2013 has been used in the report, see also www.whocc.no NorPD also has a website where you can find complementary information. The website is: www. norpd.no (English version) or www.reseptregisteret.no (Norwegian version). It is also possible to apply for data from NorPD for research or for other purposes which are according to the objec - tives of NorPD. More information about this can be found in part 2 of the report, and at the website of the Norwegian Institute of Public Health (www.fhi.no). Department of Pharmacoepidemiology Norwegian Institute of Public Health May 2013Bruken av legemidler befolkningen til andre form\u00e5l som er Reseptregisteret. Mer 7 1. General information about the Norwegian Prescription Database and drug statistics .................... 11 1.1 About the NorPD .................................................................................................................................... 11 1.2 Prescription statistic in the other Nordic countries ........................................................................ 14 1.3 The Norwegian Drug Wholesales Statistics ..................................................................................... 15 1.4 The Anatomical Therapeutic Chemical (ATC) classification system ............................................ 15 1.5 The Defined Daily Dose (DDD) ............................................................................................................. 16 1.6 The WHO Collaborating Centre for Drug Statistics Methodology ................................................ 17 2. The Norwegian Prescription Database (NorPD) 2008-2012 .................................................................. 19 2.1 Selected key figures from NorPD ....................................................................................................... 19 2.2 Prescription categories and re imbursement of medicinal expenses .......................................... 23 2.3 Description of the main tables ............................................................................................................ 27 2.4 ATC main groups .................................................................................................................................... 31 2.5 ATC group A - Alimentary tract and metabolism ............................................................................ 32 2.6 ATC group B - Blood and bloodforming organs ................................................................................ 43 2.7 ATC group C - Cardiovascular system ............................................................................................... 46 2.8 ATC group D - Dermatologicals ........................................................................................................... 53 2.9 ATC group G - Genito urinary system and sex hormones .............................................................. 59 2.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins .................. 64 2.11 ATC group J - Antiinfectives for systemic use .................................................................................. 67 2.12 ATC group L - Antineoplastic and immunomodulating agents ..................................................... 73 2.13 ATC group M - Musculo-skeletal system .......................................................................................... 76 2.14 ATC group N - Nervous system .......................................................................................................... 80 2.15 ATC group P - Antiparasitic products, insecticides and repellents .............................................. 89 2.16 ATC group R - Respiratory system .................................................................................................... 91 2.17 ATC group S - Sensory organs ............................................................................................................ 95 2.18 ATC group V - Various ........................................................................................................................... 99 Some abbreviations and definitions .............................................................................................................. 100 Population in Norway 2008-2012 (as of 1st July) ....................................................................................... 101 Population by age in 2012 (as of 1st July) ...................................................................................................... 101 List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2013 ............................................................................................................. 102Forord .................................................................................................................................................................... 6 D\u00f8gndose (DDD) ..................................................................................................................... 16 1.6 WHO Collaborating Centre for Drug Statistics Methodology ........................................................ 17 2. Reseptregisteret 2008-2012 ...................................................................................................................... 23 2.3 av hovedtabellene .......................................................................................................... 27 2.4 ATC main groups .................................................................................................................................... 31 2.5 ATC group A - Alimentary tract and metabolism ............................................................................ 32 2.6 ATC group B - Blood and bloodforming organs ................................................................................ 43 2.7 ATC group C - Cardiovascular system ............................................................................................... 46 2.8 ATC group D - Dermatologicals ........................................................................................................... 53 2.9 ATC group G - Genito urinary system and sex hormones .............................................................. 59 2.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins .................. 64 2.11 ATC group J - Antiinfectives for systemic use .................................................................................. 67 2.12 ATC group L - Antineoplastic and immunomodulating agents ..................................................... 73 2.13 ATC group M - Musculo-skeletal system .......................................................................................... 76 2.14 ATC group N - Nervous system .......................................................................................................... 80 2.15 ATC group P - Antiparasitic products, insecticides and repellents .............................................. 89 2.16 ATC group R - Respiratory system .................................................................................................... 91 2.17 ATC group S - Sensory organs ............................................................................................................ 95 2.18 ATC group V - Various ........................................................................................................................... 99 Noen forkortelser og definisjoner ...................................... 102ContentsLegemiddelstatistikk 2013:2 Folkehelseinstituttet 11 1. General information about the Norwegian Prescription Databa-se and drug statistics 1.1 About the NorPD Data collection and variables in NorPD New legislation in the Norwegian pharmacy sector came into force on March 1st 2001. According to the new act, pharmacies were obliged to forward prescrip - tion data to a new national drug database. In October 2003, new, detailed regulations for the NorPD were approved (1). The objectives of the NorPD, as defined in authoritative regulations, are to collect and prepare data on drug use in individuals and animals in order to: 1. describe drug use patterns, highlighting changes over time 2. promote and form a basis for research and review of the safety and effectiveness of drug use 3. serve as a management tool for the authorities in order to assure prescribing quality in addition to general surveillance, control and planning 4. give the prescribing doctors a basis for internal control, as part of an audit method to improve the quality of prescribing practices All NorPD data use must be in accordance with these objectives. The regulation also determines what kind of data can be collected from the pharmacies and admin- istrative registers. 1. Generelt tr\u00e5dte kraft 1. mars 2001, og loven ble apotek utredning inn fra apotek og administrative registre. Part 12 Legemiddelstatistikk 2013:2 Folkehelseinstituttet Legemiddelstatistikk 2013:2 Folkehelseinstituttet 13 Data protection As illustrated in figure 1.1 the pharmacy records of dispensed drugs are electronically and automatically transferred through Statistics Norway before they arrive at NIPH and are included in NorPD. Statistics Norway acts as a so-called \"trusted third party centre\" and is a part of the data protection to ensure confi- dentiality of personal information. Statistics Norway only has access to the patient personal identification number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The term \"Pseud- onymous health data\" is defined in the Personal Health Data Filing System Act (in Norwegian: Helseregister - loven): \"personal health data in which the identity has been encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person through the health system without his identity being revealed\" (3). This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries. Quality checks For quality assurance, a number of queries are carried out monthly or half-yearly to identify possible errors or inconsistencies. NIPH performs different routine checks on the data before they are transferred to the NorPD. In the NorPD, the Nordic article number is linked to the national register of medicinal products with validated aggregerte Person -identifier (encrypted), month/year of birth, month/year of death, gender, place of residence (municipality & county) Prescriber Person -identifier (encrypted), year of birth, gender, profession, speciality Drug Nordic article number (unique product identifier stating brand name, strength, pharmaceutical form and pack size), number of packs, ATC code, number of Defined Daily Doses (DDD), prescription category, reimbursement code (from March 2008: ICD10, ICPC codes or codes defined by the Norwegian Medi- cines Agency, completely implemented from March 2009), intended use and prescribed dose (free-text according to pharmacy label), dispensing date, price (pharmacy retail price) Pharmacy Name , licence number, municipality and county The Nordic article number is the important link to other registries providing detailed information about the drugs. The indication for prescribing was in the first years not recorded in the database, only the code of reimbursement which in some cases, acted as a proxy of diagnosis. From March 2008, prescribers had to use either the International Classification of Diseases version 10 (ICD10), or the International Classification of Primary Care Codes (ICPC) or special codes assigned by the Norwegian Medicines Agency as the code of reimbursement on the prescriptions. This was fully implemented from March 2009. Since 1 st January 2004, the NIPH has received monthly data on prescriptions from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. NorPD contains information about all drugs prescribed (reimbursed or not) and dispensed at pharmacies to individual patients living outside institutions, i.e. ambulant care. Unlicensed drugs are also included, but drugs sold over-the-counter (OTC) are not recorded in NorPD. However, if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database. The main data in NorPD are based on prescriptions to individual humans, but also prescribed drugs by veter - inarians to animals and prescribing to a physician's own practice are collected in NorPD. For patients in nursing homes and hospitals, the register collects figures on drug use at the level of the institution or the department, i.e. on an aggregate m\u00e5nedlig informasjon kun inn Figure (NorPD) prescriptionsencryptedPrescriptionswith pseudo-nymised pseudonyms *Trusted third Folkehelseinstituttet Legemiddelstatistikk 2013:2 Folkehelseinstituttet 15 1.3 The Norwegian Drug Wholesales Statistics Statistics based on total sales of drugs from whole - salers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwe - gian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user. Drug Consumption in Norway - published annually Data from the Norwegian Drug Wholesales Statis- tics Database have been published annually in Drug Consumption in Norway (6) since 1977. Each issue includes total sales data for 5 year periods for both prescription- and non-prescription drugs in Norway. The book is available from the website www.drugcon- sumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no. 1.4 The Anatomical Therapeutic Chemical (ATC) classification system In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmaco - logical/ therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/ thera- peutic sub-groups and the 5th level is the chemical substance. The ATC code A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system:C Cardiovascular system (1st level, anatomical main group) C03 Diuretics (2nd level, therapeutic codes DDD values (4). This register is updated monthly. NIPH also checks if the data deliveries from each pharmacy are of a reasonable size. The total number of prescription records and the total number of patients and prescribers are checked every month. Statistics for the pharmacies are checked by routine. Unusual variations in size of data files from month to month are identified and any missing data is caught, such as missing special data type deliveries or empty data files caused by technical error at the pharmacy or at the trusted third party. The Personal Identification Number is checked in Statistics Norway against the Central Population Registry. If the Personal Identifica-tion Number is invalid or missing, Statistics Norway creates a special pseudonym, but it is not possible to track these individuals or link them to other data sources. However, the reported total number of ordina- tions and DDDs can be included in the total statistics. 1.2 Prescription statistic in the other Nordic countries During the late 1980s, pharmacies in the Nordic countries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, inde - pendent of socioeconomic status, have unrestricted access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The databases together cover 25 million inhabitants (Denmark: 5.6 million; and Sweden: 9.6 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also offer a sound evidence base for national decision-making in the field of drug utilization. An article from 2010 provides an overview of the data collection proce - dures and content of the Nordic countries' prescription databases (5). In addition, the article discusses their unique potential for cross-national record linkage and for analytical pharmacoepidemiological studies.kontroller p\u00e5 data 2004 Norge, siden 2005 i 17 When this is impossible, as is the case with combi- nation preparations and some liquid preparations, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evalu- ating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit. The sales can be given as the number of DDDs/1000 inhabitants/day, calculated as follows: Total consumption measured in number of DDDs x 1000 365 x number of inhabitants This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose. 1.6 The WHO Collaborating Centre for Drug Statistics Methodology The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Pharmacoepidemiology at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (7). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (8). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no.ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2013 has been used in the book. The ATC/DDD publications can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology.DDD representer ikke tallet gi som faktisk brukes. 1.6 WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av for ATC classifica- tion and DDD assignment (7). ATC Index with DDDs, som inneholder en liste over alle - nene kan bestilles fra WHO Collaborating Centre for Drug Statistics Methodology.All medicinal products containing plain spironolac - tone (Aldactone\u00ae and Spirix\u00ae) are thus assigned the code C03DA01. The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C - Cardiovas - cular system (1st level), figures for the various sub-groups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient. The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from the pharmacy medicinal product register and in the monographs of the national drug catalogue \"Felleskatalogen\" . The yellow section of the latter, entitled The Anatomical Therapeutic Chemical Medicines Register, lists all medicinal products belonging to each of the ATC 5th level codes. 1.5 The Defined Daily Dose (DDD) In some tables in part 2 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults. The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should there - fore be regarded as a technical measuring unit. Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their admin-istration route will have more than one DDD, each of them linked to a specific dosage form. For medications where a booster dose is followed by a smaller main- tenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. Alle spironolakton niv\u00e5), tall for de ulike under - gruppene (2., 3. og 4. niv\u00e5) og ned til tall preparater Filing Lov av 18.mai 2001 4. R\u00f8nning M, Litleskare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. Italian J Public Health 2006;3(1):30-35. 5. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, S\u00f8rensen HT. The Nordic countries as cohort pharmacoepi-demiological research. Basic Clin Pharmacol Toxicol 2010;106(2):86-94. 6. Sakshaug S Norway 2008-2012. [Legemiddelforbruket i Norge 2008-2012] Oslo: Norwegian Institute of Public Health, 2013. 7. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2013. Oslo, 2012. 8. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2013. Oslo 2012.Legemiddelstatistikk 2013:2 Folkehelseinstituttet 19 2. The Norwegian Prescription Database (NorPD) 2008-2012 2.1 Selected key figures from NorPD NorPD contains information from all Norwegian phar - macies of prescriptions to individuals, to a prescriber's own practice and to institutions. In 2012, about 95% of DDDs in NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 4.2% of the DDDs and about 0.3% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in NorPD. OTC sales constitute 15% of total sales of pharmaceuticals in Norway in 2012, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health). 2. Reseptregisteret 2008-2012 rundt % av legemidlene i Number of individuals and one-year prevalence (%) of the population who had at least one prescrip - tion dispensed in Norway 2008-2012 Women n (%)Men n (%)Both genders n (%) 2008 1 800 541 (75,3) 1 470 215 (61,8) 3 270 756 (68,6) 2009 1 839 960 (76,1) 1 523 065 (63,2) 3 363 025 (69,6) 2010 1 842 575 (75,4) 1 510 186 (61,8) 3 352 761 (68,6) 2011 1 879 445 (76,0) 1 551 598 (62,6) 3 431 043 (69,3) 2012 1 887 735 (75,5) 1 560 303 (62,0) 3 448 038 2013:2 Folkehelseinstituttet 21Since January 2004 more than 5 million individuals have been included in NorPD with at least one prescription medication dispensed from a pharmacy. The number of prescriptions dispensed to patients in the same period (2004-2012 ) is 327 million. In 2012, 68.7% of the Norwegian population had at least one prescription dispensed, 75.5% of women and 62% of men (table 2.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identification number was 3.7%. In the period 2005-2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identification number has declined further to just below 1.4 % in 2008 and 2009. In 2010-2012 the proportion was less than 1% (0.76% in 2012). The age-specific one year prevalence for having a drug dispensed in 2012 was lowest in both genders at about 10-14 years of age (figure 2.1). About 90 % of individuals aged 70 years and older received prescrip - tion medications. Excluding women who received only hormonal contraception for systemic use (ATC code G03A), the prevalence of drug use was reduced by about 10-15 percentage points in women aged 15-29, although the proportion of drug users among women over 15 years of age was still higher than in men.Reseptregisteret ble opprettet 1. januar 2004 og i 2009 har den ligget p\u00e5 i underkant 2.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one prescription in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R). Table 2.1.c lists the medicines with most users in Norway in 2012. The medicines (defined as ATC 5th levels) used by most individuals are analgesics (diclof- enac, and the combination of codeine / paracetamol). Phenoxymethylpenicillin (antibacterial) has for the last four years been number two on the list. Paracetamol (analgesic) is number five on the list in 2012 as in 2011 compared to number 7 and 8 in the two previous years. Paracetamol is also used by many individuals without prescription and this use is not covered by NorPD. In general the list comprises mainly the same medicines as previous years, but with some changes in the sequence. Tabell 2.1.b i 2012. De legemidlene som 5. niv\u00e5er) som p\u00e5 henholdsvis 8. 2.1.b: One-year prevalence (%) of the population who had at least one prescription dispensed in Norway in 2012 according to the main ATC groups ATC Women %Men %Both genders % A Alimentary tract and metabolism 17,9 13,4 15,7 B Blood and blood forming 5,8 15,1 H Systemic hormonal preparations, excl. sex hormones and insulins 11,1 5,4 8,2 0,4Figure 2.1: One-year prevalence (%) of the population who had at least one prescription dispensed in 2012 in Norway according to age and gender Women MenProportion (%) of the population100 80 60 40 highest number of users in Norway 2012 ATC code Active ingredient UseNumber of individualsProportion (%) of the population 1 857 30 N06AB10 escitalopram Antidepressant 109 164 2,2 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.2.2 Prescription categories and re imbursement of medicinal expenses NorPD contains information about the number of individuals having at least one drug dispensed in the various prescription categories. Prescription categories are divided into: Non-reimbursable prescriptions Reimbursement prescriptions Health Trust prescriptions (HELFO) The following is not included: Contribution according to National Insurance Act \u00a7 5.22 in which a contribution may be granted to cover the cost of healthcare when expenses are not otherwise covered by other laws and medicinal support during military service and railway personnel. Non-reimbursable prescriptions These are prescriptions paid in full by the patient. Reimbursement prescriptions (\"Blue Prescription\") The costs under the various reimbursement schemes are combined in the tables (\u00a7\u00a7 2, 3a, 3b, 4). Reimbursement according to \u00a7 2 Drugs listed on the reimbursement list \u00a7 2 will always be reimbursed when prescribed for the diagnoses (indicated by the ICPC and ICD codes) specified in the reimbursement list. The Norwegian Medicines Agency decides which medicines are included in the list and which diagnostic codes/ conditions should be subject to reimbursement prescribing. Reimbursement according to \u00a7 \u00a7 3a and 3b HELFO can decide to reimburse drugs that are not listed in the reimbursement list attached to \u00a7 2, provided that use of the drug is covered by a diagnostic code in the reimbursement list (\u00a7 3a). Decisions are made for the individual patient based on an application from the treating physician. For other expensive drugs for chronic diseases not mentioned in the reimbursement list, in special cases HELFO may grant reimbursement for an individual patient based on the physician's application (\u00a7 3b). NorPD will not contain a complete listing of reimbursement according to \u00a7\u00a7 3a and 3b. Reimbursement according to \u00a7 4 Drugs used for communicable diseases are reimbursed according to \u00a7 4 according to a specified disease list. The reimbursement is granted for antiinfective, immunostimulants individer er tatt med i tabellen.This support is provided to all who live in Norway, regardless of citizenship. The physician may prescribe these drugs for use in their own practice without giving the person-identifier of the patient. Such prescriptions will not be available on an individual level in the NorPD. Information regarding self-payment is not available in NorPD. Health Trust Prescription The regional health trusts provide a dedicated funding for certain expensive drugs. These include immune- modulating drugs for the treatment of rheumatic disorders (TNF inhibitors), multiple sclerosis and cancer. Only drugs that are dispensed by prescription to individuals are included in the table. Table 2.2.a Sales of drugs by prescription categories, overview 2012 Number of individuals Proportion (%) of the population Number of DDDs Sales in 1000 NOK Non-reimbursable prescriptions 2 981 914 59.4 577 069 899 2 626 442 Reimbursement prescriptions 2 157 984 43.0 1 580 232 738 9 287 941 Health Trust prescriptions 16 157 0.3 4 855 611 1 324 416 Table 2.2.b: Sales of reimbursed drugs (\u00a7\u00a7 2, 3a, 3b, 4) by ATC main groups 2012 ATC main groups Number of individuals Proportion (%) of the population Number of DDDs Sales in 1000 NOK A Alimentary tract and metabolism 438 210 8,7 172 980 440 1 220 214 B Blood and blood forming organs 270 133 5,4 80 483 698 627 739 C Cardiovascular system 956 239 19,1 713 202 626 1 654 963 D Dermatologicals 238 808 4,8 321 626 119 178 G Genito urinary system and sex hormones 110 797 2,2 34 975 064 257 906 H Systemic hormonal preparations, excl. sex hormones and insulins 324 631 6,5 61 462 526 395 167 J Antiinfectives for systemic use 111 676 2,2 9 957 974 522 215 L Antineoplastic and immunomodulating agents 73 345 1,5 881 50 834 223 173 199 N Nervous system 573 651 11,4 179 932 273 1 666 617 P Antiparasitic products, insecticides and repellents 6 269 0,1 731 611 4 387 R Respiratory system 744 583 14,8 220 784 711 1 301 169 S Sensory organs 255 204 5,1 32 595 772 214 253 V Various 13 746 0,3 254 628 72 288Table 2.2.c: Reimbursed drugs (\u00a7\u00a7 2, 3a, 3b, 4) with the highest number of users 2012 ATC code Active ingredient Use Number of individuals Proportion (%) of the population Number of DDDsSales in 1000 NOK 1 C10AA01 simvastatin Cholesterol-lowering 313 103 C07AB02 metoprolol Antihypertensive/cardiac disease264 162 cetirizine Anti-allergic 243 541 4,9 692 864 53 4 H03AA01 levothyroxine sodium Thyroxine supplement 186 198 3,7 40 114 945 52 880 5 R03AC02 salbutamol Asthma/COPD 180 559 3,6 18 351 550 72 661 6 C10AA05 atorvastatin Cholesterol-lowering 166 142 3,3 92 592 7 C08CA01 amlodipine Antihypertensive/cardiac disease125 291 2,5 56 276 070 53 8 R01AD09 mometasone Anti-allergic nose spray 111 161 2,2 13 170 989 44 523 9 N02BE01 paracetamol Analgesic 109 242 2,2 11 843 818 28 977 10 N06AB10 escitalopram Antidepressant 107 960 2,2 34 106 171 72 884 11 A10BA02 metformin Diabetes 102 568 2,0 H02AB06 warfarin Antithrombotic 94 265 1,9 R03AK06 salmeterol and fluticasone Asthma/COPD 94 059 1,9 594 15 A02BC05 esomeprazole Reflux oesofagitis 91 280 1,8 27 171 625 126 16 A02BC02 pantoprazole Reflux oesofagitis 90 514 R06AX27 desloratadine Anti-allergic 85 400 1,7 13 537 214 29 141 19 R03AK07 formoterol and budesonideAsthma/COPD 83 189 1,7 Anti-allergic losartan and diuretics Antihypertensive/cardiac loratadine Anti-allergic 66 638 fluticasone furoate Anti-allergic nose spray 64 799 1,3 17 107 25 C09CA01 losartan Antihypertensive/cardiac R03BA05 fluticasone Asthma/COPD 57 647 1,1 5 064 D07AB02 hydrocortisone butyrate Inflammatory skin disorders/ 29 M01AB05 diclofenac NSAID/analgesic 55 438 1,1 6 671 960 13 30 D07AC13 mometasone Inflammatory skin disorders/ eczema/psoriasis55 368 1,1 * 13 246 * No DDD assigned for this ATC 5th level 26 Legemiddelstatistikk 2013:2 og spesielt for 2.3 Description of the main tables The tables in section 2 of this book provide an over - view of the number of individuals who have had prescriptions dispensed from pharmacies in Norway. Anyone who has had at least one prescription dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same medicine several times, he or she is counted as a user only once. Only dispensing data to individuals with a personal identification number are included in the tables. In NorPD the complete personal identification number is missing for 0.76% of the dispensed medicines to individuals in 2012. The tables contain figures for the period 2008-2012. In addition, the following information for 2012 includes: Share of women (%) of the total number of individuals who have had at least one prescription dispensed The number of individuals who have had at least one prescription dispensed in the following age groups: <15, 15-44, 45-69, 70 Sales in million Norwegian kroner (mNOK), i.e. for prescriptions dispensed to individuals with a personal identification number. The amount in NOK corresponds to the actual retail price from the pharmacy. The tables are arranged according to the ATC system (see further description in p. 15). The majority of ATC groups containing drugs on the Norwegian market are included. Medicine use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of medicine users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or institutions. The following ATC groups have been omitted: B05 Blood substitutes and perfusion solutions S01J Diagnostic agents S01L Ocular vascular disorder agents V Various (ATC group V01 Allergens is included in the table)Table 2.2.d: Reimbursed drugs (\u00a7\u00a7 2, 3a, 3b, 4) with highest sales in NOK 2012 ATC code Active ingredient Use Number of individuals Proportion (%) of the population Number of DDDsSales in 1000 NOK 1 R03AK06 salmeterol and Asthma/COPD 594 2 R03AK07 formoterol and budesonideAsthma/COPD 83 189 1,7 805 047 3 A02BC05 esomeprazole Reflux oesofagitis 91 280 1,8 27 171 625 172 126 4 B02BD02 coagulation factor VIII Bleeding disorder 166 0,0 43 029 149 706 5 H01AC01 somatropin Growth hormone deficiency 1 6 R03BB04 tiotropium bromide COPD 39 417 0,8 10 N06BA04 methylphenidate ADHD 26 856 C10AA01 simvastatin Cholesterol-lowering 313 103 6,2 99 400 C09CA06 candesartan Antihypertensive/cardiac atorvastatin Cholesterol-lowering 166 142 C07AB02 metoprolol Antihypertensive/cardiac disease264 162 5,3 43 508 529 123 950 12 A10AC01 insulin human Diabetes 31 937 0,6 11 533 Antihypertensive/cardiac 1,1 17 395 102 085 14 R03DC03 montelukast Asthma 37 844 0,8 8 572 758 101 696 15 L01XE01 imatinib Cancer 465 0,0 53 058 100 948 16 A10AB05 insulin aspart Diabetes 26 980 0,5 8 661 322 86 129 17 L02BX03 abiraterone Cancer 470 0,0 74 640 85 404 sumatriptan Migraine 43 N03AX09 lamotrigine Epilepsy/bipolar disorders 25 963 0,5 6 20 A07EC02 mesalazine Ulcerative colitis/Crohn's disease14 847 B01AA03 warfarin Antithrombotic 94 265 1,9 20 591 537 77 074 22 L03AA13 pegfilgrastim Cancer 2 206 0,0 161 380 77 069 23 N06AB10 escitalopram Antidepressent 107 960 2,2 34 106 171 72 884 24 R03AC02 salbutamol Asthma/COPD 180 559 3,6 18 351 550 72 25 N03AX16 pregabalin Neuropathic pain/ epilepsy 8 700 299 26 J05AR03 tenofovir disoproxil and emtricitabineHIV infections 1 403 0,0 399 090 69 869 27 L04AD01 ciclosporin Immune suppression 3 260 0,1 716 C09DA04 irbesartan and Cholesterol-lowering 30 H01CB02 octreotide Cancer (se ogs\u00e5 s. 15). I tabellene i del 2 i denne minst ett av Non-prescription medicines are sometimes prescribed, but the majority of the OTC medicine sales will not be included in the tables in this book. Sales of OTC medicines are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in \"Drug Consumption in Norway\" (see also p. 15). A footnote is used in the tables in part 2 of this book in the various ATC codes where OTC medicines are available in Norway. In 2012, OTC medicines had a share of 15% of total sales measured in DDDs. These shares have remained almost unchanged over time. Most prescribed medicines have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without approved marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some medicines that are part of a so-called \"negative list\" which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these medicines is often low. If the number of individuals is less than five, <5 is used in the tables. Many individuals use more than one medicine. Please be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the Figure 2.2: The report generator at www.reseptregisteret.no (English version at kroner som filbehandling m\u00e5 p\u00e5regnes.tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of sleeping pills (ATC group N05C) is lower than the sum of the number of users of the individual medicines that are classified in N05C. This means that some individuals have been given more than one type of sleeping pill during a year, either through the use of more than one simultaneously or by switching from one agent to another. The NorPD website: www.norpd.no The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 2.2), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name. The following data on drug use can be extracted from the website: Number of users, split by gender, 5-year age groups, county or health region Number of users per 1 000 population (prevalence per 1 000) Turnover in NOK (pharmacy retail price) Turnover in doses (DDD - defined daily doses) Population base for the statistics, split by gender, age, county or health region Data are available from 2004 with an annual update for the preceding year. The figures in this book may differ slightly from the numbers found on the website. This is because the data extraction for the book was made at another date than the data on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Besides, individuals without known address are included in the tables in this book but not on the website. Access to data from NorPD It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required. 30 Legemiddelstatistikk 2013:2 av \u00e5ret (utleverings\u00e5r minus f\u00f8dsels\u00e5r).Calculation of prevalence per 1000 inhabitants Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one prescrip - tion dispensed in a pharmacy during a specific time period. The number of individuals listed in the tables can be used to calculate the prevalence of drug users in the population. Please read the following example: The population in Norway for the years 2008-2012 is shown on p. 101. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year). Antall individer x 1000 1 017 917 x 1000 Antall innbyggere = 5 018 415 202,8 individer som 2012: 917 Antall innbyggere i Norge per 1. juli 2012: 5 018 av prevalens (per 1000) for av hjerte-/ karmidler i Norge i 2012: The number of individuals x 1000 1 017 917 x 1000 The number of inhabitants = 5 018 415 = 202.8 individuals per 1000 inhabitantsThe number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2012: 1 017 917 The number of inhabitants in Norway as of 1st July 2012: 5 018 415Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2012: 2.4 ATC main groups ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 A ALIMENTARY 826 678 403 702 509 742 204 787 544 57 21 153 183 105 353 754 229 532 1 472 867 B BLOOD AND BLOOD FORMING ORGANS 541 141 562 344 581 349 597 921 616 372 50 2 637 59 063 268 325 286 347 787 836 C CARDIOVASCULAR SYSTEM 917 229 945 886 975 141 998 461 1 018 128 51 6 118 95 480 532 968 383 562 1 691 608 D DERMATOLOGICALS 589 450 587 812 611 440 624 493 628 955 54 76 390 237 819 212 640 102 106 235 358 G GENITO URINARY SYSTEM AND SEX HORMONES 692 715 703 423 721 846 745 367 760 023 81 3 267 420 137 234 951 101 668 862 673 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 357 070 375 465 387 821 402 923 413 526 67 16 074 108 837 178 811 109 804 430 101 J ANTIINFECTIVES FOR SYSTEMIC USE 1 247 202 1 394 508 1 252 392 1 326 405 1 330 660 59 164 678 534 345 435 678 195 959 802 758 L ANTINEOPLASTIC AND IMMU-NOMODULATING AGENTS 70 154 72 795 76 656 81 612 86 248 54 1 255 18 728 40 814 25 451 2 400 496 M MUSCULO-SKELETAL SYSTEM 907 360 891 127 901 910 927 355 935 824 57 14 643 332 879 429 400 158 902 303 497 N NERVOUS SYSTEM 1 208 796 1 230 918 1 248 505 1 279 676 1 301 538 59 30 853 414 409 565 804 290 472 2 626 256 P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 89 343 86 714 88 743 92 296 94 797 63 3 329 42 623 37 887 10 958 33 814 R RESPIRATORY SYSTEM 1 151 928 1 183 767 1 183 735 1 223 490 1 234 841 56 169 146 451 770 445 061 168 864 1 448 923 S SENSORY ORGANS 596 101 596 290 609 467 617 742 614 238 57 112 776 177 918 192 459 131 085 302 360 32 Legemiddelstatistikk 2013:2 Folkehelseinstituttet Legemiddelstatistikk 2013:2 Folkehelseinstituttet 332.5 Alimentary tract and metabolism ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 A ALIMENTARY 826 678 403 702 509 742 204 787 544 57 21 153 183 105 353 754 229 532 1 472 867 A01 STOMATOLOGICAL PREPARATIONS 18 176 11 205 6 463 9 155 15 069 57 404 6 273 4 981 3 411 2 596 A01A STOMATOLOGICAL PREPARATIONS 18 176 11 205 6 463 9 155 15 069 57 404 6 273 4 981 3 411 2 596 A01AA Caries prophylactic agents 618 665 776 4 792 10 844 57 111 4 472 3 568 2 693 1 774 A01AA01 sodium fluoride 1)618 665 776 4 792 10 844 57 111 4 472 3 568 2 693 1 774 A01AB Antiinfectives and antisep - tics for local oral treatment 8 943 8 998 4 088 2 553 2 396 54 143 969 790 494 241 A01AB02 hydrogen peroxide1)0 0 <5 <5 0 - 0 0 0 0 0 A01AB03 chlorhexidine1)2 312 2 293 2 540 2 482 2 341 53 141 951 770 479 206 A01AB04 amphotericin B 6 554 6 690 1 529 52 36 78 0 12 12 12 31 A01AB09 miconazole <5 5 <5 <5 <5 2 A01AB17 metronidazole 108 45 0 0 0 - 0 0 0 0 0 A01AC Corticosteroids for local oral treatment 8 434 1 026 1 155 1 379 1 408 63 110 495 567 236 361 A01AC01 triamcinolone 8 434 1 026 1 155 1 379 1 397 63 110 493 559 235 349 A01AD Other agents for local oral treatment 550 598 508 516 530 59 40 366 104 20 221 A01AD01 epinephrine 7 6 9 10 10 50 0 <5 6 0 10 A01AD02 benzydamine 515 562 475 494 494 59 30 351 95 18 207 A01AD11 various 28 30 24 12 26 69 10 11 <5 <5 3 A02 DRUGS FOR ACID RELATED DISORDERS 298 397 316 609 338 746 366 465 392 558 54 6 792 86 931 188 818 110 017 339 723 A02A ANTACIDS 4 296 4 537 4 691 4 772 4 415 43 126 837 1 598 1 854 5 572 A02AA Magnesium compounds 0 0 0 0 <5 50 0 0 0 <5 1 A02AA04 magnesium hydroxide 0 0 0 0 <5 50 0 0 0 <5 1 A02AC Calcium compounds 1 398 1 293 1 229 1 085 1 001 36 17 133 368 483 666 A02AC01 calcium carbonate 1)1 398 1 293 1 229 1 085 1 001 36 17 133 368 483 666 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1 240 1 495 1 485 1 526 1 024 61 26 455 332 211 148 A02AD01 ordinary salt combinations 1)1 240 1 495 1 485 1 526 1 024 61 26 455 332 211 148 A02AH Antacids with sodium bicarbonate 2 166 2 187 2 341 2 471 2 676 36 46 283 1 013 1 334 4 495 A02B DRUGS FOR PEPTIC ULCER AND GASTRO- OESOPHAGEAL REFLUX DISEASE (GORD) 296 148 314 287 336 339 364 176 390 415 55 6 700 86 566 188 120 109 029 334 151 A02BA H2-receptor antagonists 59 188 58 630 57 804 57 052 54 899 59 1 179 14 814 25 342 13 564 16 658A02BA01 cimetidine 356 56 46 34 28 64 0 <5 18 8 25 A02BA02 ranitidine1)55 440 55 484 54 984 54 650 53 271 59 1 172 14 607 24 573 12 919 15 232 A02BA03 famotidine1)3 448 2 878 2 547 2 313 1 614 56 7 193 768 646 1 372 A02BA07 ranitidine bismuth citrate <5 0 0 0 0 - 0 0 0 0 0 A02BA53 famotidine, combinations1)351 378 367 221 127 58 0 34 56 37 29 A02BB Prostaglandins 267 248 259 255 346 81 <5 214 86 44 192 A02BB01 misoprostol 267 248 259 255 346 81 <5 214 86 44 192 A02BC Proton pump inhibitors 250 321 269 754 292 835 321 967 351 006 54 5 686 75 822 170 509 98 989 316 703 A02BC01 omeprazole 44 880 46 873 47 082 48 114 47 239 55 3 141 9 584 21 048 13 466 48 764 A02BC02 pantoprazole1)74 965 85 176 102 237 125 091 148 280 54 586 34 201 71 066 42 427 43 846 A02BC03 lansoprazole 50 410 50 018 48 809 47 348 46 270 51 418 8 519 23 599 13 734 31 609 A02BC05 esomeprazole 108 181 111 446 117 963 125 642 134 776 55 1 945 30 160 67 346 35 325 192 485 A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 1 837 1 807 1 909 2 143 2 310 63 182 803 792 533 598 A02BX02 sucralfate 424 403 366 419 440 61 <5 119 188 131 255 A02BX13 alginic acid 1 424 1 414 1 549 1 739 1 880 64 180 685 610 405 343 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 58 718 60 485 62 554 65 509 69 438 71 1 562 24 008 26 338 17 530 14 911 A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 3 364 3 471 3 623 3 150 3 500 55 152 769 1 248 1 331 1 657 A03AA Synthetic anticholinergics, esters with tertiary amino group 45 28 29 26 26 65 0 9 15 <5 29 A03AA04 mebeverine 42 27 29 26 26 65 0 9 15 <5 29 A03AA07 dicycloverine <5 <5 0 0 0 - 0 0 0 0 0 A03AB Synthetic anticholinergics, quaternary ammonium compounds 32 112 132 160 44 <5 14 78 116 269 A03AB02 glycopyrronium bromide 25 105 128 155 201 45 <5 8 76 116 261 A03AB05 propantheline 7 7 <5 5 8 13 0 6 <5 0 8 A03AD Papaverine and derivatives 48 37 59 47 62 13 0 <5 35 23 117 A03AD01 papaverine 48 37 59 47 62 13 0 <5 35 23 117 A03AX Other drugs for functional gastrointestinal disorders 3 239 3 302 3 405 2 924 3 209 57 151 742 1 124 1 192 1 242 A03AX13 silicones 3 239 3 302 3 405 2 924 3 209 57 151 742 1 124 1 192 1 242 A03B BELLADONNA AND DERIVATIVES, PLAIN 1 101 1 382 1 617 1 910 2 125 59 1 297 1 510 1 664 58 7 691 681 285 548ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 34 Legemiddelstatistikk 2013:2 Folkehelseinstituttet Legemiddelstatistikk 2013:2 Folkehelseinstituttet 35A03BA01 atropine 27 26 18 0 <5 18 6 14 A03BA03 hyoscyamine 834 1 072 1 276 1 487 1 636 59 7 687 663 279 535 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 242 285 321 406 468 63 7 169 217 75 260 A03BB01 butylscopolamine 223 267 300 386 455 63 6 165 211 73 256 A03BB03 methylscopolamine 19 18 23 21 13 69 <5 <5 6 <5 3 A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS 27 18 19 20 16 44 0 <5 12 <5 29 A03CA Synthetic anticholinergic agents in combination with psycholeptics 27 18 19 20 16 44 0 <5 12 <5 29 A03CA02 clidinium and psycholeptics 27 18 19 20 16 44 0 <5 12 <5 29 A03F PROPULSIVES 54 797 56 321 58 104 61 221 64 702 72 1 412 22 589 24 578 16 123 12 418 A03FA Propulsives 54 797 56 321 58 104 61 221 64 702 72 1 412 22 589 24 578 16 123 12 418 A03FA01 metoclopramide 54 676 56 214 57 999 61 099 64 570 72 1 392 22 558 24 521 16 099 11 830 A03FA02 cisapride 116 93 83 79 83 58 13 24 34 12 451 A03FA03 domperidone 39 44 55 71 62 56 8 11 26 17 110 A03FA05 alizapride 0 0 0 0 11 82 0 8 <5 0 28 A04 ANTIEMETICS AND ANTINAUSEANTS 12 918 13 055 13 797 14 669 15 259 59 304 2 640 8 396 3 919 33 276 A04A ANTIEMETICS AND ANTINAUSEANTS 12 918 13 055 13 797 14 669 15 259 59 304 2 640 8 396 3 919 33 276 A04AA Serotonin (5HT 3) antagonists 10 498 10 867 11 434 11 986 12 399 59 228 1 641 7 011 3 519 25 567 A04AA01 ondansetron 10 010 10 437 11 150 11 784 12 270 59 228 1 634 6 931 3 477 24 900 A04AA02 granisetron <5 <5 0 0 27 A04AA03 tropisetron 755 613 440 324 210 62 <5 16 131 62 630 A04AA05 palonosetron 6 <5 <5 11 A04AD Other antiemetics 3 138 3 194 3 887 4 658 5 178 68 78 1 392 3 009 699 7 709 A04AD01 scopolamine 2 412 2 112 2 135 2 400 2 313 57 75 885 995 358 739 A04AD05 metopimazine <5 0 0 0 0 - 0 0 0 0 0 A04AD10 dronabinol 7 5 <5 5 5 0 0 <5 <5 0 65 A04AD12 aprepitant 719 1 078 1 761 2 269 2 871 77 <5 505 2 020 343 6 904 A05 BILE AND LIVER THERAPY 1 749 1 909 2 015 2 303 2 592 75 75 938 1 176 403 9 325 A05A BILE THERAPY 1 749 1 909 2 015 2 303 2 592 75 75 938 1 176 403 9 325 A05AA Bile acid preparations 1 749 1 909 2 015 2 303 2 592 75 75 938 1 176 403 9 325 A05AA02 ursodeoxycholic acid 1 749 1 909 2 015 2 303 2 592 75 75 938 1 176 403 9 325 A06 DRUGS FOR CONSTIPATION 28 856 31 408 44 230 50 571 49 659 57 5 865 7 157 16 837 19 800 27 774 A06A DRUGS FOR CONSTIPATION 28 856 31 408 44 230 50 571 49 659 57 5 865 7 157 16 837 19 800 27 774ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales 1000 NOK <15 15-44 45-69 70 A06AA Softeners, emollients 69 105 112 208 365 47 61 40 107 157 290 A06AA01 liquid paraffin1)69 105 112 194 351 47 55 37 105 154 154 A06AB Contact laxatives 12 341 13 383 15 058 21 757 22 471 58 354 2 380 8 828 10 909 6 951 A06AB02 bisacodyl1)3 847 3 858 4 056 6 514 6 005 63 80 690 1 977 3 258 1 961 A06AB06 senna glycosides1)2 002 2 020 2 120 4 322 2 808 62 19 168 848 1 773 1 342 A06AB08 sodium picosulfate1)7 574 8 584 10 082 10 948 11 635 55 258 1 227 4 369 5 781 2 448 A06AB20 contact laxatives in combination <5 dantron, combinations <5 <5 <5 0 0 0 A06AB56 senna glycosides, combinations 1)17 17 10 12 11 82 0 <5 5 5 3 A06AB58 sodium picosulfate, combinations 1)0 0 31 1 581 3 529 60 <5 421 2 161 944 1 195 A06AC Bulk-forming laxatives 1 508 1 772 1 996 2 054 2 080 60 42 566 791 681 582 A06AC01 ispaghula (psylla seeds)1)1 505 1 772 1 996 2 054 2 080 60 42 566 791 681 582 A06AC51 ispaghula, combinations1)<5 0 0 0 0 - 0 0 0 0 0 A06AD Osmotically acting l axatives 17 176 18 687 30 442 30 643 29 153 55 5 354 4 112 9 083 10 604 11 951 A06AD11 lactulose 1)13 475 13 507 14 464 14 513 14 509 51 645 1 805 5 396 6 663 3 964 A06AD12 lactitol 68 78 59 58 51 55 33 9 5 <5 36 A06AD15 macrogol 0 0 45 79 134 54 122 11 <5 0 122 A06AD17 sodium phosphate1)923 847 9 665 7 334 2 814 59 <5 589 1 434 787 568 A06AD65 macrogol, combinations1)3 327 4 947 7 273 9 943 12 875 57 4 679 1 827 2 709 3 660 7 261 A06AG Enemas 4 522 4 649 4 892 5 458 5 288 50 532 1 190 1 775 1 791 6 975 A06AG02 bisacodyl1)1 468 1 475 1 410 1 680 1 671 47 47 459 683 482 724 A06AG04 glycerol1)689 772 827 905 852 48 188 220 212 232 3 158 A06AG10 docusate sodium, incl. combinations 1)1 213 1 217 1 394 1 484 1 365 50 93 281 480 511 1 595 A06AG11 laurilsulfate, incl. combinations 1)1 511 1 567 1 647 1 826 1 767 52 226 297 541 703 1 498 A06AH Peripheral opioid receptor antagonists 18 164 197 195 180 51 <5 17 108 54 1 001 A06AH01 methylnaltrexone bromide 18 164 197 195 180 51 <5 17 108 54 1 001 A06AX Other drugs for constipation <5 0 0 0 9 78 0 7 <5 <5 24 A06AX05 prucalopride 0 0 0 0 0 7 <5 <5 24 A06AX06 tegaserod <5 0 0 0 0 - 0 0 0 0 0 A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAM - MATORY/ANTIINFECTIVE AGENTS 60 714 62 586 69 807 72 492 72 187 59 4 873 20 234 30 464 16 616 127 222ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 25 618 31 199 32 204 30 625 65 4 327 7 901 11 208 7 189 12 190 A07AA Antibiotics 24 718 25 618 31 199 32 204 30 625 65 4 327 7 901 11 208 7 189 12 190 A07AA02 nystatin 24 493 25 376 30 730 31 544 29 999 65 4 312 7 649 10 946 7 092 10 628 A07AA06 paromomycin 90 81 154 316 257 71 13 142 100 <5 190 A07AA09 vancomycin 158 177 182 200 234 60 <5 41 97 94 818 A07AA11 rifaximin 0 <5 184 211 188 73 <5 93 87 7 522 A07AA12 fidaxomicin 0 0 0 0 <5 50 0 0 <5 <5 31 A07B INTESTINAL ADSORBENTS 146 95 80 84 101 44 13 37 33 18 18 A07BA Charcoal preparations 146 95 80 84 95 42 13 36 30 16 12 A07BA01 medicinal charcoal1)146 95 80 84 95 42 13 36 30 16 12 A07BB Bismuth preparations 0 0 0 0 6 67 0 <5 <5 <5 7 A07C ELECTROLYTES WITH CARBOHYDRATES 118 182 259 279 356 56 176 92 52 36 186 A07CA Oral rehydration salt formulations 1)118 182 259 279 356 56 176 92 52 36 186 A07D ANTIPROPULSIVES 15 904 16 106 16 710 17 200 18 001 56 141 3 584 8 114 6 162 7 441 A07DA Antipropulsives 15 904 16 106 16 710 17 200 18 001 56 141 3 584 8 114 6 162 7 441 A07DA01 A07DA02 opium 99 94 124 112 99 54 0 6 44 49 234 A07DA03 loperamide1)15 718 15 829 16 464 16 933 17 689 57 136 3 482 7 986 6 085 7 165 A07DA53 loperamide, combinations1)221 326 294 283 356 56 5 108 147 96 121 A07E INTESTINAL ANTI-INFLAMMATORY AGENTS 21 365 21 914 22 753 23 690 24 459 52 218 8 614 11 819 3 808 104 840 A07EA Corticosteroids acting locally 4 806 5 014 5 212 5 155 5 204 60 62 1 795 2 411 936 15 304 A07EA01 prednisolone 1 002 1 011 1 175 1 292 1 220 50 7 503 550 160 1 212 A07EA02 hydrocortisone 1 195 1 233 1 154 408 355 71 6 123 180 46 679 A07EA06 budesonide 2 820 2 972 3 190 3 583 3 764 63 54 1 235 1 727 748 13 412 A07EB Antiallergic agents, excl. corticosteroids 63 54 53 64 50 76 17 12 19 <5 435 A07EB01 cromoglicic acid 63 54 53 64 50 76 17 12 19 <5 435 A07EC Aminosalicylic acid and similar agents 18 950 19 275 19 918 20 669 21 322 50 171 7 730 10 325 3 096 89 101 A07EC01 sulfasalazine 6 461 6 194 6 104 5 966 5 800 55 <5 1 419 3 288 1 089 6 740 A07EC02 mesalazine 11 965 12 549 13 330 14 229 15 066 48 166 6 173 6 796 1 931 78 624 A07EC03 olsalazine 494 488 494 452 406 46 <5 104 224 76 1 444 A07EC04 balsalazide 859 809 750 687 612 43 0 216 313 83 2 294 A07F ANTIDIARRHEAL MICROORGANISMS 302 694 1 252 1 507 1 243 73 35 668 470 70 2 129A07FA Antidiarrheal microorganisms 302 694 1 252 1 507 1 243 73 35 668 470 70 2 129 A07FA01 lactic acid producing organisms 204 581 918 912 767 73 13 440 297 17 1 579 A07FA02 saccharomyces boulardii 98 116 283 381 431 69 24 198 157 52 340 A07FA51 lactic acid producing organisms, combinations 0 0 0 0 16 69 0 9 5 <5 25 A07X OTHER ANTIDIARRHEALS 107 139 99 117 64 83 <5 34 24 <5 41 A07XA Other antidiarrheals 107 139 99 117 64 83 <5 34 24 <5 41 A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 37 873 38 343 19 168 10 373 7 674 77 <5 2 866 4 155 651 11 743 A08A ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 37 873 38 343 19 168 10 373 7 674 77 <5 2 866 4 155 651 11 743 A08AA Centrally acting antiobesity products 22 024 25 710 5 782 0 0 - 0 0 0 0 0 A08AA10 sibutramine 22 024 25 710 5 782 0 0 - 0 0 0 0 0 A08AB Peripherally acting antiobesity products 14 563 14 540 14 575 10 373 7 674 77 <5 2 866 4 155 651 11 743 A08AB01 orlistat 14 563 14 540 14 575 10 373 7 674 77 <5 2 866 4 155 651 11 743 A08AX Other antiobesity drugs 4 206 <5 <5 0 0 - 0 0 0 0 0 A08AX01 rimonabant 4 206 <5 <5 0 0 - 0 0 0 0 0 A09 DIGESTIVES, INCL. ENZYMES 5 053 5 126 5 479 5 758 5 732 58 131 959 2 722 1 920 15 035 A09A DIGESTIVES, INCL. ENZYMES 5 053 5 126 5 479 5 758 5 732 58 131 959 2 722 1 920 15 035 A09AA Enzyme preparations 4 965 5 070 5 441 5 699 5 684 58 130 947 2 709 1 898 15 009 A09AA02 multienzymes (lipase, protease etc.) 4 965 5 070 5 441 5 699 5 679 58 130 946 2 705 1 898 14 994 A09AB Acid preparations 104 65 50 61 52 63 <5 9 19 23 21 A09AB01 glutamic acid hydrochloride 1)66 52 44 54 39 72 0 <5 16 19 18 A09AB02 betaine hydrochloride 0 0 0 <5 1 A09AB04 citric acid 35 10 0 0 0 - 0 0 0 0 0 A09AC Enzyme and acid preparations, combinations 0 0 15 17 9 78 0 8 <5 0 6 A09AC02 multienzymes and acid preparations 0 0 15 17 9 78 0 8 <5 0 6 A10 DRUGS USED IN DIABETES 139 101 145 677 152 065 156 542 160 789 44 1 802 23 046 83 009 52 932 580 953 A10A INSULINS AND ANALOGUES 51 156 52 603 54 014 54 994 56 373 43 1 780 14 038 25 481 15 074 343 169 A10AB Insulins and analogues for injection, fast-acting 32 514 33 562 34 874 35 659 36 860 43 1 775 12 753 16 085 6 247 124 674ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 38 Legemiddelstatistikk 2013:2 Folkehelseinstituttet Legemiddelstatistikk 2013:2 823 1 604 1 403 1 293 39 9 217 702 365 2 655 A10AB03 insulin (pork) <5 0 0 0 0 - 0 0 0 0 0 A10AB04 insulin lispro 8 672 8 615 8 835 9 021 9 091 42 184 3 947 3 973 987 34 660 A10AB05 insulin aspart 22 740 23 900 25 159 25 860 27 003 43 1 639 8 802 11 613 4 949 86 202 A10AB06 insulin glulisine 145 270 375 404 379 47 <5 142 194 41 1 157 A10AC Insulins and analogues for injection, intermediate-acting 33 505 33 129 32 520 31 916 31 962 42 618 5 474 15 288 10 582 103 184 A10AC01 insulin (human) 33 503 33 129 32 520 31 916 31 962 42 618 5 474 15 288 10 582 103 184 A10AC03 insulin (pork) <5 0 0 0 0 - 0 0 0 0 0 A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting 10 261 9 736 9 112 8 304 7 684 43 6 498 3 589 3 591 35 198 A10AD01 insulin (human) 33 17 <5 <5 <5 0 0 0 0 <5 18 A10AD03 insulin (pork) 0 0 0 <5 0 - 0 0 0 0 0 A10AD04 Insulin lispro 750 672 647 643 607 44 <5 102 317 186 2 721 A10AD05 insulin aspart 9 506 9 075 8 476 7 672 7 091 43 <5 399 3 276 3 412 32 459 A10AE Insulins and analogues for injection, long-acting 9 845 11 310 13 695 15 222 16 394 45 731 6 633 7 129 1 901 80 114 A10AE03 (pork) <5 <5 <5 <5 0 0 19 A10AE04 insulin glargine 6 167 6 958 8 433 9 559 10 603 45 241 4 349 4 737 1 276 47 484 A10AE05 insulin detemir 3 802 4 493 5 526 5 927 6 017 46 504 2 385 2 488 640 32 610 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 105 413 111 436 117 293 121 207 124 901 44 25 10 615 69 396 44 865 237 784 A10BA Biguanides 88 638 95 537 101 637 103 523 104 983 45 18 9 564 59 517 35 884 50 711 A10BA02 metformin 88 638 95 537 101 637 103 523 104 983 45 18 9 564 59 517 35 884 50 711 A10BB Sulfonamides, urea derivatives 47 057 47 349 46 112 43 116 40 597 41 7 1 809 20 895 17 886 17 870 A10BB01 glibenclamide 1 912 1 738 1 539 1 343 1 177 43 6 A10BB02 2 A10BB07 glipizide 5 707 5 229 4 807 4 281 3 856 42 0 114 1 596 2 146 2 192 A10BB12 glimepiride 39 867 40 684 40 028 37 733 35 737 41 <5 1 662 18 852 15 222 15 056 A10BD Combinations of oral blood glucose lowering drugs 2 652 3 852 8 219 10 974 13 273 37 0 978 8 941 3 354 59 582 A10BD03 metformin and rosiglitazone 2 641 2 575 2 284 0 0 - 0 0 0 0 0 A10BD04 glimepiride and rosiglitazone <5 <5 0 0 0 - 0 0 0 0 A10BD05 metformin and pioglitazone <5 27 32 35 26 <5 19 <5 107 A10BD07 metformin and sitagliptin 0 318 2 187 4 053 5 215 37 0 386 3 533 1 296 23 023 A10BD08 metformin and vildagliptin 10 1 068 4 791 7 030 8 144 37 0 595 5 465 2 084 36 452A10BF Alpha glucosidase inhibitors 988 922 813 701 640 44 0 33 310 297 950 A10BF01 acarbose 988 922 813 701 640 44 0 33 310 297 950 A10BG Thiazolidinediones 5 719 5 401 4 672 1 912 1 637 39 0 97 1 082 458 6 956 A10BG02 rosiglitazone 4 193 3 798 3 104 20 <5 0 0 0 <5 0 1 A10BG03 pioglitazone 1 568 1 641 1 779 1 894 1 636 39 0 97 1 081 458 6 955 A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 798 1 752 6 478 9 436 11 088 42 0 716 6 724 3 648 46 906 A10BH01 sitagliptin 793 1 491 4 799 6 711 7 196 41 0 464 4 466 2 266 32 690 A10BH02 vildagliptin 6 288 935 1 274 1 749 45 0 116 974 659 5 086 A10BH03 saxagliptin 0 0 854 1 616 1 763 40 0 121 1 126 516 7 892 A10BH05 linagliptin 0 0 0 0 608 41 0 25 276 307 1 239 A10BX Other blood glucose lowering drugs, excl. insulins 725 847 1 335 3 523 5 421 46 0 781 3 950 690 54 808 A10BX02 repaglinide 399 330 283 252 234 36 0 5 127 102 445 A10BX03 nateglinide 13 13 11 9 10 30 0 <5 6 <5 25 A10BX04 exenatide 314 491 554 795 873 47 0 124 654 95 6 684 A10BX07 liraglutide 0 19 535 2 605 4 427 46 0 667 3 253 507 47 654 A11 VITAMINS 79 347 91 052 93 046 102 139 118 610 60 805 29 723 45 597 42 485 67 050 A11A MUL TIVITAMINS, COMBINATIONS 0 0 0 28 92 49 46 42 <5 0 389 A11AA Multivitamins with minerals 0 0 0 28 92 49 46 42 <5 0 389 A11AA03 multivitamins and other minerals, incl. combinations 0 0 0 28 92 49 46 42 <5 0 389 A11B MUL TIVITAMINS, PLAIN 39 78 100 74 59 86 15 44 0 0 51 A11BA Multivitamins, plain 39 78 100 74 59 86 15 44 0 0 51 A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO 7 962 9 836 11 360 17 026 25 067 58 365 9 183 10 279 5 240 15 805 A11CA Vitamin A, plain 38 29 30 42 58 71 <5 26 24 <5 157 A11CA01 retinol (vit A) 22 13 14 20 37 76 0 16 18 <5 38 A11CA02 betacarotene 16 16 16 22 21 62 <5 10 6 <5 119 A11CC Vitamin D and analogues 7 931 9 815 11 337 16 992 25 029 58 361 9 166 10 265 5 237 15 648 A11CC01 ergocalciferol 2 034 3 096 4 250 8 654 13 261 64 140 5 972 5 507 1 642 4 546 A11CC03 alfacalcidol 3 526 3 790 3 884 4 123 4 852 47 139 825 1 910 1 978 6 684 A11CC04 calcitriol 2 085 2 297 2 396 2 632 2 930 46 15 527 1 224 1 164 3 413 A11CC05 colecalciferol 367 753 939 1 733 4 359 63 72 1 954 1 815 518 1 005 A11D VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 1)697 762 790 749 798 37 6 123 475 194 598 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 786 37 6 118 472 190 592 A11DA01 thiamine (vit B1)1)677 745 782 739 786 37 6 118 472 190 592 A11DB Vitamin B1 in combination with vitamin B6 and/or vitamin B12 20 17 8 10 12 83 0 5 <5 <5 6 A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS 68 574 78 387 78 352 82 349 92 260 60 290 20 237 35 488 36 245 47 388 A11EA Vitamin B-complex, plain 1)67 559 77 313 77 144 80 810 90 830 61 256 19 963 34 927 35 684 45 979 A11EB Vitamin B-complex with vitamin C 58 114 92 155 231 60 <5 82 89 58 58 A11EX Vitamin B-complex, other combinations 986 1 008 1 155 1 443 1 266 39 32 201 501 532 1 351 A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS 3 410 3 507 3 677 3 759 3 639 66 9 339 788 2 503 1 076 A11GA Ascorbic acid (vitamin C), plain 3 410 3 507 3 677 3 759 3 639 66 9 339 788 2 503 1 076 A11GA01 ascorbic acid (vit C) 1)3 410 3 507 3 677 3 759 3 639 66 9 339 788 2 503 1 076 A11H OTHER PLAIN VITAMIN PREPARATIONS 1 181 1 462 1 604 1 730 1 501 62 124 874 355 148 1 040 A11HA Other plain vitamin preparations 1 181 1 462 1 604 1 730 1 501 62 124 874 355 148 1 040 A11HA01 nicotinamide 14 5 13 11 19 47 <5 9 A11HA02 pyridoxine (vit B6) 1)568 871 1 072 1 134 1 030 61 55 691 212 72 416 A11HA03 tocopherol (vit E)1)590 572 442 412 311 55 62 95 86 68 445 A11HA04 riboflavin (vit B2) 13 16 12 11 9 56 <5 <5 <5 <5 3 A11HA06 pyridoxal phosphate 0 0 131 88 <5 83 43 <5 60 A11HA08 tocofersolan 0 0 0 <5 <5 50 <5 0 0 0 106 A11J OTHER VITAMIN PRODUCTS, COMBINATIONS 63 59 61 91 84 74 36 36 12 0 117 A11JA Combinations of vitamins 63 59 48 53 45 58 36 9 0 0 85 A11JB Vitamins with minerals 0 0 13 38 39 92 0 27 12 0 32 A12 MINERAL SUPPLEMENTS 83 190 91 581 100 943 111 514 125 310 78 424 11 747 51 030 62 109 82 885 A12A CALCIUM 62 611 70 986 80 569 91 211 104 272 82 240 10 410 43 860 49 762 66 290 A12AA Calcium 1 515 1 467 1 417 1 137 1 066 67 60 168 447 391 1 215 A12AA02 calcium glubionate <5 8 7 <5 6 33 5 0 <5 0 21 A12AA04 calcium carbonate1)397 371 412 188 <5 1 A12AA06 calcium lactate gluconate1)1 123 1 090 984 928 1 029 68 55 163 434 377 1 160 A12AA12 calcium acetate anhydrous 22 12 28 24 32 38 <5 5 13 13 34 A12AX Calcium, combinations with vitamin D and/or other drugs 61 293 69 722 79 351 90 245 103 401 82 181 10 265 43 500 49 455 65 074A12B POTASSIUM 20 403 20 533 20 544 20 029 20 949 65 86 1 062 6 807 12 994 12 954 A12BA Potassium 20 403 20 533 20 544 20 029 20 949 65 86 1 062 6 807 12 994 12 954 A12BA01 potassium chloride 18 834 18 968 18 800 18 295 19 019 65 21 884 6 179 11 935 10 061 A12BA02 potassium citrate 1 860 1 828 2 055 2 034 2 256 63 67 218 747 1 224 2 874 A12BA30 combinations 5 <5 <5 <5 <5 50 0 <5 <5 0 18 A12C OTHER MINERAL SUPPLEMENTS 3 628 3 773 4 004 4 809 5 366 61 101 576 1 998 2 691 3 424 A12CA Sodium 464 622 715 878 979 66 <5 44 304 628 527 A12CA01 sodium chloride 1)464 622 715 878 979 66 <5 44 304 628 527 A12CB Zinc 909 865 767 697 764 68 43 152 258 311 346 A12CB01 zinc sulfate 909 865 767 697 764 68 43 152 258 311 346 A12CC Magnesium 2 292 2 338 2 591 3 300 3 690 58 56 385 1 472 1 777 2 551 A12CC04 magnesium citrate 19 <5 0 0 0 - 0 0 0 0 0 A12CC10 magnesium oxide 9 13 18 103 173 55 <5 25 67 80 123 A12CC30 magnesium (different salts in combination) 1)2 272 2 328 2 573 3 212 3 537 59 45 365 1 412 1 715 2 158 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 660 728 847 866 885 82 <5 237 575 71 595 A14A ANABOLIC STEROIDS 660 728 847 866 885 82 <5 237 575 71 595 A14AA Androstan derivatives 561 645 827 841 847 84 <5 226 549 70 468 A14AA07 prasterone 560 644 827 841 847 549 70 468 A14AA08 oxandrolone <5 <5 0 0 0 - 0 0 0 0 0 A14AB Estren derivatives 100 84 21 25 24 17 0 5 18 <5 72 A14AB01 nandrolone 100 84 21 25 24 17 0 5 18 <5 72 A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 329 293 548 663 598 66 95 286 199 18 159 653 A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 329 293 317 335 373 56 88 159 110 16 159 399 A16AA Amino acids and derivatives 93 107 123 131 152 56 60 63 26 <5 3 035 A16AA01 levocarnitine 63 73 87 79 82 50 51 22 6 <5 1 244 A16AA03 glutamine 13 17 12 19 11 36 0 7 <5 0 17 A16AA04 mercaptamine 8 7 10 8 8 38 5 <5 0 0 826 A16AA06 betaine 10 11 16 20 21 48 5 12 <5 0 937 A16AB Enzymes 44 51 50 56 59 39 5 26 24 <5 122 990 A16AB02 imiglucerase 9 10 7 7 0 <5 <5 0 12 047 A16AB03 agalsidase alfa 17 16 32 33 34 35 <5 17 12 <5 56 752 A16AB04 agalsidase beta 19 23 18 7 14 43 0 5 9 0 16 304 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 <5 <5 <5 A16AB08 galsulfase 0 0 0 0 <5 100 <5 10 964 A16AB10 velaglucerase alfa 0 0 0 6 5 20 0 <5 <5 0 13 234 A16AX Various alimentary tract and metabolism products 198 139 149 151 165 61 24 71 61 9 33 373 A16AX01 thioctic acid 180 122 121 109 112 64 <5 42 59 9 176 252 A16AX04 nitisinone 12 12 13 14 14 21 11 <5 0 0 10 123 A16AX05 zinc acetate <5 <5 7 8 11 55 <5 miglustat 0 0 <5 <5 0 0 0 2 597 A16AX07 sapropterin 0 0 5 15 22 73 <5 17 <5 0 20 135 B BLOOD AND BLOOD FORMING ORGANS 541 172 562 393 581 403 597 973 616 453 50 2 641 59 109 268 354 286 349 813 935 B01 ANTITHROMBOTIC AGENTS 455 766 472 410 485 783 497 174 508 904 45 402 22 096 222 773 263 633 417 935 B01A ANTITHROMBOTIC AGENTS 455 766 472 410 485 783 497 174 508 904 45 402 22 096 222 773 263 633 417 935 B01AA Vitamin K antagonists 84 246 86 427 88 730 92 222 94 644 40 56 3 395 28 862 62 331 77 944 B01AA01 dicoumarol 88 93 90 93 81 51 0 10 32 39 434 B01AA02 phenindione 33 27 24 15 <5 75 0 0 <5 <5 80 B01AA03 warfarin 84 154 86 322 88 631 92 133 94 563 40 56 3 385 28 830 62 292 77 430 B01AB Heparin group 28 157 32 041 36 949 42 027 46 904 58 170 10 136 21 190 15 408 107 362 B01AB01 heparin 789 826 926 943 1 043 55 99 200 491 253 2 382 B01AB02 antithrombin III <5 <5 <5 0 0 0 0 0 0 0 0 B01AB04 dalteparin 15 439 15 917 21 249 25 588 28 569 59 47 5 983 13 128 9 411 65 075 B01AB05 enoxaparin 12 275 15 744 15 363 16 078 17 952 57 25 4 060 7 915 5 952 39 866 B01AB10 tinzaparin 0 0 0 6 7 71 0 <5 39 B01AC Platelet 206 380 882 390 081 394 911 399 381 44 188 10 211 184 478 204 504 208 146 B01AC04 clopidogrel 25 178 26 429 28 372 29 470 28 302 34 <5 836 14 168 13 296 33 149 B01AC05 ticlopidine 429 420 327 273 229 48 0 0 93 136 622 B01AC06 acetylsalicylic acid 359 578 370 132 376 011 377 738 379 659 44 186 9 787 176 106 193 580 100 589 B01AC07 dipyridamole 18 072 18 755 19 310 19 501 19 708 44 0 316 7 530 11 862 21 802 B01AC09 epoprostenol 9 7 <5 <5 <5 2 605 B01AC21 treprostinil 9 9 9 8 9 78 0 7 <5 0 16 977 B01AC22 prasugrel 0 31 214 487 1 126 22 0 73 812 241 4 169 B01AC24 ticagrelor 0 0 0 26 2 335 26 0 104 1 435 796 9 654 B01AC30 combinations 2 230 5 557 8 788 11 324 13 193 44 <5 285 5 563 7 344 15 028 B01AC56 acetylsalicylic acid and esomeprazole 0 0 0 0 80 49 0 <5 35 44 28 B01AD Enzymes <5 Direct thrombin inhibitors <5 9 187 1 168 4 098 43 0 82 1 509 2 507 20 504 B01AE07 dabigatran etexilate <5 9 187 1 168 4 098 43 0 82 1 509 2 507 20 504 B01AF Direct factor Xa inhibitors 0 45 191 899 1 663 56 <5 139 769 754 3 288 B01AF01 rivaroxaban 0 45 191 899 1 329 54 <5 133 591 604 2 905 B01AF02 apixaban 0 0 0 0 335 61 0 6 178 151 383 B01AX Other antithrombotic agents 7 16 17 8 5 80 0 <5 0 <5 88 B01AX05 fondaparinux 7 16 17 8 5 80 0 <5 0 <5 88 B02 ANTIHEMORRHAGICS 12 599 12 439 12 210 12 954 13 285 92 277 6 474 5 855 679 204 832ATC group A ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.6 ATC group B - Blood and bloodforming organs ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 034 11 846 12 577 12 871 94 188 6 322 5 770 591 6 640 B02AA Amino acids 12 204 12 033 11 845 12 575 12 869 94 188 6 320 5 770 591 4 741 B02AA02 tranexamic acid 12 204 12 033 11 845 12 575 12 869 94 188 6 320 5 770 591 B02B VITAMIN K AND OTHER HEMOSTATICS 451 468 419 427 492 36 104 190 105 93 198 192 B02BA Vitamin K 263 275 212 208 212 65 34 69 36 73 121 B02BA01 phytomenadione 263 275 212 208 212 65 34 69 36 73 121 B02BB Fibrinogen 0 0 0 <5 <5 100 0 0 <5 0 95 B02BB01 fibrinogen, human 0 0 0 <5 <5 100 0 0 <5 0 95 B02BD Blood coagulation factors 188 187 189 190 238 8 70 113 49 6 188 203 B02BD01 coagulation factor IX, II, VII and X in factor VIII 138 129 134 132 166 1 54 77 33 <5 149 706 B02BD03 factor VIII inhibitor bypassing activity 6 0 0 <5 <5 <5 9 008 B02BD04 coagulation factor IX 23 30 28 30 37 0 10 21 5 <5 14 272 B02BD06 von Willebrand factor and coagulation factor VIII in combination 14 15 12 9 14 64 <5 7 <5 <5 5 049 B02BD07 coagulation factor 0 <5 100 0 0 <5 0 19 B02BD08 eptacog alfa (activated) <5 7 7 7 10 30 5 <5 <5 0 547 B02BD09 <5 0 <5 <5 <5 67 <5 0 0 3 843 B02BX Other systemic hemostatics 0 6 18 28 41 49 0 8 19 14 9 774 B02BX04 romiplostim 0 6 14 15 17 35 0 <5 6 7 6 566 B02BX05 eltrombopag 0 0 <5 15 25 60 0 5 13 7 3 208 B03 ANTIANEMIC PREPARATIONS 113 448 120 950 129 328 135 640 144 194 65 1 817 32 810 54 056 55 511 118 247 B03A IRON PREPARATIONS 20 058 22 178 24 019 25 072 25 520 68 1 098 7 042 5 518 11 862 7 957 B03AA Iron bivalent, oral preparations 18 754 20 801 22 588 23 597 23 942 67 1 092 6 216 5 026 11 608 6 111 B03AA01 ferrous glycine sulfate 1)2 024 2 892 3 574 4 189 4 937 70 52 1 666 1 182 2 037 2 495 B03AA02 ferrous fumarate1)1 337 1 333 1 320 1 324 1 281 50 852 192 75 162 198 B03AA03 ferrous gluconate 10 112 101 52 0 - 0 0 0 0 0 B03AA07 ferrous sulfate1)15 544 16 693 17 767 18 255 18 052 67 192 4 413 3 834 9 613 3 418 B03AC Iron trivalent, parenteral preparations 1 395 1 461 1 524 1 577 1 697 85 7 867 527 296 1 846B03AC01 ferric oxide polymaltose complexes 0 0 0 <5 18 72 0 11 5 <5 57 B03AC02 saccharated iron oxide 297 288 280 325 303 77 <5 132 99 70 404 B03AC06 ferric oxide dextran complexes 1 113 1 189 1 254 1 267 1 393 86 5 732 428 228 1 385 B03B VITAMIN B12 AND FOLIC ACID 94 767 100 602 107 727 113 339 121 848 65 732 27 036 48 951 45 129 33 291 B03BA Vitamin B12 (cyanocobal-amin and analogues) 65 578 69 156 76 095 79 008 85 251 67 127 19 579 31 782 33 763 19 251 B03BA01 cyanocobalamin 5 696 6 558 7 389 7 469 8 479 69 24 2 651 3 183 2 621 1 764 B03BA02 cyanocobalamin tannin complex 34 255 36 404 39 772 40 827 44 083 67 37 10 280 16 334 17 432 9 582 B03BA03 hydroxocobalamin 27 457 28 055 31 131 32 969 35 193 67 65 7 352 13 208 14 568 7 790 B03BA05 mecobalamin 26 16 38 91 125 75 5 66 50 <5 115 B03BB Folic acid and derivatives 34 058 36 595 36 321 39 074 41 579 61 617 8 204 18 841 13 917 14 040 B03BB01 folic acid 1)34 058 36 595 36 321 39 074 41 579 61 617 8 204 18 841 13 917 14 040 B03X OTHER ANTIANEMIC PREPARATIONS 3 520 3 639 3 485 3 456 3 427 40 36 309 1 228 1 854 76 999 B03XA Other antianemic preparations 3 520 3 639 3 485 3 456 3 427 40 36 309 1 228 1 854 76 999 B03XA01 erythropoietin 681 470 334 279 280 43 <5 25 106 146 6 056 B03XA02 darbepoetin alfa 2 716 2 785 2 714 2 704 2 859 39 33 263 1 022 1 541 62 233 B03XA03 methoxy polyethylene glycol-epoetin beta 230 452 475 516 445 40 0 40 160 245 8 710 B06 OTHER HEMATOLOGICAL AGENTS 31 49 54 52 81 60 <5 46 29 <5 26 099 B06A OTHER HEMATOLOGICAL AGENTS 31 49 54 52 81 60 <5 46 29 <5 26 099 B06AC Drugs used in hereditary angioedema 29 41 47 46 76 58 <5 42 28 <5 25 500 B06AC01 c1-inhibitor, plasma derived 29 39 37 29 44 64 <5 26 13 <5 15 650 B06AC02 icatibant 0 6 14 23 53 57 0 29 23 <5 9 148 B06AC04 conestat alfa 0 0 0 0 <5 75 0 <5 <5 0 702 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group B ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group B ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 SYSTEM 917 229 945 886 975 141 998 461 1 018 128 51 6 118 95 480 532 968 383 562 1 691 608 C01 CARDIAC THERAPY 129 660 124 930 122 995 120 544 118 979 48 4 373 8 331 40 218 66 057 82 799 C01A CARDIAC GLYCOSIDES 27 043 25 820 24 749 23 214 20 073 49 36 133 3 682 16 222 5 024 C01AA Digitalis glycosides 27 043 25 820 24 749 23 214 20 073 49 36 133 3 682 16 222 5 024 C01AA04 digitoxin 25 926 24 736 23 709 22 197 14 045 49 0 65 2 364 11 616 3 467 C01AA05 digoxin 1 144 1 123 1 068 1 084 10 585 49 36 93 2 176 8 280 1 557 C01B ANTIARRHYTHMICS, CLASS I AND III 9 879 10 321 11 688 12 400 13 113 35 52 607 7 110 5 344 25 468 C01BA Antiarrhythmics, class Ia 184 173 159 131 121 54 0 5 46 70 303 C01BA01 quinidine 5 <5 <5 <5 28 C01BA03 disopyramide 179 170 156 126 117 52 0 5 45 67 276 C01BB Antiarrhythmics, class Ib 26 23 17 17 18 39 0 5 9 <5 129 C01BB01 lidocaine 0 0 0 0 <5 100 0 0 <5 0 0 C01BB02 mexiletine 26 23 17 17 17 35 0 5 8 <5 129 C01BC Antiarrhythmics, class Ic 5 517 5 783 6 393 6 735 7 030 39 48 446 4 434 2 102 13 605 C01BC03 propafenone <5 <5 7 C01BC04 flecainide 5 515 5 780 6 390 6 730 7 027 39 48 445 4 432 2 102 13 598 C01BD Antiarrhythmics, class III 4 273 4 475 5 432 5 809 6 265 30 <5 166 2 839 3 256 11 431 C01BD01 amiodarone 4 273 4 475 4 853 4 912 5 232 28 <5 136 2 230 2 862 4 033 C01BD07 dronedarone 0 0 767 1 034 1 166 36 0 34 694 438 7 398 C01C CARDIAC STIMU-LANTS EXCL. CARDIAC GLYCOSIDES 12 191 12 217 14 121 15 618 18 359 58 4 286 6 466 6 259 1 348 12 596 C01CA Adrenergic and dopaminergic agents 12 191 12 217 14 121 15 618 18 359 58 4 286 6 466 6 259 1 348 12 596 C01CA01 etilefrine 115 114 95 112 110 61 0 33 44 33 260 C01CA02 isoprenaline 0 0 0 0 <5 100 0 <5 0 0 1 C01CA03 norepinephrine <5 0 0 0 0 - 0 0 0 0 0 C01CA17 midodrine 14 14 16 20 20 70 0 13 6 <5 156 C01CA24 epinephrine 12 058 12 082 14 006 15 480 18 221 58 4 286 6 417 6 204 1 314 12 158 C01CA26 ephedrine 6 7 6 8 8 0 0 <5 6 0 22 C01D VASODILATORS USED IN CARDIAC DISEASES 88 490 83 930 79 479 75 844 73 206 47 <5 1 167 24 434 47 604 39 683 C01DA Organic nitrates 88 490 83 930 79 479 75 844 73 206 47 <5 1 167 24 434 47 604 39 683 C01DA02 glyceryl trinitrate 68 613 65 061 60 717 58 282 56 554 46 <5 1 097 21 351 34 105 13 835 C01DA08 isosorbide dinitrate 3 257 2 787 2 311 1 950 1 703 53 0 <5 234 1 465 1 278 C01DA14 isosorbide mononitrate 38 046 35 905 34 145 31 873 30 269 51 0 129 6 202 23 938 24 570 C01E OTHER CARDIAC PREPARATIONS 133 138 138 67 11 64 0 <5 6 <5 27 C01EB Other cardiac preparations 133 138 138 67 11 64 0 <5 6 <5 27C01EB09 ubidecarenone 123 129 126 59 0 - 0 0 0 0 0 C01EB15 trimetazidine 10 9 10 6 7 57 0 <5 5 <5 9 C01EB17 ivabradine 0 0 0 75 0 <5 <5 0 18 C02 ANTIHYPERTENSIVES 17 795 17 689 17 442 17 597 17 535 27 21 724 8 268 8 522 60 883 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING 7 114 6 702 6 469 6 521 6 512 41 <5 322 3 622 2 567 6 118 C02AB Methyldopa 1 084 410 141 107 88 68 0 37 28 23 210 C02AB01 methyldopa (levorotatory) 1 084 410 141 107 88 68 0 37 28 23 210 C02AC Imidazoline receptor agonists 6 119 6 347 6 340 6 427 6 432 40 <5 285 3 601 2 545 5 909 C02AC01 clonidine 74 78 64 85 77 55 <5 26 41 9 95 C02AC05 moxonidine 6 045 6 269 6 276 6 342 6 356 40 0 259 3 561 2 536 5 814 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 10 920 11 234 11 221 11 285 11 258 18 0 370 4 842 6 046 13 981 C02CA Alpha-adrenoreceptor antagonists 10 920 11 233 11 221 11 285 11 258 18 0 370 4 842 6 046 13 981 C02CA04 doxazosin 10 920 11 233 11 221 11 285 11 258 18 0 370 4 842 6 046 13 981 C02CC Guanidine derivatives 0 <5 0 0 0 - 0 0 0 0 0 C02CC02 guanethidine 0 <5 0 0 0 - 0 0 0 0 0 C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 331 319 301 317 318 36 5 16 134 163 320 C02DB Hydrazinophthalazine derivatives 300 285 270 288 294 37 5 11 119 159 200 C02DB02 hydralazine 300 285 270 288 294 37 5 11 119 159 200 C02DC Pyrimidine derivatives 31 34 32 29 23 26 0 5 15 <5 120 C02DC01 minoxidil 31 34 32 29 23 26 0 5 15 <5 120 C02DD Nitroferricyanide derivatives 0 0 0 0 <5 100 0 0 0 <5 0 C02DD01 nitroprusside 0 0 0 0 <5 100 0 0 0 <5 0 C02K OTHER ANTIHYPERTENSIVES 106 119 142 161 177 68 15 52 77 33 40 464 C02KD Serotonin antagonists 22 18 19 20 14 93 0 <5 9 <5 479 C02KD01 ketanserin 22 18 19 20 14 93 0 <5 9 <5 479 C02KX Other antihypertensives 85 102 124 142 165 67 15 51 69 30 39 985 C02KX01 bosentan 83 91 103 114 123 65 15 41 46 21 28 341 C02KX02 ambrisentan <5 12 19 33 46 74 0 12 24 10 11 644 C02KX03 sitaxentan <5 0 <5 0 0 - 0 0 0 0 0 C03 DIURETICS 233 975 235 555 223 842 208 905 201 658 60 185 8 578 77 149 115 746 86 711 C03A LOW-CEILING DIURETICS, THIAZIDES 71 861 74 216 66 001 53 889 49 010 61 9 2 089 25 098 21 814 22 523 C03AA Thiazides, plain 44 489 45 271 36 364 16 033 14 920 58 <5 727 7 734 6 455 4 2762.7 ATC group C - Cardiovascular system ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group C ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 0 - 0 0 0 0 0 C03AA03 hydrochlorothiazide 13 766 13 625 16 731 16 032 14 920 58 <5 727 7 734 6 455 4 276 C03AB Thiazides and potassium in combination 28 814 30 363 41 642 38 130 34 245 62 5 1 370 17 433 15 437 18 247 C03AB01 bendroflumethiazide and potassium 28 814 30 363 41 642 38 130 34 245 62 5 1 370 17 433 15 437 18 247 C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES 6 6 5 6 8 38 0 0 <5 5 23 C03BA Sulfonamides, plain 6 6 5 6 8 38 0 0 <5 5 23 C03BA04 chlortalidone 6 6 5 6 6 50 0 0 <5 <5 20 C03BA08 metolazone 0 0 0 0 0 0 <5 3 C03C HIGH-CEILING DIURETICS 128 686 127 997 127 391 125 517 125 149 60 162 5 266 38 460 81 261 46 848 C03CA Sulfonamides, plain 128 686 127 997 127 391 125 517 125 149 60 162 5 266 38 460 81 261 46 848 C03CA01 furosemide 104 728 101 621 99 010 95 661 93 391 62 161 4 466 30 306 58 458 19 852 C03CA02 bumetanide 28 833 31 193 33 444 34 790 36 730 53 <5 909 9 281 C03D POTASSIUM-SPARING AGENTS 17 302 17 602 17 636 17 868 18 190 48 23 921 7 110 10 136 11 983 C03DA Aldosterone antagonists 17 287 17 589 17 623 17 851 18 175 48 22 919 7 104 10 130 11 842 C03DA01 spironolactone 16 795 17 028 17 038 17 160 17 397 50 22 861 6 650 9 864 6 865 C03DA02 potassium canrenoate 0 0 <5 <5 0 - 0 0 0 0 0 C03DA04 eplerenone 579 658 678 798 912 13 0 65 532 315 4 978 C03DB Other potassium-sparing agents 15 18 18 22 16 31 <5 <5 7 6 141 C03DB01 amiloride 15 18 18 22 16 31 <5 <5 7 6 141 C03E DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION 35 388 34 026 31 692 28 452 25 722 66 14 704 11 796 13 208 4 600 C03EA Low-ceiling diuretics and potassium-sparing agents 35 388 34 026 31 692 28 452 25 722 66 14 704 11 796 13 208 4 600 C03EA01 hydrochlorothiazide and potassium-sparing agents 35 388 34 026 31 692 28 452 25 722 66 14 704 11 796 13 208 4 600 C03X OTHER DIURETICS 0 0 <5 <5 17 59 0 <5 8 8 734 C03XA Vasopressin antagonists 0 0 <5 <5 17 59 0 8 8 734 C03XA01 tolvaptan 0 0 <5 <5 17 59 0 <5 8 8 734 C04 PERIPHERAL VASODILATORS 1 524 1 340 1 165 1 019 926 45 0 22 265 639 965 C04A PERIPHERAL VASODILATORS 1 524 1 340 1 165 1 019 926 45 0 22 265 639 965 C04AD Purine derivatives 1 520 1 334 1 160 1 018 925 45 0 22 264 639 961 C04AD03 pentoxifylline 1 520 1 334 1 160 1 018 925 45 0 22 264 639 961 C04AX Other peripheral vasodilators <5 6 5 0 <5 0 4 C05 VASOPROTECTIVES 55 015 56 622 59 372 62 337 61 591 57 732 25 015 24 911 10 933 11 731 C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE 49 681 51 350 54 315 56 902 56 107 56 686 24 078 22 582 8 761 9 887 C05AA Corticosteroids 48 507 49 667 52 387 54 740 53 649 56 648 22 920 21 590 8 491 7 242 C05AA01 hydrocortisone 1)9 924 9 649 9 749 9 666 11 127 54 219 4 491 4 495 1 922 2 194 C05AA04 prednisolone1)40 337 41 682 44 303 46 731 45 152 56 441 19 553 18 131 7 027 5 048 C05AE Muscle relaxants 1 360 2 137 2 732 2 893 3 160 52 28 1 547 1 334 251 2 428 C05AE01 glyceryl trinitrate 1 360 2 137 2 732 2 893 3 160 52 28 1 547 1 334 251 2 428 C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use 993 901 826 852 1 132 55 23 476 397 236 218 C05AX03 other preparations, combinations 963 885 807 832 1 110 55 23 459 392 236 180 C05B ANTIVARICOSE THERAPY 5 555 5 490 5 250 5 664 5 651 67 46 993 2 386 2 226 1 819 C05BA Heparins or heparinoids for topical use 5 551 5 486 5 245 5 654 5 646 67 46 992 2 382 2 226 1 816 C05BA01 organo-heparinoid 1)5 525 5 462 5 211 5 627 5 615 67 46 989 2 366 2 214 715 C05BA04 pentosan polysulfate sodium 26 25 34 27 31 90 0 <5 16 12 1 101 C05BB Sclerosing agents for local injection <5 <5 5 10 0 <5 <5 0 3 C05BB02 polidocanol <5 <5 0 <5 <5 0 3 C05C CAPILLARY STABILIZING AGENTS 0 0 0 0 48 83 0 <5 22 24 25 C05CA Bioflavonoids 0 0 0 0 <5 100 0 0 <5 <5 3 C05CA01 rutoside 0 0 0 0 0 0 <5 <5 3 C05CX Other capillary stabilizing agents 0 0 0 0 45 82 0 <5 21 22 22 C05CX03 Hippocastani semen 0 0 0 0 45 82 0 <5 21 22 22 C07 BETA BLOCKING AGENTS 351 983 356 313 361 077 364 247 368 143 49 403 20 475 165 793 181 472 177 261 C07A BETA BLOCKING AGENTS 346 545 350 748 355 652 359 141 363 574 49 403 20 242 162 961 179 968 174 105 C07AA Beta blocking agents, non-selective 27 359 25 833 24 967 24 720 24 299 59 150 4 748 10 520 8 881 11 579 C07AA03 pindolol 31 28 28 26 20 70 0 <5 9 9 31 C07AA05 propranolol 16 403 16 540 16 856 17 413 17 616 64 140 4 549 8 127 4 800 7 350 C07AA06 timolol 1 337 636 13 082 7 269 6 703 47 <5 185 2 415 4 099 4 061 C07AA12 nadolol 12 13 17 29 39 59 8 25 5 <5 119 C07AB Beta blocking agents, selective 299 225 305 475 311 151 315 104 320 560 49 240 13 546 143 471 163 303 145 695 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group C ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group C ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 953 256 754 261 252 266 647 48 221 11 348 120 115 134 963 124 642 C07AB03 atenolol 42 914 39 561 36 754 33 974 31 783 59 17 1 381 13 484 16 901 8 014 C07AB07 bisoprolol 15 502 18 388 21 004 23 115 25 371 46 <5 973 11 271 13 125 13 039 C07AG Alpha and beta blocking agents 24 683 24 389 23 887 23 378 22 876 45 24 2 305 10 823 9 724 16 831 C07AG01 labetalol 2 173 2 324 2 392 2 447 2 468 81 5 1 548 580 335 2 277 C07AG02 carvedilol 22 530 22 092 21 525 20 958 20 426 41 19 768 10 249 9 390 14 553 C07B BETA BLOCKING AGENTS AND THIAZIDES 5 991 6 057 5 815 5 485 5 212 55 0 270 3 163 1 779 3 156 C07BB Beta blocking agents, selective, and thiazides 5 991 6 057 5 815 5 485 5 212 55 0 270 3 163 1 779 3 156 C07BB07 bisoprolol and thiazides 5 991 6 057 5 815 5 485 5 212 55 0 270 3 163 1 779 3 156 C08 CALCIUM CHANNEL BLOCKERS 208 610 214 671 221 256 224 233 229 861 48 73 9 156 110 219 110 413 147 484 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS 185 199 192 742 200 625 205 165 211 928 48 65 8 392 103 503 99 968 129 687 C08CA Dihydropyridine derivatives 185 199 192 742 200 625 205 165 211 928 48 65 8 392 103 503 99 968 129 687 C08CA01 amlodipine 113 649 115 250 119 283 121 607 125 737 46 42 4 246 61 169 60 280 53 934 C08CA02 felodipine 17 106 16 692 16 309 16 008 15 415 51 0 382 6 738 8 295 11 371 C08CA03 isradipine 955 C08CA05 nifedipine 28 302 29 940 31 649 32 708 34 526 49 22 2 577 16 871 15 056 40 428 C08CA06 nimodipine 36 32 44 51 56 54 0 13 39 <5 46 C08CA13 lercanidipine 28 958 33 491 36 038 37 460 39 034 51 <5 1 337 20 132 17 564 22 953 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 24 757 23 260 21 851 20 196 19 100 56 8 792 7 141 11 159 17 797 C08DA Phenylalkylamine derivatives 18 204 17 237 16 444 15 365 14 673 56 8 715 5 469 8 481 9 501 C08DA01 verapamil 18 204 17 237 16 444 15 365 14 673 56 8 715 5 469 8 481 9 501 C08DB Benzothiazepine derivatives 6 633 6 091 5 473 4 875 4 462 55 0 79 1 684 2 699 8 296 C08DB01 diltiazem 6 633 6 091 5 473 4 875 4 462 55 0 79 1 684 2 699 8 296 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 452 974 473 388 498 501 517 053 534 991 48 437 28 634 291 236 214 684 697 864 C09A ACE INHIBITORS, PLAIN 123 584 125 439 130 265 132 249 134 580 41 375 7 268 63 202 63 735 58 498 C09AA ACE inhibitors, plain 123 584 125 439 130 265 132 249 134 580 41 375 7 268 63 202 63 735 58 498 C09AA01 captopril 3 500 3 233 2 858 2 509 2 178 45 160 90 713 1 215 3 975 C09AA02 enalapril 42 623 43 095 45 453 45 871 46 428 46 211 3 043 22 424 20 750 18 352 C09AA03 lisinopril 27 936 27 084 26 749 26 060 25 476 47 <5 1 448 12 445 11 581 11 081 C09AA05 ramipril 50 153 52 684 55 804 58 431 61 100 35 6 2 721 27 854 30 519 24 895C09AA10 trandolapril 119 111 92 85 83 23 0 6 44 33 194 C09B ACE INHIBITORS, COMBINATIONS 35 757 35 260 35 985 35 727 35 191 49 <5 1 197 18 012 15 981 26 059 C09BA ACE inhibitors and diuretics 35 757 35 023 35 193 34 459 33 691 49 <5 1 106 17 141 15 443 24 254 C09BA02 enalapril and diuretics 20 161 20 154 20 520 20 244 20 030 48 <5 719 10 335 8 975 15 189 C09BA03 lisinopril and diuretics 15 625 14 889 14 697 14 237 13 702 49 0 388 6 828 6 486 9 066 C09BB ACE inhibitors and calcium channel blockers 0 259 820 1 307 1 533 45 0 93 890 550 1 804 C09BB02 enalapril and lercanidipine 0 259 820 1 307 1 533 45 0 93 890 550 1 804 C09C ANGIOTENSIN II ANTAGONISTS, PLAIN 162 375 168 742 180 140 187 470 197 152 51 86 14 228 111 285 71 553 256 856 C09CA Angiotensin II antagonists, plain 162 375 168 742 180 140 187 470 197 152 51 86 14 228 111 285 71 553 256 856 C09CA01 losartan 44 127 42 955 51 872 57 364 61 555 51 35 3 836 34 114 23 570 38 193 C09CA02 eprosartan 2 386 2 322 2 063 1 785 1 601 52 0 54 726 821 3 129 C09CA03 valsartan 20 016 20 380 20 748 22 462 25 144 47 0 1 656 14 555 8 933 29 423 C09CA04 irbesartan 23 422 22 328 21 419 20 347 19 729 50 <5 907 11 227 7 594 39 468 C09CA06 candesartan 67 536 74 704 78 234 79 742 83 507 53 47 7 451 47 274 28 735 130 946 C09CA07 telmisartan 5 222 5 866 5 988 5 977 5 825 44 0 338 3 423 2 064 12 375 C09CA08 olmesartan medoxomil 1 539 1 751 1 680 1 642 1 640 50 <5 145 1 013 479 3 322 C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 172 489 184 232 195 551 202 970 210 260 49 <5 8 297 122 298 79 664 356 224 C09DA Angiotensin II antagonists and diuretics 168 660 174 848 179 893 180 857 181 843 51 <5 6 478 104 187 71 177 277 942 C09DA01 losartan and diuretics 64 598 63 952 66 088 66 981 67 478 53 <5 2 219 37 118 28 140 49 994 C09DA02 eprosartan and diuretics 1 840 2 042 1 924 1 774 1 661 48 0 54 889 718 3 569 C09DA03 valsartan and diuretics 24 767 25 424 25 643 25 522 25 924 49 0 992 15 106 9 826 43 312 C09DA04 irbesartan and diuretics 31 288 31 418 30 818 29 807 28 619 50 0 794 16 166 11 659 66 770 C09DA06 candesartan and diuretics 43 908 48 685 51 649 52 876 54 252 50 0 2 272 32 537 19 443 102 210 C09DA07 telmisartan and diuretics 3 320 3 724 3 991 3 940 3 818 41 0 146 2 337 1 335 9 779 C09DA08 olmesartan medoxomil and diuretics 813 1 144 1 124 1 146 1 116 49 0 42 700 374 2 308 C09DB Angiotensin II antagonists and calcium channel blockers 5 351 11 764 16 484 18 665 21 164 41 0 1 350 13 400 6 414 46 202 C09DB01 valsartan and amlodipine 5 351 11 764 16 483 18 494 20 892 41 0 1 323 13 226 6 343 45 572 C09DB02 olmesartan medoxomil and amlodipine 0 0 <5 185 277 40 0 28 177 72 630 C09DX Angiotensin II antagonists, other combinations 0 0 4 017 8 368 12 224 38 0 775 7 855 3 594 32 080 C09DX01 valsartan, amlodipine and hydrochlorothiazide 0 0 4 017 8 368 12 224 38 0 775 7 855 3 594 32 080ATC group C ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group C ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 47 93 93 84 78 40 0 <5 50 24 226 C09XA Renin-inhibitors 47 93 93 84 78 40 0 <5 50 24 226 C09XA02 aliskiren 47 93 92 84 78 40 0 <5 50 24 226 C09XA52 aliskiren and hydrochlorothiazide 0 0 <5 0 0 - 0 0 0 0 0 C10 LIPID MODIFYING AGENTS 426 023 452 790 478 362 495 451 503 792 46 140 21 097 277 221 205 334 425 910 C10A LIPID MODIFYING AGENTS, PLAIN 425 411 452 090 477 639 494 337 501 407 46 140 21 008 275 643 204 616 414 305 C10AA HMG CoA reductase inhibitors 421 813 447 810 472 860 488 704 494 804 46 124 20 233 271 846 202 601 312 627 C10AA01 simvastatin 348 045 356 768 349 782 336 480 314 174 47 21 10 729 161 726 141 698 129 817 C10AA02 lovastatin 1 715 1 424 1 260 1 134 1 048 57 0 16 408 624 1 633 C10AA03 pravastatin 23 056 22 329 21 340 20 827 20 320 49 6 468 9 745 10 101 22 197 C10AA04 fluvastatin 7 268 7 465 7 510 7 474 7 443 47 <5 544 4 303 2 595 12 232 C10AA05 atorvastatin 59 209 79 686 112 783 140 852 166 510 44 74 8 714 104 759 52 963 126 152 C10AA07 rosuvastatin 355 571 2 115 4 420 6 708 45 23 738 4 584 1 363 20 595 C10AB Fibrates 328 317 331 317 314 30 <5 61 223 29 1 749 C10AB02 bezafibrate 70 64 58 49 50 36 0 <5 39 7 174 C10AB04 gemfibrozil 105 101 104 103 93 28 0 14 66 13 920 C10AB05 fenofibrate 156 154 170 167 173 29 <5 43 120 9 656 C10AC Bile acid sequestrants 2 134 2 090 2 238 2 413 2 438 54 13 491 1 323 611 7 818 C10AC01 colestyramine 1 563 1 566 1 686 1 817 1 795 58 12 426 904 453 2 274 C10AC02 colestipol 384 308 292 273 280 44 <5 15 156 108 743 C10AC04 colesevelam 204 237 280 351 406 43 0 57 291 58 4 801 C10AD Nicotinic acid and derivatives 234 285 396 391 350 26 0 46 264 40 1 451 C10AD02 nicotinic acid 216 218 153 107 30 30 0 5 22 <5 473 C10AD06 acipimox 20 11 12 9 9 22 0 0 8 <5 50 C10AD52 nicotinic acid, combinations 0 69 249 301 314 25 0 42 236 36 929 C10AX Other lipid modifying agents 12 591 14 589 16 505 19 315 22 152 43 <5 1 758 14 895 5 495 90 659 C10AX06 omega-3-triglycerides incl. other esters and acids 2 417 754 3 038 3 591 3 988 30 <5 585 2 851 550 25 873 C10AX09 ezetimibe 10 425 12 126 13 819 16 166 18 703 45 <5 1 215 12 471 5 015 64 786 C10B LIPID MODIFYING AGENTS, COMBINATIONS <5 0 81 1 370 2 661 40 0 138 1 791 732 9 017 C10BA HMG CoA reductase inhibitors in combination with other lipid modifying agents <5 0 81 1 370 2 661 40 0 138 1 791 732 9 017 C10BA02 simvastatin and ezetimibe <5 0 81 1 370 2 661 40 0 138 1 791 732 9 017D DERMATOLOGICALS 589 450 587 812 611 440 624 493 628 955 54 76 390 237 819 212 640 102 106 235 358 D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 113 854 111 682 116 703 120 515 120 328 47 11 029 44 592 44 169 20 538 30 895 D01A ANTIFUNGALS FOR TOPICAL USE 98 958 96 750 101 082 105 109 104 211 48 10 771 38 328 36 418 18 694 16 014 D01AA Antibiotics 3 467 219 54 52 36 81 <5 20 7 5 7 D01AA01 nystatin 3 467 219 54 52 36 81 <5 20 7 5 7 D01AC Imidazole and triazole derivatives 73 508 74 998 79 238 83 294 82 436 48 8 769 29 659 28 475 15 533 10 378 D01AC01 clotrimazole 1)8 369 8 811 9 516 8 746 7 893 52 1 076 2 754 2 109 1 954 1 185 D01AC02 miconazole1)1 927 1 880 2 121 2 193 1 909 46 256 664 645 344 309 D01AC03 econazole1)2 197 2 177 1 119 588 691 61 34 127 230 300 88 D01AC08 ketoconazole1)15 005 14 992 15 121 16 258 16 162 41 1 023 7 241 5 739 2 159 2 691 D01AC20 combinations1)49 639 50 909 55 208 59 481 59 415 49 6 671 20 211 20 957 11 576 6 105 D01AC60 bifonazole, combinations <5 0 0 0 0 - 0 0 0 0 0 D01AE Other antifungals for topical use 24 966 24 330 24 671 24 755 24 760 46 2 250 9 785 9 000 3 725 5 628 D01AE02 methylrosaniline 1)716 696 694 751 687 159 75 D01AE14 ciclopirox1)14 <5 <5 13 47 55 6 23 12 6 9 D01AE15 terbinafine1)17 148 16 909 17 514 17 812 18 128 43 1 804 7 785 5 984 2 555 3 074 D01AE16 amorolfine 7 481 7 081 6 829 6 520 6 226 55 286 1 929 2 959 1 052 2 470 D01B ANTIFUNGALS FOR SYSTEMIC USE 18 326 18 300 19 232 19 020 19 723 40 375 7 809 9 301 2 238 14 881 D01BA Antifungals for systemic use 18 326 18 300 19 232 19 020 19 723 40 375 7 809 9 301 2 238 14 881 D01BA01 griseofulvin 16 19 15 19 21 48 19 <5 0 0 10 D01BA02 terbinafine 18 314 18 285 19 222 19 009 19 705 40 359 7 807 9 301 2 238 14 871 D02 EMOLLIENTS AND PROTECTIVES 1 750 1 841 2 223 2 338 2 503 51 381 848 803 471 921 D02A EMOLLIENTS AND PROTECTIVES 1 750 1 841 2 223 2 338 2 503 51 381 848 803 471 921 D02AB Zinc products 1)10 6 10 15 6 50 0 <5 <5 <5 1 D02AE Carbamide products 459 670 859 971 1 173 53 146 438 338 251 610 D02AE01 carbamide1)459 670 859 971 1 173 53 146 438 338 251 610 D02AF Salicylic acid preparations 1 197 1 048 1 229 1 206 1 154 50 128 373 449 204 176 D02AX Other emollients and protectives 93 125 148 168 221 49 122 51 29 19 134 D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 143 91 60 68 80 49 5 10 33 32 20 D03A CICATRIZANTS 143 91 60 68 80 49 5 10 33 32 20 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group C ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.8 ATC group D - Dermatologicals ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 7 0 0 0 - 0 0 0 0 0 D03AX Other cicatrizants 89 84 60 68 80 49 5 10 33 32 20 D03AX03 dexpanthenol 89 84 60 68 80 49 5 10 33 32 20 D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 3 195 3 676 3 871 4 259 4 297 66 497 1 723 1 181 896 829 D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 3 195 3 676 3 871 4 259 4 297 66 497 1 723 1 181 896 829 D04AA Antihistamines for mepyramine <5 0 0 0 0 0 0 0 D04AA13 dimetindene 6 D04AB Anesthetics for topical use 2 094 2 637 2 798 3 097 3 650 68 373 1 586 1 034 657 751 D04AB01 lidocaine 1)2 094 2 637 2 798 3 097 3 650 68 373 1 586 1 034 657 751 D04AX Other antipruritics 1 119 1 052 1 093 1 169 662 57 125 141 154 242 73 D05 ANTIPSORIATICS 26 570 27 497 29 930 31 269 31 690 45 487 9 644 16 319 5 240 46 972 D05A ANTIPSORIATICS FOR TOPICAL USE 25 328 26 165 28 654 29 921 30 239 45 481 9 337 15 400 5 021 39 093 D05AA Tars 1)1 007 980 1 044 1 017 900 60 75 279 325 221 230 D05AC Antracen derivatives 15 11 9 7 <5 33 <5 0 <5 <5 1 D05AC01 0 <5 <5 1 D05AD Psoralens for topical use 10 6 <5 0 0 - 0 0 0 0 0 D05AD01 trioxysalen 10 6 <5 0 0 - 0 0 0 0 0 D05AX Other antipsoriatics for topical use 24 515 25 359 27 804 29 076 29 508 45 406 9 125 15 155 4 822 38 862 D05AX02 calcipotriol 9 932 8 744 8 029 5 640 2 223 40 24 514 1 225 460 1 103 D05AX03 calcitriol 1 125 1 084 1 127 1 092 1 170 49 30 322 629 189 827 D05AX52 calcipotriol, combinations 17 660 19 312 22 343 25 237 27 735 45 376 8 729 14 178 4 452 36 933 D05B ANTIPSORIATICS FOR SYSTEMIC USE 1 765 1 886 1 880 1 943 2 106 43 6 487 1 302 311 7 880 D05BA Psoralens for systemic use 35 34 40 32 26 46 0 9 13 <5 23 D05BA02 methoxsalen 29 33 35 29 26 46 0 9 13 <5 23 D05BA03 bergapten 7 <5 5 <5 0 - 0 0 0 0 0 D05BB Retinoids for treatment of psoriasis 1 709 1 819 1 808 1 866 2 019 43 6 454 1 257 302 5 447 D05BB02 acitretin 1 709 1 819 1 808 1 866 2 019 43 6 454 1 257 302 5 447 D05BX Other antipsoriatics for systemic use 25 41 42 50 71 39 0 28 38 5 2 410 D05BX51 fumaric acid derivatives, combinations 25 41 42 50 71 39 0 28 38 5 2 410D06 ANTIBIOTICS AND CHEMO - THERAPEUTICS FOR DERMATOLOGICAL USE 108 179 105 182 111 213 113 829 110 220 58 13 393 44 931 34 713 17 183 22 713 D06A ANTIBIOTICS FOR TOPICAL USE 57 269 54 026 58 829 61 008 58 208 56 11 228 18 497 18 127 10 356 5 123 D06AA Tetracycline and derivatives 2 844 2 682 2 729 2 878 2 916 56 374 868 1 077 597 368 D06AA02 chlortetracycline 16 23 19 28 27 44 <5 12 10 <5 9 D06AA03 oxytetracycline 2 828 2 2 710 56 373 856 1 069 593 359 D06AX Other antibiotics for topical use 54 594 51 499 56 239 58 299 55 451 56 10 874 17 683 17 102 9 792 4 755 D06AX01 fusidic acid 52 409 49 106 53 684 55 137 52 776 56 9 914 16 874 16 584 9 404 4 367 D06AX05 bacitracin 1 972 1 802 1 739 2 378 1 961 50 614 611 396 340 241 D06AX09 mupirocin 19 17 14 31 40 60 9 20 8 <5 8 D06AX13 retapamulin 374 746 1 008 1 005 867 56 407 227 155 78 138 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE 52 801 53 024 54 414 54 942 53 937 61 2 300 27 197 17 220 7 220 17 590 D06BA Sulfonamides 3 491 3 202 3 373 3 410 3 549 53 605 1 199 1 083 662 526 D06BA01 silver sulfadiazine 3 491 3 202 3 373 3 410 3 549 53 605 1 199 1 083 662 526 D06BB Antivirals 41 381 41 307 41 885 40 813 38 973 59 1 515 21 842 10 765 4 851 15 188 D06BB03 aciclovir 1)20 673 20 098 19 696 18 274 16 749 72 1 051 7 824 6 245 1 629 2 803 D06BB04 podophyllotoxin 13 170 13 402 13 567 13 738 12 921 46 135 11 559 1 170 57 2 761 D06BB06 penciclovir1)5 031 4 000 3 349 2 738 1 885 70 82 761 792 250 378 D06BB10 imiquimod 3 407 4 705 6 196 7 040 8 404 53 257 2 515 2 682 2 950 9 246 D06BB11 docosanol 6 <5 0 0 0 - 0 0 0 0 0 D06BX Other chemotherapeutics 8 151 8 721 9 426 11 017 11 719 68 185 4 275 5 500 1 759 1 875 D06BX01 metronidazole 8 151 8 721 9 426 11 017 11 719 68 185 4 275 5 500 1 759 1 875 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 349 460 347 215 359 113 361 203 363 604 54 50 502 112 261 131 827 69 014 80 509 D07A CORTICOSTEROIDS, PLAIN 285 574 286 433 299 004 300 645 309 061 55 45 086 94 992 110 582 58 401 62 344 D07AA Corticosteroids, weak (group I) 27 439 26 763 28 352 28 849 29 943 55 12 978 8 072 5 282 3 611 3 513 D07AA02 hydrocortisone 1)27 439 26 763 28 352 28 849 29 943 55 12 978 8 072 5 282 3 611 3 513 D07AB Corticosteroids, moder-ately potent (group II) 95 779 96 512 102 087 102 552 101 418 55 23 183 30 541 30 188 17 506 13 653 D07AB02 hydrocortisone butyrate 64 610 64 889 67 907 70 580 96 967 55 22 518 29 405 28 446 16 598 13 016 D07AB08 desonide 32 620 33 079 35 702 33 950 5 819 52 908 1 444 2 269 1 198 636 D07AC Corticosteroids, potent (group III) 154 910 153 609 158 099 157 096 164 253 54 16 662 52 893 61 606 33 092 33 425 D07AC01 betamethasone 52 701 50 086 52 441 54 076 58 061 54 3 624 18 633 23 359 12 445 7 710 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group D ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 13 701 12 998 12 647 53 533 3 490 5 549 3 075 4 816 D07AC04 fluocinolone acetonide 7 162 6 572 6 500 6 008 5 844 53 194 1 237 2 652 1 761 1 065 D07AC08 fluocinonide 872 792 724 670 601 50 9 113 307 172 113 D07AC13 mometasone 71 674 74 342 78 920 78 528 82 615 54 10 993 27 724 28 672 15 226 16 551 D07AC17 fluticasone 16 949 15 468 13 078 11 896 12 032 54 1 965 4 076 3 843 2 148 3 169 D07AD Corticosteroids, very potent (group IV) 48 233 49 945 52 825 54 584 57 304 56 1 779 17 359 26 948 11 218 11 753 D07AD01 clobetasol 48 233 49 945 52 825 54 584 57 304 56 1 779 17 359 26 948 11 218 11 753 D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS 41 193 37 064 36 056 37 823 29 301 49 3 019 9 020 11 115 6 147 3 019 D07BB Corticosteroids, moderately potent, combinations with antiseptics 29 399 17 785 15 445 15 218 194 51 37 49 62 46 24 D07BB02 desonide and antiseptics 13 954 17 619 15 445 15 217 194 51 37 49 62 46 24 D07BB03 triamcinolone and antisep - tics <5 0 0 <5 0 - 0 0 0 0 0 D07BB04 hydrocortisone butyrate and antiseptics 15 968 193 0 0 0 - 0 0 0 0 0 D07BC Corticosteroids, potent, combinations with antiseptics 13 184 20 114 21 373 23 508 29 135 49 2 988 8 975 11 063 6 109 2 996 D07BC01 betamethasone and anti-septics 9 686 17 301 18 864 21 243 26 780 49 2 789 8 334 10 054 5 603 2 770 D07BC02 fluocinolone acetonide and antiseptics 3 872 2 918 2 601 2 358 2 463 48 206 670 1 054 533 226 D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS 26 606 26 357 26 769 26 158 26 106 54 5 096 7 674 8 539 4 797 3 243 D07CA Corticosteroids, weak, combinations with antibiotics 25 877 26 351 26 768 26 158 26 102 54 5 096 7 672 8 538 4 796 3 242 D07CA01 hydrocortisone and anti-biotics 25 877 26 351 26 768 26 158 26 102 54 5 096 7 672 8 538 4 796 3 242 D07CC Corticosteroids, potent, combinations with antibiotics 768 6 <5 D07CC05 fluocinonide and antibiotics 0 0 0 0 <5 100 0 <5 0 0 1 D07X CORTICOSTEROIDS, OTHER COMBINATIONS 27 135 26 626 26 439 25 912 26 232 49 784 8 835 11 591 5 022 11 902 D07XB Corticosteroids, moderately potent, other combinations 556 0 0 0 0 - 0 0 0 0 0 D07XB02 triamcinolone 556 0 0 0 0 - 0 0 0 0 0D07XC Corticosteroids, potent, other combinations 26 672 26 626 26 439 25 912 26 232 49 784 8 835 11 591 5 022 11 902 D07XC01 betamethasone 26 672 26 626 26 439 25 912 26 232 49 784 8 835 11 591 5 022 11 902 D08 ANTISEPTICS AND DISINFECTANTS 18 291 18 621 19 280 19 088 19 058 59 3 079 7 658 6 135 2 186 2 560 D08A ANTISEPTICS AND DISINFECTANTS 1)18 291 18 621 19 280 19 088 19 058 59 3 079 7 658 6 135 2 186 2 560 D08AB Aluminium agents 265 285 278 338 411 47 142 110 114 45 64 D08AC Biguanides and amidines 14 689 15 171 15 910 15 689 15 682 61 2 121 6 676 5 235 1 650 2 012 D08AC01 dibrompropamidine1)5 342 5 115 5 282 3 802 4 662 52 1 562 1 420 918 762 518 D08AC02 chlorhexidine1)9 595 10 315 10 883 12 095 11 235 65 651 5 333 4 341 910 1 494 D08AG Iodine products 53 54 74 62 85 54 11 11 28 35 18 D08AG01 iodine/octylphenoxypoly - glycolether1)15 5 <5 0 0 - 0 0 0 0 0 D08AG02 povidone-iodine 0 20 31 26 56 48 <5 8 17 27 15 D08AG03 iodine1)38 29 42 36 29 66 7 <5 11 8 3 D08AJ Quaternary ammonium compounds 147 135 151 173 131 49 17 31 40 43 52 D08AJ03 cetylpyridinium 1)147 135 151 173 131 49 17 31 40 43 52 D08AL Silver compounds 0 0 <5 <5 3 D08AX antiseptics and disinfectants 3 292 3 131 3 022 2 970 2 884 52 847 865 740 432 411 D08AX01 hydrogen peroxide 1)2 223 2 059 1 829 1 740 1 657 54 517 523 385 232 182 D08AX06 potassium permanganate1)1 090 1 095 1 207 1 240 1 238 50 335 346 357 200 230 D09 MEDICATED DRESSINGS 2 077 1 937 1 913 1 848 1 761 57 120 390 582 669 503 D09A MEDICATED DRESSINGS 2 077 1 937 1 913 1 848 1 761 57 120 390 582 669 503 D09AA Medicated dressings with antiinfectives 2 077 1 937 1 913 1 848 1 678 58 118 385 555 620 235 D09AA02 fusidic acid 2 077 1 937 1 913 1 848 1 678 58 118 385 555 620 235 D09AB Zinc bandages 0 0 0 0 84 51 <5 5 27 50 269 D09AB01 zinc bandage without supplements 0 0 0 0 84 51 <5 5 27 50 269 D10 ANTI-ACNE PREPARATIONS 48 261 51 472 54 317 60 886 66 617 65 4 033 49 171 10 623 2 790 33 690 D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE 45 378 47 904 50 390 56 374 61 511 66 3 923 44 426 10 383 2 779 18 100 D10AD Retinoids for topical use in acne 21 578 24 388 27 056 32 174 35 937 66 2 581 27 519 4 340 1 497 11 184 D10AD01 tretinoin 9 451 9 888 10 547 10 221 10 953 78 382 5 859 3 403 1 309 1 092 D10AD02 retinol 97 117 170 176 185 59 27 49 90 19 68 D10AD03 adapalene 10 560 8 449 7 113 6 598 5 944 65 488 4 883 427 146 1 291 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group D ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 7 081 10 280 16 392 20 070 61 1 799 17 773 472 26 8 732 D10AE Peroxides 2 001 2 245 2 267 2 354 2 614 56 278 2 197 120 19 485 D10AE01 benzoyl peroxide1)2 001 2 245 2 267 2 354 2 614 56 278 2 197 120 19 485 D10AF Antiinfectives for treatment of acne 16 763 16 046 16 076 16 714 17 015 65 1 211 12 810 2 561 433 3 390 D10AF01 clindamycin 16 729 16 009 16 054 16 677 16 976 65 1 208 12 779 2 556 433 3 369 D10AF02 erythromycin 39 41 24 38 41 63 <5 32 6 0 21 D10AX Other anti-acne preparations for topical use 13 521 13 292 13 285 13 815 14 915 69 669 9 559 3 820 867 3 041 D10AX03 azelaic acid 13 516 13 286 13 276 13 810 14 908 69 669 9 556 3 818 865 3 039 D10AX30 various combinations 7 7 11 5 7 71 0 <5 <5 <5 2 D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE 4 227 5 153 5 748 6 609 7 829 47 219 7 275 317 18 15 590 D10BA Retinoids for treatment of acne 4 227 5 153 5 748 6 609 7 829 47 219 7 275 317 18 15 590 D10BA01 isotretinoin 4 227 5 153 5 748 6 609 7 829 47 219 7 275 317 18 15 590 D11 OTHER DERMATOLOGICAL PREPARATIONS 14 730 15 690 16 780 18 059 18 362 56 2 733 8 554 5 400 1 675 15 494 D11A OTHER DERMATOLOGICAL PREPARATIONS 14 730 15 690 16 780 18 059 18 362 56 2 733 8 554 5 400 1 675 15 494 D11AC Medicated shampoos 1 027 974 1 059 1 205 1 210 53 96 767 261 86 155 D11AC03 selenium compounds 1)1 027 974 1 059 1 205 1 210 53 96 767 261 86 155 D11AF Wart and anti-corn preparations 1)1 375 1 498 1 926 2 068 1 956 52 829 735 293 99 301 D11AH Agents for dermatitis, excluding corticosteroids 9 500 10 323 10 818 12 174 12 626 57 1 796 5 814 4 024 992 10 534 D11AH01 tacrolimus 6 175 6 804 7 498 8 318 8 675 56 1 216 4 019 2 744 696 4 167 D11AH02 pimecrolimus 3 511 3 712 3 534 3 996 3 937 59 610 1 827 1 208 292 1 887 D11AH04 alitretinoin 0 0 0 80 221 55 0 77 137 7 4 480 D11AX Other dermatologicals 2 868 2 940 3 036 2 677 2 626 58 12 1 270 844 500 4 504 D11AX01 minoxidil 192 175 202 161 194 67 <5 108 68 16 119 D11AX10 finasteride eflornithine 0 0 <5 126 296 99 5 189 81 21 208 D11AX18 diclofenac 1 697 1 702 1 604 1 51 0 16 286 407 772G GENITO URINARY SYSTEM AND SEX HORMONES 692 715 703 423 721 846 745 367 760 023 81 3 267 420 137 234 951 101 668 862 673 G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 30 558 30 699 32 068 33 034 33 485 99 113 24 192 7 673 1 507 7 200 G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS 30 558 30 699 32 068 33 034 33 485 99 113 24 192 7 673 1 507 7 200 G01AA Antibiotics 14 416 15 244 20 707 20 475 20 853 100 57 15 185 4 936 675 4 858 G01AA10 clindamycin 14 416 15 244 20 707 20 475 20 853 100 57 15 185 4 936 675 4 858 G01AD Organic acids 0 0 0 0 <5 50 0 0 <5 <5 4 G01AD02 acetic acid 0 0 0 0 <5 50 0 0 <5 <5 4 G01AF Imidazole derivatives 17 328 16 777 12 788 13 896 13 937 99 59 10 011 2 993 874 2 327 G01AF01 metronidazole 10 346 9 685 5 467 6 546 7 306 99 5 5 389 1 661 251 1 016 G01AF02 clotrimazole 1)5 028 5 326 5 614 5 949 5 591 99 33 3 916 1 090 552 1 068 G01AF04 miconazole1)960 768 634 64 0 - 0 0 0 0 0 G01AF05 econazole1)1 407 1 324 1 335 1 621 1 321 96 21 910 299 91 244 G01AX Other antiinfectives and antiseptics 18 6 <5 <5 <5 10 G01AX03 <5 <5 10 G02 OTHER GYNECOLOGICALS 42 936 44 047 45 250 46 752 47 182 99 11 41 429 5 569 173 49 314 G02A OXYTOCICS 26 12 15 11 7 100 0 6 <5 0 1 G02AB Ergot alkaloids 26 12 15 11 7 100 0 6 <5 0 1 G02AB01 methylergometrine 26 12 15 11 7 100 0 6 <5 0 1 G02B CONTRACEPTIVES FOR TOPICAL USE 40 634 41 674 42 960 44 425 45 010 100 9 40 127 4 868 6 46 372 G02BA Intrauterine contraceptives 24 795 24 803 24 858 25 084 25 460 100 <5 21 050 4 404 5 29 378 G02BA03 plastic IUD with progestogen 24 795 24 803 24 858 25 084 25 460 100 <5 21 050 4 404 5 29 378 G02BB Intravaginal contraceptives 16 010 17 064 18 263 19 552 19 776 100 8 19 298 469 <5 16 994 G02BB01 vaginal ring with progestogen and estrogen 16 010 17 064 18 263 19 552 19 776 100 8 19 298 469 <5 16 994 G02C OTHER GYNECOLOGICALS 2 381 2 458 2 367 2 414 2 261 77 <5 1 389 703 167 2 941 G02CB Prolactine inhibitors 2 381 2 458 2 367 2 414 2 261 77 <5 1 389 703 167 2 941 G02CB01 bromocriptine 1 247 1 312 1 226 1 248 1 052 90 <5 776 219 55 676 G02CB03 cabergoline 987 943 921 948 1 004 64 <5 513 393 97 1 395 G02CB04 quinagolide 189 302 284 260 244 75 0 127 100 17 869 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 512 608 515 229 525 683 538 164 544 066 99 2 481 361 117 141 669 38 799 404 442 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.9 ATC group G - Genito urinary system and sex hormones ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE 304 423 307 262 315 379 321 843 326 053 100 1 102 312 156 12 783 12 174 580 G03AA Progestogens and estrogens, fixed combinations 212 576 214 962 221 431 225 448 227 640 100 931 222 120 4 580 9 127 009 G03AA07 levonorgestrel and ethinylestradiol 88 668 87 148 90 257 97 290 113 028 100 617 110 459 1 948 <5 51 249 G03AA09 desogestrel and ethinylestradiol 48 476 55 278 61 035 63 104 56 331 100 208 55 036 1 084 <5 20 112 G03AA12 drospirenone and ethinylestradiol 79 229 74 740 72 600 68 101 59 567 100 139 58 093 1 333 <5 48 648 G03AA13 norelgestromin and ethinylestradiol 9 016 8 924 8 982 9 054 8 927 100 7 8 688 232 0 6 392 G03AA14 nomegestrol and estradiol 0 0 0 0 965 100 <5 938 23 0 609 G03AB Progestogens and estrogens, sequential preparations 22 034 18 862 17 640 16 199 14 775 100 37 13 988 749 <5 5 765 G03AB03 levonorgestrel and ethinylestradiol <5 <5 0 0 0 0 0 0 G03AB04 norethisterone and ethinylestradiol 22 031 18 546 16 059 14 345 12 772 100 27 12 107 637 <5 3 933 G03AB08 dienogest and estradiol 0 326 1 624 1 895 2 042 100 11 1 916 115 0 1 833 G03AC Progestogens 87 693 89 490 92 562 96 460 100 145 100 185 92 305 7 653 <5 41 776 G03AC01 norethisterone 9 195 8 182 7 402 6 657 6 110 100 <5 5 244 862 0 1 400 G03AC03 levonorgestrel 193 141 115 <5 0 - 0 0 0 0 0 G03AC06 medroxyprogesterone 21 186 19 971 19 607 19 338 18 818 100 42 15 421 3 353 <5 4 482 G03AC08 etonogestrel 2 683 2 807 3 298 4 147 5 354 100 11 5 193 150 0 6 198 G03AC09 desogestrel 56 589 60 277 64 136 68 331 72 036 100 130 68 565 3 341 0 29 696 G03AD Emergency contraceptives 119 100 159 165 133 99 <5 125 6 0 31 G03AD01 levonorgestrel 1)119 99 79 87 81 99 <5 75 5 0 16 G03AD02 ulipristal 0 <5 80 78 53 100 <5 51 <5 0 15 G03B ANDROGENS 4 801 5 234 5 552 6 300 7 254 8 39 2 024 4 253 938 23 296 G03BA 3-oxoandrosten (4) derivatives 4 801 5 231 5 550 6 282 7 246 8 39 2 018 4 251 938 23 284 G03BA03 testosterone 4 801 5 231 5 550 6 282 7 246 8 39 2 018 4 251 938 23 284 G03BB 5-androstanon (3) derivatives 0 <5 <5 22 8 0 6 <5 0 12 G03BB01 mesterolone 0 <5 <5 22 8 0 0 6 <5 0 12 G03C ESTROGENS 109 009 112 831 116 574 121 775 123 225 100 164 5 092 83 765 34 204 76 662 G03CA Natural and semisynthetic estrogens, plain 99 840 104 463 108 549 114 351 116 281 100 164 4 896 77 713 33 508 66 685 G03CA01 ethinylestradiol 146 140 127 112 71 92 29 31 10 <5 444G03CA03 estradiol 83 236 89 792 95 212 102 308 105 452 100 35 4 611 74 741 26 065 60 934 G03CA04 estriol1)18 208 16 213 14 807 13 574 12 294 100 100 273 3 679 8 242 5 306 G03CA53 estradiol, combinations 0 <5 0 0 0 - 0 0 0 0 0 G03CA57 conjugated estrogens 5 <5 0 1 G03CX Other estrogens 10 007 9 183 8 841 8 224 7 702 100 0 241 6 704 757 9 977 G03CX01 tibolone 10 007 9 183 8 841 8 224 7 702 100 0 241 6 704 757 9 977 G03D PROGESTOGENS 40 529 37 790 38 788 39 101 40 006 100 1 163 29 256 9 424 163 18 257 G03DA Pregnen (4) derivatives 13 004 13 106 12 990 13 134 13 765 100 46 10 045 3 524 150 15 721 G03DA02 medroxyprogesterone 7 504 7 215 6 869 6 816 6 623 100 46 3 597 2 871 109 1 236 G03DA04 progesterone 5 588 5 987 6 240 6 465 7 279 100 0 6 564 674 41 14 485 G03DB Pregnadien derivatives 0 0 0 12 125 100 0 106 19 0 260 G03DB08 dienogest 0 0 0 12 125 100 0 106 19 0 260 G03DC Estren derivatives 28 284 25 413 26 536 26 716 26 878 100 1 117 19 696 6 051 14 2 276 G03DC02 norethisterone 28 284 25 413 26 536 26 716 26 878 100 1 117 19 696 6 051 14 2 276 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 47 395 45 758 44 082 43 373 41 772 100 0 2 559 35 895 3 318 31 630 G03FA Progestogens and estrogens, fixed combinations 37 409 36 195 35 051 34 460 33 173 100 0 784 29 233 3 156 25 837 G03FA01 norethisterone and estrogen 36 729 35 628 34 521 33 827 32 500 100 0 744 28 632 3 124 25 037 G03FA12 medroxyprogesterone and estrogen 474 527 715 764 795 0 44 712 799 G03FA15 dienogest and estrogen 280 233 <5 <5 0 0 0 Progestogens and estrogens, sequential preparations 11 369 10 851 10 322 10 082 9 636 100 0 1 855 7 608 173 5 793 G03FB05 norethisterone and estrogen 11 369 10 851 10 322 10 082 9 636 100 0 1 855 7 608 173 5 793 G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS 10 938 11 093 10 343 10 634 10 433 95 0 10 162 270 <5 70 050 G03GA Gonadotropins 5 884 6 013 6 137 6 273 6 238 97 0 6 121 117 0 68 456 G03GA01 chorionic gonadotrophin 1 667 1 277 1 476 1 660 1 314 91 0 1 261 53 0 633 G03GA02 human menopausal gonadotrophin 1 405 1 601 1 540 1 842 2 059 100 0 2 031 28 0 19 441 G03GA04 urofollitropin 0 0 85 154 198 100 0 195 <5 0 1 870 G03GA05 follitropin alfa 1 631 1 770 1 743 1 799 1 936 99 0 1 917 19 0 19 886 G03GA06 follitropin beta 3 052 2 916 3 016 2 824 2 406 100 0 2 385 21 0 21 199 G03GA07 lutropin alfa 62 65 26 21 16 100 0 16 0 0 58 G03GA08 choriogonadotropin alfa 4 179 4 556 4 538 4 600 4 813 99 0 4 756 57 0 2 975 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group G ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group G ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 132 316 283 100 0 281 <5 0 1 983 G03GA30 combinations <5 8 <5 <5 16 100 0 16 0 0 412 G03GB Ovulation stimulants, synthetic 6 453 6 483 5 387 5 646 5 284 92 0 5 110 173 <5 1 595 G03GB02 clomifene 6 453 6 483 5 387 5 646 5 284 92 0 5 110 173 <5 1 595 G03H ANTIANDROGENS 16 971 16 171 16 764 17 326 18 020 99 114 17 430 384 92 7 421 G03HA Antiandrogens, plain 189 181 205 199 177 6 0 34 52 91 471 G03HA01 cyproterone 189 181 205 199 177 6 0 34 52 91 471 G03HB Antiandrogens and estrogens 16 792 15 999 16 565 17 130 17 849 100 114 17 402 332 <5 6 950 G03HB01 cyproterone and estrogen 16 792 15 999 16 565 17 130 17 849 100 114 17 402 332 <5 6 950 G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 1 507 1 298 1 142 979 867 95 <5 24 303 539 2 545 G03XA Antigonadotropins and similar agents 51 50 49 50 51 31 <5 17 27 6 186 G03XA01 danazol 51 50 49 50 51 31 <5 17 27 6 186 G03XB Antiprogestogens <5 0 <5 G03XB01 <5 0 <5 <5 0 5 G03XC Selective estrogen receptor modulators 1 452 1 248 1 092 927 810 99 0 <5 275 533 2 354 G03XC01 raloxifene 1 452 1 248 1 092 927 810 99 0 <5 275 533 2 354 G04 UROLOGICALS 141 633 148 765 156 067 166 514 174 852 20 676 16 647 90 573 66 956 401 718 G04B UROLOGICALS 106 579 109 819 113 502 119 124 122 872 28 674 14 504 70 096 37 598 329 667 G04BA Acidifiers <5 <5 0 0 0 - 0 0 0 0 0 G04BA01 ammonium chloride <5 <5 0 0 0 - 0 0 0 0 0 G04BD Drugs for urinary frequency and incontinence 42 828 44 578 46 177 49 166 50 146 68 658 3 910 21 623 23 955 155 132 G04BD04 oxybutynin 1 690 1 480 1 504 1 516 1 523 66 181 341 552 449 8 932 G04BD07 tolterodine 21 577 18 355 15 679 14 238 12 760 72 392 729 4 831 6 808 39 966 G04BD08 solifenacin 15 757 17 349 19 877 21 934 22 310 68 89 1 822 9 998 10 401 63 355 G04BD10 darifenacin 5 430 5 630 5 126 4 566 4 054 71 <5 230 1 723 2 099 11 469 G04BD11 fesoterodine 1 818 5 380 7 639 10 610 12 938 66 22 1 082 6 028 5 806 31 410 G04BE Drugs used in erectile dysfunction 65 120 66 640 68 779 71 519 74 409 0 14 10 698 49 492 14 205 174 511 G04BE01 alprostadil 2 335 2 180 2 543 2 525 2 808 0 0 122 1 910 776 4 782 G04BE03 sildenafil 34 776 34 734 34 385 34 578 34 330 1 13 4 842 22 106 7 369 76 214 G04BE04 yohimbine 13 19 15 10 6 0 0 <5 <5 <5 3 G04BE08 tadalafil 23 981 26 821 29 887 32 997 36 616 0 <5 5 734 25 114 5 767 78 012G04BE09 vardenafil 11 561 10 376 9 934 9 427 9 060 0 0 1 148 6 225 1 687 14 682 G04BE30 combinations 537 616 495 539 347 0 0 23 233 91 818 G04BX Other urologicals 10 10 11 11 13 46 <5 6 5 0 24 G04BX01 magnesium hydroxide 10 10 11 11 13 46 <5 6 5 0 24 G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY 41 018 45 440 49 918 55 531 60 946 1 <5 2 335 24 889 33 720 72 051 G04CA Alpha-adrenoreceptor antagonists 31 502 34 945 38 363 43 210 48 567 1 <5 1 305 21 435 25 825 51 089 G04CA01 alfuzosin 777 536 498 451 398 2 0 12 164 222 575 G04CA02 tamsulosin 30 169 33 877 37 383 41 362 43 535 1 <5 1 201 19 205 23 127 40 357 G04CA03 terazosin 898 744 649 598 599 1 0 90 247 262 499 G04CA52 tamsulosin and dutasteride 0 0 <5 1 628 6 160 0 0 9 2 784 3 367 9 659 G04CB Testosterone-5-alpha reductase inhibitors 13 253 14 939 16 984 18 676 18 623 0 0 1 039 5 695 11 889 20 961 G04CB01 finasteride 10 194 12 852 15 194 17 122 17 266 0 0 1 008 5 340 10 918 17 033 G04CB02 dutasteride 4 054 2 331 1 939 1 661 1 421 0 0 37 368 1 016 3 928ATC group G ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group G ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 HORMONAL PREPARATIONS, SEX HORMONES AND INSULINS 357 070 375 465 387 821 402 923 413 526 67 16 074 108 837 178 811 109 804 430 101 H01 PITUITARY AND HYPOTHA - LAMIC HORMONES AND ANALOGUES 24 310 24 490 24 833 24 910 24 913 66 9 134 12 836 1 838 1 105 289 370 H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES 1 485 1 577 1 658 1 767 1 863 43 1 000 536 297 30 155 967 H01AA ACTH <5 <5 tetracosactide <5 <5 <5 <5 0 - 0 0 H01AB Thyrotropin 0 0 <5 7 10 100 0 7 <5 <5 96 H01AB01 thyrotropin 0 0 <5 <5 96 H01AC Somatropin and somat-ropin agonists 1 470 1 555 1 631 1 735 1 822 43 1 000 517 277 28 146 901 H01AC01 somatropin 1 470 1 555 1 631 1 735 1 822 43 1 000 517 277 28 146 901 H01AX Other anterior pituitary lobe hormones and analogues 13 21 24 24 31 39 0 12 18 <5 8 970 H01AX01 pegvisomant 13 21 24 24 31 39 0 12 18 <5 8 970 H01B POSTERIOR PITUITARY LOBE HORMONES 18 859 18 807 18 982 19 167 18 668 62 8 167 8 519 1 160 822 36 432 H01BA Vasopressin and analogues 11 623 11 288 11 248 11 388 11 182 37 8 134 1 100 1 128 820 34 975 H01BA02 desmopressin 11 623 11 288 11 248 11 387 11 182 37 8 134 1 100 1 128 820 34 975 H01BA04 terlipressin 0 0 0 <5 0 - 0 0 0 0 0 H01BB Oxytocin and analogues 7 237 7 522 7 736 7 781 7 489 99 33 7 421 33 <5 1 457 H01BB02 oxytocin 7 237 7 522 7 736 7 781 7 489 99 33 7 421 33 <5 1 457 H01C HYPOTHALAMIC HORMONES 4 147 4 315 4 430 4 218 4 634 92 6 3 920 451 257 96 971 H01CA Gonadotropin-releasing hormones 3 101 2 829 2 314 2 076 2 357 100 0 2 333 24 0 6 100 H01CA02 nafarelin 3 101 2 829 2 314 2 076 2 357 100 0 2 333 24 0 6 100 H01CB Somatostatin and analogues 494 498 593 630 724 48 6 64 397 257 85 567 H01CB02 octreotide 406 398 472 497 567 49 6 50 319 192 63 186 H01CB03 lanreotide 118 118 137 148 184 47 <5 18 89 73 22 381 H01CC Anti-gonadotropin-releasing hormones 675 1 246 1 887 1 774 1 810 100 0 1 778 32 0 5 304 H01CC01 ganirelix 555 975 1 513 1 397 1 425 100 0 1 398 27 0 3 946 H01CC02 cetrorelix 149 298 481 413 406 100 0 401 5 0 1 358 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 177 573 190 388 197 259 208 089 214 161 56 4 808 61 514 89 532 58 307 52 034H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN 177 454 190 244 197 075 207 853 213 941 56 4 808 61 470 89 404 58 259 51 959 H02AA Mineralocorticoids 1 160 1 178 1 223 1 267 1 322 57 86 400 601 235 352 H02AA02 fludrocortisone 1 160 1 178 1 223 1 267 1 322 57 86 400 601 235 352 H02AB Glucocorticoids 177 308 190 110 196 940 207 710 213 785 56 4 801 61 439 89 346 58 199 51 607 H02AB01 betamethasone 1 736 1 700 1 637 1 528 1 476 44 850 216 325 85 477 H02AB02 dexamethasone 1 931 2 118 2 552 2 786 3 188 48 81 317 1 730 1 060 3 400 H02AB04 methylprednisolone 10 159 10 745 10 812 11 020 11 087 53 49 2 697 5 753 2 588 4 016 H02AB06 prednisolone 136 459 143 524 152 240 159 525 167 532 58 3 184 38 719 71 992 53 637 30 851 H02AB07 prednisone <5 <5 82 246 266 73 0 130 94 665 H02AB08 triamcinolone 29 048 34 538 32 179 35 711 33 504 49 534 20 119 10 990 1 861 4 686 H02AB09 hydrocortisone 422 437 481 549 596 68 57 237 262 40 1 298 H02AB10 cortisone 2 510 2 593 2 662 2 750 2 813 52 133 733 1 376 571 6 096 H02AB13 deflazacort 17 18 17 25 24 46 12 <5 7 <5 118 H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINA - TIONS 340 332 372 415 409 63 0 73 217 119 75 H02BX Corticosteroids for systemic use, combinations 340 332 372 415 409 63 0 73 217 119 75 H02BX01 methylprednisolone, combi-nations 340 332 372 415 409 63 0 73 217 119 75 H03 THYROID THERAPY 167 746 174 354 180 847 185 868 191 754 82 1 345 35 960 96 166 58 283 60 990 H03A THYROID PREPARATIONS 164 071 170 772 177 261 182 151 187 631 82 1 321 34 814 94 338 57 158 57 934 H03AA Thyroid hormones 164 071 170 772 177 261 182 151 187 631 82 1 321 34 814 94 338 57 158 57 934 H03AA01 levothyroxine sodium 163 750 170 484 176 910 181 641 186 965 82 1 312 34 580 93 978 57 095 53 255 H03AA02 liothyronine sodium 3 986 4 095 4 142 4 538 4 697 89 24 1 467 2 804 402 3 368 H03AA03 combinations of levothy - roxine and liothyronine 404 429 328 549 698 90 <5 268 402 26 847 H03AA05 thyroid gland preparations 0 0 182 187 265 91 0 111 141 13 464 H03B ANTITHYROID PREPARA - TIONS 5 131 5 019 5 125 5 432 5 905 80 42 1 856 2 703 1 304 3 056 H03BA Thiouracils 552 552 521 651 propylthiouracil 552 552 521 515 H03BB Sulfur-containing imida-zole derivatives 4 741 4 590 4 727 5 042 5 491 80 40 1 634 2 561 1 256 2 541 H03BB01 carbimazole 4 741 4 590 4 727 5 042 5 491 80 40 1 634 2 561 1 256 2 541 H04 PANCREATIC HORMONES 5 265 5 336 5 490 5 591 5 578 46 1 117 2 763 1 404 294 2 378 H04A GLYCOGENOLYTIC HORMONES 5 265 5 336 5 490 5 591 5 578 46 1 117 2 763 1 404 294 2 378 H04AA Glycogenolytic hormones 5 265 5 336 5 490 5 591 5 578 46 1 117 2 763 1 404 294 2 3782.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group H ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 336 5 490 5 591 5 578 46 1 117 2 763 1 404 294 2 378 H05 CALCIUM HOMEOSTASIS 644 748 803 916 1 084 58 <5 122 530 431 25 329 H05A PARATHYROID HORMONES AND ANALOGUES 225 237 263 294 377 78 0 42 212 123 10 629 H05AA Parathyroid hormones and analogues 225 237 263 294 377 78 0 42 212 123 10 629 H05AA02 teriparatide 201 213 253 281 367 78 0 41 206 120 10 125 H05AA03 parathyroid hormone 25 25 12 13 11 91 0 <5 7 <5 504 H05B ANTI-PARATHYROID AGENTS 421 511 541 623 707 48 <5 80 318 308 14 700 H05BA Calcitonin preparations 110 86 80 83 69 86 0 6 16 47 257 H05BA01 calcitonin (salmon synthetic) 110 86 80 83 69 86 0 6 16 47 257 H05BX Other anti-parathyroid agents 313 425 461 540 638 44 <5 74 302 261 14 443 H05BX01 cinacalcet 304 391 418 474 499 48 <5 52 225 221 11 888 H05BX02 paricalcitol 11 44 59 87 184 32 <5 28 95 60 2 555J ANTIINFECTIVES FOR SYSTEMIC USE 1 247 202 1 394 508 1 252 392 1 326 405 1 330 660 59 164 678 534 345 435 678 195 959 802 758 J01 ANTIBACTERIALS FOR SYSTEMIC USE 1 181 387 1 138 247 1 180 410 1 250 480 1 255 603 59 160 267 495 562 410 706 189 068 302 241 J01A TETRACYCLINES 172 668 161 073 167 058 188 189 206 035 57 2 310 89 333 81 214 33 178 38 006 J01AA Tetracyclines 172 668 161 073 167 058 188 189 206 035 57 2 310 89 333 81 214 33 178 38 006 J01AA02 doxycycline 135 973 124 472 129 848 148 596 164 478 57 1 208 59 937 71 981 31 352 21 044 J01AA04 lymecycline 12 748 13 528 14 771 19 412 22 455 56 598 15 971 4 918 968 11 417 J01AA06 oxytetracycline 5 605 5 244 5 164 2 625 <5 100 0 0 <5 0 0 J01AA07 tetracycline 20 731 20 086 19 710 21 378 22 112 56 561 15 333 5 148 1 070 5 364 J01AA08 minocycline 8 16 58 85 145 60 <5 7 165 J01AA12 tigecycline 6 <5 AMPHENICOLS <5 0 <5 0 0 - 0 0 0 0 0 J01BA Amphenicols <5 0 <5 0 0 - 0 0 0 0 0 J01BA01 chloramphenicol <5 0 <5 0 0 - 0 0 J01C BETA-LACTAM ANTIBACTE-RIALS, PENICILLINS 764 657 744 434 776 398 797 519 797 966 60 115 812 307 792 249 508 124 854 126 464 J01CA Penicillins with extended spectrum 281 587 283 578 301 349 309 246 316 692 74 37 215 101 129 103 654 74 694 51 536 J01CA01 ampicillin 35 19 39 24 56 48 <5 17 35 49 J01CA02 pivampicillin <5 0 0 <5 0 - 0 0 0 0 0 J01CA04 amoxicillin 123 464 118 112 127 541 131 915 136 857 55 32 583 32 194 45 007 27 073 18 664 J01CA08 pivmecillinam 169 588 176 709 186 059 189 598 193 245 87 4 956 72 303 63 251 52 735 32 802 J01CA11 mecillinam 8 <5 <5 Beta-lactamase sensitive penicillins 475 189 444 689 458 149 466 195 455 868 54 82 487 190 020 134 499 48 862 43 429 J01CE01 benzylpenicillin 54 58 52 64 85 48 <5 7 21 56 50 J01CE02 phenoxymethylpenicillin 475 113 444 622 458 036 466 096 455 753 54 82 486 189 979 134 462 48 826 43 177 J01CE08 benzathine benzylpenicillin 46 40 99 83 74 20 <5 42 24 7 202 J01CF Beta-lactamase resistant penicillins 79 411 85 870 92 702 100 307 104 650 48 5 821 44 820 36 582 17 427 31 082 J01CF01 dicloxacillin 77 178 84 083 91 099 98 912 103 429 48 5 740 44 383 36 149 17 157 30 039 J01CF02 cloxacillin 2 683 2 153 1 929 1 714 1 515 49 73 549 533 360 1 005 J01CF05 flucloxacillin 19 32 22 17 18 56 13 <5 0 <5 38 J01CR Combinations of penicil-lins, incl. beta-lactamase inhibitors 52 120 135 114 178 58 101 16 24 37 418 J01CR02 amoxicillin and enzyme inhibitor 38 101 118 94 141 63 100 8 11 22 208 J01CR05 piperacillin and enzyme inhibitor 14 19 17 20 37 38 <5 8 13 15 210ATC group H ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.11 ATC group J - Antiinfectives for systemic use ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 291 24 378 23 566 23 142 21 414 59 2 613 7 726 7 409 3 666 7 108 J01DB First-generation cephalosporins 26 924 23 974 23 116 22 707 20 600 60 2 567 7 454 7 112 3 467 3 012 J01DB01 cefalexin 26 914 23 952 23 099 22 698 20 581 60 2 565 7 452 7 107 3 457 2 987 J01DB03 cefalotin 10 23 17 9 20 35 <5 <5 6 10 25 J01DC Second-generation cephalosporins 67 63 71 72 102 65 0 9 30 63 85 J01DC02 cefuroxime 67 63 71 72 102 65 0 9 30 63 85 J01DD Third-generation cephalosporins 316 346 388 362 704 39 51 254 259 140 2 450 J01DD01 cefotaxime 30 39 42 47 104 33 <5 9 41 51 97 J01DD02 ceftazidime 57 71 80 57 68 44 9 32 16 11 993 J01DD04 ceftriaxone 148 155 190 177 194 39 33 68 60 33 532 J01DF Monobactams 12 11 13 8 9 33 0 9 0 0 330 J01DF01 aztreonam 12 11 13 8 9 33 0 9 0 0 330 J01DH Carbapenems 31 56 43 53 69 49 5 24 24 16 1 231 J01DH02 meropenem 30 46 39 40 58 43 5 21 21 11 929 J01DH03 ertapenem <5 8 <5 271 J01DH04 doripenem 0 0 0 J01E SULFONAMIDES AND TRIMETHOPRIM 123 869 118 489 117 088 116 661 114 441 76 13 823 29 885 37 737 32 996 10 987 J01EA Trimethoprim and derivatives 93 084 88 503 86 108 84 347 80 448 85 7 941 22 070 25 930 24 507 6 502 J01EA01 trimethoprim 93 084 88 503 86 108 84 347 80 448 85 7 941 22 070 25 930 24 507 6 502 J01EE Combinations of sulfon-amides and trimethoprim, incl. derivatives 34 915 34 027 34 976 36 389 38 324 57 6 419 8 610 13 174 10 121 4 485 J01EE01 sulfamethoxazole and trimethoprim 34 915 34 027 34 976 36 389 38 324 57 6 419 8 610 13 174 10 121 4 485 J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 310 374 283 337 301 083 349 643 342 304 57 49 242 150 578 111 227 31 257 57 070 J01FA Macrolides 272 328 244 678 257 943 304 755 294 690 57 44 865 131 285 93 726 24 814 45 411 J01FA01 erythromycin 142 942 123 140 129 188 170 347 152 191 58 31 380 59 993 47 071 13 747 18 895 J01FA02 spiramycin 3 575 3 033 2 794 2 744 2 645 61 50 1 000 1 247 348 435 J01FA09 clarithromycin 44 208 36 958 37 830 43 161 48 422 57 7 008 17 709 17 984 5 721 7 924 J01FA10 azithromycin 92 794 90 850 98 413 101 180 104 940 58 8 476 58 526 31 969 5 969 18 131 J01FA15 telithromycin 0 0 0 0 <5 50 0 <5 0 0 26 J01FF Lincosamides 46 064 45 847 51 154 53 678 56 442 54 5 396 23 391 20 346 7 309 11 659J01FF01 clindamycin 46 064 45 847 51 154 53 678 56 442 54 5 396 23 391 20 346 7 309 11 659 J01G AMINOGLYCOSIDE ANTIBACTERIALS 278 289 273 252 253 53 69 106 63 15 10 214 J01GA Streptomycins <5 0 0 0 0 - 0 0 0 0 0 J01GA01 streptomycin <5 0 0 0 0 - 0 0 0 0 0 J01GB Other aminoglycosides 277 289 273 252 253 53 69 106 63 15 10 214 J01GB01 tobramycin 245 258 250 219 228 53 66 101 53 8 9 414 J01GB03 gentamicin 28 26 16 19 13 31 <5 <5 5 5 91 J01GB06 amikacin 6 5 <5 710 J01M QUINOLONE ANTIBACTERIALS 59 957 60 651 64 703 67 271 69 544 49 619 17 063 30 033 21 829 16 139 J01MA Fluoroquinolones 59 957 60 651 64 703 67 271 69 544 49 619 17 063 30 033 21 829 16 139 J01MA01 ofloxacin 3 012 2 717 2 516 2 242 2 055 42 <5 586 879 589 720 J01MA02 ciprofloxacin 57 335 58 298 62 445 65 193 67 597 50 618 16 320 29 301 21 358 14 504 J01MA12 levofloxacin 5 15 21 31 20 55 0 5 14 <5 194 J01MA14 moxifloxacin 65 71 142 205 260 52 0 238 20 <5 722 J01X OTHER ANTIBACTERIALS 47 875 51 069 54 632 58 484 59 424 84 1 431 11 722 20 462 25 809 36 253 J01XA Glycopeptide antibacterials 29 27 23 27 35 40 5 <5 12 15 333 J01XA01 vancomycin 23 26 21 24 35 40 5 <5 12 15 333 J01XA02 teicoplanin 6 <5 <5 <5 0 - 0 0 0 0 0 J01XB Polymyxins 60 64 55 63 72 53 14 31 20 7 2 136 J01XB01 colistin 60 64 55 63 72 53 14 31 20 7 2 136 J01XC Steroid antibacterials 865 711 757 663 591 54 22 222 208 411 J01XC01 fusidic acid 865 711 757 663 591 54 22 222 208 139 411 J01XD Imidazole derivatives 17 23 24 26 25 52 0 <5 14 8 59 J01XD01 metronidazole 17 23 24 26 25 52 0 <5 14 8 59 J01XE Nitrofuran derivatives 29 536 31 296 33 594 36 784 36 138 85 1 302 8 959 12 504 13 373 3 944 J01XE01 nitrofurantoin 29 536 31 296 33 594 36 784 36 138 85 1 302 8 959 12 504 13 373 3 944 J01XX Other antibacterials 21 193 23 185 24 887 25 921 28 054 84 125 3 273 9 631 15 025 29 370 J01XX01 fosfomycin 0 0 0 0 <5 100 0 0 <5 0 2 J01XX05 methenamine 21 023 22 969 24 644 25 647 27 808 84 123 3 226 9 520 14 939 20 441 J01XX08 linezolid 177 223 252 279 252 42 <5 50 110 90 8 862 J01XX09 daptomycin 0 0 0 0 <5 50 0 0 <5 <5 64 J02 ANTIMYCOTICS FOR SYSTEMIC USE 40 785 42 646 45 330 46 501 47 629 86 430 30 047 13 733 3 419 32 847 J02A ANTIMYCOTICS FOR SYSTEMIC USE 40 785 42 646 45 330 46 501 47 629 86 430 30 047 13 733 3 419 32 847 J02AA Antibiotics <5 <5 0 <5 <5 0 <5 0 0 0 770ATC group J ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group J ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 0 0 770 J02AB Imidazole derivatives 2 294 2 262 2 163 2 227 2 255 45 19 1 532 633 71 702 J02AB02 ketoconazole 2 294 2 262 2 163 2 227 2 255 45 19 1 532 633 71 702 J02AC Triazole derivatives 38 599 40 488 43 283 44 379 45 482 88 412 28 577 13 137 3 356 25 132 J02AC01 fluconazole 38 354 40 227 42 967 43 936 45 173 88 400 28 452 13 004 3 317 14 155 J02AC02 itraconazole 307 526 471 635 607 79 11 338 218 40 827 J02AC03 voriconazole 66 65 80 80 88 43 <5 20 46 18 6 705 J02AC04 posaconazole 7 9 22 40 55 45 <5 20 30 <5 3 445 J02AX Other antimycotics for <5 0 0 0 0 642 J04 ANTIMYCOBACTERIALS 917 1 336 1 573 1 645 1 775 49 98 780 552 345 5 181 J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 486 931 1 126 1 194 1 353 52 90 692 360 211 4 821 J04AB Antibiotics 318 401 444 474 610 51 65 153 220 172 1 656 J04AB02 rifampicin 303 377 422 458 598 52 65 151 213 169 1 090 J04AB04 rifabutin 16 25 24 17 13 54 0 <5 8 <5 199 J04AB30 capreomycin <5 0 0 0 0 <5 0 0 367 J04AC Hydrazides 38 64 75 88 72 56 13 23 25 11 72 J04AC01 isoniazid 38 64 75 88 72 56 13 23 25 11 72 J04AD Thiocarbamide derivatives <5 <5 0 0 0 - 0 0 0 0 0 J04AD01 protionamide <5 <5 0 0 0 - 0 0 0 0 0 J04AK Other drugs for treatment of tuberculosis 99 126 203 207 260 53 <5 138 81 37 876 J04AK01 pyrazinamide 13 20 28 37 44 61 <5 30 8 <5 100 J04AK02 ethambutol 97 115 198 200 247 53 <5 131 78 35 776 J04AM Combinations of drugs for treatment of tuberculosis 112 493 645 684 717 52 23 532 124 38 2 217 J04AM02 rifampicin and isoniazid 82 433 578 619 665 52 23 498 112 32 1 813 J04AM05 rifampicin, pyrazinamide and isoniazid 36 76 138 111 164 48 0 107 37 20 404 J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid 13 58 47 47 0 - 0 0 0 0 0 J04B DRUGS FOR TREATMENT OF LEPRA 433 405 449 454 422 40 8 88 192 134 360 J04BA Drugs for treatment of lepra 433 405 449 454 422 40 8 88 192 134 360 J04BA01 clofazimine <5 0 0 0 0 - 0 0 0 0 0J04BA02 dapsone 432 405 449 454 422 40 8 88 192 134 360 J05 ANTIVIRALS FOR SYSTEMIC USE 24 595 304 693 31 034 32 722 34 699 61 722 17 154 12 730 4 093 393 420 J05A DIRECT ACTING ANTIVIRALS 24 595 304 693 31 034 32 722 34 699 61 722 17 154 12 730 4 093 393 420 J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 21 809 23 038 24 889 27 463 29 957 64 591 14 753 10 784 3 829 54 696 J05AB01 aciclovir 9 892 10 264 11 316 12 172 12 627 67 415 6 485 4 105 1 622 4 958 J05AB04 ribavirin 803 770 705 760 898 35 <5 20 203 J05AB06 ganciclovir <5 0 <5 <5 0 - 0 0 0 0 0 J05AB09 famciclovir 0 0 0 0 <5 0 0 <5 0 0 5 J05AB11 valaciclovir 11 348 12 244 13 096 14 811 16 758 64 180 8 128 6 235 2 215 14 842 J05AB12 cidofovir <5 0 0 0 0 - 0 0 0 0 0 J05AB14 valganciclovir 223 246 283 319 348 36 <5 90 210 46 14 687 J05AD Phosphonic acid derivatives 0 0 0 0 <5 100 0 0 <5 0 21 J05AD01 foscarnet 0 0 0 0 <5 100 0 0 <5 0 21 J05AE Protease inhibitors 588 728 860 1 105 1 <5 766 742 19 113 609 J05AE01 saquinavir 17 11 9 7 6 17 0 295 0 13 499 604 720 atazanavir 517 660 780 920 1 060 36 <5 580 461 16 40 375 J05AE09 tipranavir <5 <5 0 0 0 - 0 0 0 0 0 J05AE10 darunavir 48 55 70 91 129 28 <5 40 87 <5 8 352 J05AE11 telaprevir 0 0 0 16 94 37 0 32 61 <5 21 007 J05AE12 boceprevir 0 0 0 76 255 37 0 117 138 0 40 219 J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 394 388 399 420 478 37 17 217 236 8 18 368 J05AF01 zidovudine 55 41 34 35 29 38 <5 18 9 <5 588 J05AF02 didanosine 77 53 37 22 17 41 0 7 8 <5 301 J05AF04 stavudine 28 13 13 <5 0 - 0 0 0 0 0 J05AF05 lamivudine 145 117 100 93 89 44 15 28 45 <5 960 J05AF06 abacavir 46 48 51 54 58 50 13 25 20 0 1 418 J05AF07 tenofovir disoproxil 148 158 163 191 222 36 <5 113 106 <5 7 881 J05AF08 adefovir dipivoxil 38 33 22 15 11 36 0 <5 9 0 591 J05AF09 emtricitabine 13 11 11 9 6 33 0 <5 <5 0 136ATC group J ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group J ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 37 0 77 76 <5 6 491 J05AF11 telbivudine 6 8 5 <5 0 - 0 0 0 0 0 J05AG Non-nucleoside reverse transcriptase inhibitors 633 573 529 176 211 13 10 421 J05AG01 nevirapine 183 186 191 184 172 40 5 71 89 7 4 119 J05AG03 efavirenz 455 382 321 258 213 39 7 98 102 6 5 168 J05AG04 etravirine 0 12 23 28 28 25 <5 7 20 0 1 125 J05AG05 rilpivirine 0 0 0 0 <5 0 0 <5 0 0 9 J05AH Neuraminidase inhibitors 1 088 282 095 3 860 2 646 1 803 53 107 876 606 214 466 J05AH01 zanamivir 109 2 542 35 36 34 62 <5 13 15 <5 8 J05AH02 oseltamivir 981 279 946 829 2 53 104 865 591 211 458 J05AR Antivirals for treatment of HIV infections, combinations 1 620 1 927 2 184 2 445 2 715 35 11 1 400 1 257 47 174 841 J05AR01 zidovudine and lamivudine 648 606 514 421 344 49 189 142 13 9 019 J05AR02 lamivudine and abacavir 230 258 279 290 328 30 <5 139 175 12 12 818 J05AR03 tenofovir disoproxil and emtricitabine 738 890 1 065 1 230 1 404 38 <5 762 621 18 70 051 J05AR04 zidovudine, lamivudine and abacavir 37 36 35 31 22 50 0 7 15 0 1 038 J05AR06 emtricitabine, tenofovir disoproxil and efavirenz 130 362 514 383 360 10 61 581 J05AR08 emtricitabine, tenofovir disoproxil and rilpivirine 0 0 0 0 142 18 0 90 52 0 6 645 J05AR10 lopinavir and ritonavir 582 583 551 510 466 50 7 292 160 7 13 691 J05AX Other antivirals 50 97 179 271 325 44 178 <5 20 998 J05AX05 inosine pranobex <5 <5 31 18 0 219 J05AX07 enfuvirtide 6 <5 0 0 0 - 0 0 0 0 0 J05AX08 raltegravir 48 96 148 190 264 35 0 101 160 <5 20 366 J05AX09 maraviroc 5 5 7 7 7 14 0 <5 6 0 413L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 70 154 72 795 76 656 81 612 86 248 54 1 255 18 728 40 814 25 451 2 400 496 L02 ENDOCRINE THERAPY 24 557 24 457 24 886 25 999 26 119 51 158 2 825 9 093 14 043 280 239 L02A HORMONES AND RELATED AGENTS 10 787 10 788 11 009 11 761 11 166 21 156 1 861 2 042 7 107 94 245 L02AA Estrogens 48 25 17 7 <5 50 0 0 <5 <5 1 L02AA02 polyestradiol phosphate 48 25 17 50 0 0 <5 <5 1 L02AB Progestogens 223 188 178 202 166 83 0 9 70 87 368 L02AB01 megestrol 186 178 178 202 166 83 0 9 70 87 368 L02AB02 medroxyprogesterone 44 12 0 0 0 - 0 0 0 0 0 L02AE Gonadotropin releasing hormone analogues 10 547 10 590 10 827 11 558 11 002 20 156 1 852 1 971 7 023 93 876 L02AE01 buserelin 1 337 1 282 1 474 1 898 1 309 99 0 1 290 12 7 2 136 L02AE02 leuprorelin 3 804 3 887 3 891 4 012 3 955 14 155 365 561 2 874 35 996 L02AE03 goserelin 5 557 5 601 5 619 5 783 5 858 7 <5 227 1 426 4 204 55 448 L02AE04 triptorelin <5 8 <5 12 13 100 0 11 <5 0 55 L02AE05 histrelin 0 0 0 12 20 0 0 0 <5 16 242 L02B HORMONE ANTAGONISTS AND RELATED AGENTS 16 898 16 800 17 127 17 878 18 845 58 <5 1 011 8 173 9 659 185 994 L02BA Anti-estrogens 5 502 4 959 4 109 3 861 3 990 97 <5 625 2 410 953 13 131 L02BA01 tamoxifen 5 251 4 716 3 893 3 597 3 758 97 <5 618 2 278 860 3 380 L02BA03 fulvestrant 270 267 242 296 266 99 0 8 146 112 9 751 L02BB Anti-androgens 6 370 6 380 6 641 7 008 6 978 0 0 <5 1 567 5 408 41 945 L02BB01 flutamide 389 352 305 253 248 1 0 <5 24 222 1 075 L02BB03 bicalutamide 6 003 6 058 6 362 6 775 6 760 0 0 <5 1 548 5 211 40 870 L02BG Aromatase inhibitors 5 968 6 601 7 219 7 378 7 770 99 0 400 4 315 3 055 38 748 L02BG03 anastrozole 3 444 3 276 2 901 2 331 1 855 98 0 25 1 049 781 8 670 L02BG04 letrozole 1 396 2 360 3 478 4 365 5 295 99 0 363 2 927 2 005 26 512 L02BG06 exemestane 1 363 1 200 1 108 929 809 99 0 18 464 327 3 565 L02BX Other hormone antago - nists and related agents 0 0 89 377 836 0 0 0 267 569 92 169 L02BX02 degarelix 0 0 89 271 380 0 0 0 134 246 4 020 L02BX03 abiraterone 0 0 0 107 484 0 0 0 147 337 88 149 L03 IMMUNOSTIMULANTS 5 353 5 663 5 883 6 294 6 762 61 60 2 480 3 656 566 346 730 L03A IMMUNOSTIMULANTS 5 353 5 663 5 883 6 294 6 762 61 60 2 480 3 656 566 346 730 L03AA Colony stimulating factors 1 928 2 085 2 222 2 426 2 693 61 41 456 1 666 530 87 962 L03AA02 filgrastim 364 362 415 587 599 48 35 113 342 109 9 907 L03AA13 pegfilgrastim 1 649 1 815 1 919 1 958 2 220 64 8 374 1 399 439 78 055 L03AB Interferons 2 667 2 666 2 649 2 756 2 886 57 20 1 423 1 414 29 172 182ATC group J ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.12 ATC group L - Antineoplastic and immunomodulating agents ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 alfa natural <5 5 11 20 20 50 0 10 10 0 2 765 L03AB03 interferon gamma 11 9 9 9 10 60 <5 6 0 0 1 013 L03AB04 interferon alfa-2a 5 14 19 19 23 35 0 5 13 5 755 L03AB05 interferon alfa-2b 80 62 74 63 49 35 0 9 34 6 1 524 L03AB07 interferon beta-1a 1 335 1 348 1 217 1 183 1 175 71 12 575 587 <5 96 346 L03AB08 interferon beta-1b 363 372 533 30 913 peginterferon alfa-2b 465 416 310 273 337 36 <5 158 166 9 14 121 L03AB11 peginterferon alfa-2a 424 468 503 594 685 7 24 745 L03AC Interleukins <5 0 0 <5 0 - 0 0 0 0 0 L03AC01 aldesleukin <5 0 0 <5 0 - 0 0 0 0 0 L03AX Other immunostimulants 862 1 023 1 148 1 266 1 358 72 0 697 654 7 86 586 L03AX03 BCG vaccine <5 7 13 12 10 10 0 <5 5 <5 76 L03AX13 glatiramer acetate 858 1 016 1 135 1 254 1 348 73 0 696 649 <5 86 510 L04 IMMUNOSUPPRESSANTS 35 076 37 221 39 932 42 913 46 329 55 899 12 749 24 391 8 290 1 432 345 L04A IMMUNOSUPPRESSANTS 35 076 37 221 39 932 42 913 46 329 55 899 12 749 24 391 8 290 1 432 345 L04AA Selective immunosuppressants 4 317 4 619 4 910 5 466 6 246 48 86 1 481 3 672 1 007 168 067 L04AA06 mycophenolic acid 2 647 2 965 3 266 3 591 3 919 37 78 949 2 329 563 41 785 L04AA10 sirolimus 68 70 101 130 149 32 <5 22 106 17 5 179 L04AA13 leflunomide 1 318 1 362 1 458 1 539 1 661 69 <5 194 1 050 415 9 329 L04AA18 everolimus 253 263 294 336 402 30 <5 55 264 80 24 413 L04AA21 efalizumab 196 118 0 0 0 - 0 0 0 0 0 L04AA23 natalizumab 42 58 49 0 0 - 0 0 0 0 0 L04AA24 abatacept 16 <5 <5 0 0 - 0 0 0 0 0 L04AA25 eculizumab 0 <5 <5 21 L04AA27 fingolimod 0 0 0 186 487 72 <5 309 177 0 66 182 L04AB Tumor necrosis factor alpha (TNF-) inhibitors 7 626 8 409 9 649 11 057 12 623 53 186 4 680 6 679 1 078 1 026 277 L04AB01 etanercept 5 280 5 162 5 078 6 122 6 944 55 118 2 259 3 880 687 479 052 L04AB02 infliximab 278 83 <5 0 0 - 0 0 0 0 0 L04AB04 adalimumab 2 329 3 519 3 993 4 121 4 588 51 77 2 066 2 173 272 414 454 L04AB05 certolizumab pegol 0 0 135 314 606 75 0 158 351 97 32 159 L04AB06 golimumab 0 0 1 038 1 208 1 218 50 0 498 655 65 100 612 L04AC Interleukin inhibitors 58 69 127 180 293 44 11 126 143 13 32 836 L04AC03 anakinra 58 68 75 85 121 46 8 50 56 7 7 308 L04AC05 ustekinumab 0 <5 50 92 166 43 0 73 87 6 15 904 L04AC08 canakinumab 0 0 <5 6 7 29 <5 <5 0 0 9 624L04AD Calcineurin inhibitors 4 388 4 578 4 799 5 027 5 279 38 151 1 394 3 006 728 122 162 L04AD01 ciclosporin 3 306 3 289 3 307 3 332 3 272 37 58 701 1 913 600 67 542 L04AD02 tacrolimus 1 161 1 349 1 570 1 770 2 085 39 93 720 1 143 129 54 620 L04AX Other immunosuppressants 25 770 26 860 28 382 29 767 31 195 59 617 7 607 16 359 6 612 83 003 L04AX01 azathioprine 6 028 6 197 6 390 6 714 7 078 52 197 3 252 2 930 699 6 309 L04AX02 thalidomide 340 330 348 320 330 50 6 7 119 198 11 043 L04AX03 methotrexate 19 466 20 347 21 622 22 692 23 678 61 415 4 376 13 255 5 632 10 425 L04AX04 lenalidomide 60 106 157 171 236 49 0 <5 127 106 51 722 L04AX05 pirfenidone 0 0 0 0 21 29 0 0 14 7 3 504ATC group L ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group L ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 927 355 935 824 57 14 643 332 879 400 ANTIRHEUMATIC PRODUCTS 829 545 815 420 824 208 833 848 836 532 57 12 780 323 870 393 317 106 565 193 810 M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS 815 299 824 121 833 776 836 481 57 12 780 323 863 393 290 106 548 192 860 M01AA Butylpyrazolidines <5 0 0 0 0 - 0 0 0 0 0 M01AA01 phenylbutazone <5 0 0 0 0 - 0 0 0 0 0 M01AB Acetic acid derivatives and related substances 498 631 491 574 505 424 508 808 484 532 55 7 381 200 608 226 123 50 420 58 537 M01AB01 indometacin 12 154 11 675 2 710 1 116 1 151 61 15 403 596 137 917 M01AB02 sulindac 600 386 16 0 0 - 0 0 0 0 0 M01AB05 diclofenac 1)471 691 464 462 481 108 483 169 460 406 54 7 345 195 692 213 181 44 188 46 001 M01AB15 ketorolac 7 11 27 23 9 56 0 <5 7 0 5 M01AB55 diclofenac, combinations 22 250 23 266 29 244 31 576 28 949 63 26 6 232 15 657 7 034 11 614 M01AC Oxicams 88 227 81 319 76 309 69 293 59 377 55 210 18 842 31 871 8 454 15 603 M01AC01 piroxicam 60 698 55 461 51 627 47 991 43 556 52 181 15 679 23 252 4 444 11 193 M01AC06 meloxicam 28 570 26 731 25 438 21 952 16 188 62 29 3 258 8 836 4 065 4 410 M01AE Propionic acid derivatives 278 524 273 810 276 001 294 401 332 008 61 5 424 127 410 155 557 43 617 79 509 M01AE01 ibuprofen1)208 791 211 641 215 745 226 838 224 736 62 4 544 94 281 101 681 24 230 32 321 M01AE02 naproxen1)66 541 59 487 58 354 62 549 65 047 58 866 22 460 30 758 10 963 21 836 M01AE03 ketoprofen 8 541 7 912 7 478 7 396 6 725 60 16 1 486 3 802 1 421 2 890 M01AE14 dexibuprofen 2 124 1 417 1 025 881 707 62 <5 283 335 88 165 M01AE52 naproxen and esomeprazole 0 0 0 5 217 50 757 63 59 14 335 27 372 8 991 22 298 M01AG Fenamates 827 669 106 304 310 82 <5 197 108 <5 248 M01AG02 tolfenamic acid 827 669 106 304 310 82 <5 197 108 <5 248 M01AH Coxibs 36 485 35 851 35 999 36 515 43 565 56 77 13 922 22 610 6 956 20 378 M01AH01 celecoxib 8 315 8 030 7 851 7 720 9 974 63 27 2 875 5 147 1 925 6 650 M01AH04 parecoxib <5 <5 0 0 <5 100 0 0 9 M01AH05 etoricoxib 28 365 28 047 28 365 29 013 33 988 54 50 11 129 17 706 5 103 13 719 M01AX Other antiinflammatory and antirheumatic agents, non-steroids 55 088 51 313 48 137 41 749 37 352 66 14 2 783 21 163 13 392 18 585 M01AX01 nabumetone 11 261 9 107 7 343 6 378 4 792 66 7 890 2 722 1 173 2 276 M01AX05 glucosamine 1)43 576 41 918 40 410 34 884 31 944 66 7 1 810 18 112 12 015 14 823 M01C SPECIFIC ANTIRHEUMATIC AGENTS 325 285 242 208 133 71 0 20 72 41 950 M01CB Gold preparations 267 241 199 171 100 79 0 14 51 35 325M01CB01 sodium aurothiomalate 97 74 36 30 26 77 0 <5 10 14 97 M01CB03 auranofin 171 167 163 141 74 80 0 12 41 21 228 M01CC Penicillamine and similar agents 15 12 14 13 12 33 0 <5 8 <5 90 M01CC01 penicillamine 15 12 14 13 12 33 0 <5 8 <5 90 M01CX Other specific antirheumatic agents 43 32 30 24 21 52 0 <5 13 5 535 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 31 768 27 101 24 394 53 477 59 086 61 2 263 17 779 23 903 15 141 5 553 M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 31 768 27 101 24 394 53 477 59 086 61 2 263 17 779 23 903 15 141 5 553 M02AA Antiinflammatory preparations, non-steroids for topical use 31 675 27 032 24 200 53 269 58 967 61 2 255 17 743 23 864 15 105 5 540 M02AA10 ketoprofen 1)27 552 23 095 20 122 47 409 51 200 61 1 890 15 355 21 044 12 911 4 157 M02AA13 ibuprofen1)4 040 3 853 3 998 4 923 5 812 60 302 1 718 2 008 1 784 987 M02AA15 diclofenac 173 160 167 1 322 2 398 58 68 740 957 633 396 M02AB Capsaicin and similar agents 8 5 6 6 8 63 0 0 <5 5 1 M02AB01 capsaicin 8 5 6 6 8 63 0 0 <5 5 1 M02AC Preparations with salicylic acid derivatives 89 69 189 207 124 55 8 41 37 38 11 M02AX Other topical products for joint and muscular pain 7 11 13 9 5 80 0 0 <5 <5 1 M02AX10 various 7 11 13 9 5 80 0 0 <5 <5 1 M03 MUSCLE RELAXANTS 12 875 5 592 5 918 6 009 5 928 56 104 1 545 3 539 740 12 752 M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS 12 660 5 388 5 657 5 654 5 575 55 103 1 333 3 407 732 9 914 M03BA Carbamic acid esters 8 594 1 087 1 097 1 030 910 68 0 218 616 76 2 764 M03BA02 carisoprodol 8 583 1 087 1 097 1 030 910 68 0 218 616 76 2 764 M03BA52 carisoprodol, combinations excl. psycholeptics 30 <5 0 0 - 0 0 0 0 0 M03BB Oxazol, thiazine, and triazine derivatives <5 0 0 <5 - 0 0 0 0 0 M03BB03 chlorzoxazone <5 0 0 <5 0 - 0 0 0 0 0 M03BC Ethers, chemically close to antihistamines <5 <5 <5 0 0 - 0 0 M03BC51 orphenadrine, combinations <5 <5 <5 0 0 - 0 0 0 0 0 M03BX Other centrally acting agents 4 236 4 318 4 583 4 652 4 686 52 103 1 124 2 803 656 7 150 M03BX01 baclofen 4 195 4 277 4 544 4 608 4 640 52 103 1 109 2 777 651 6 748 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.2.13 ATC group M - Musculo-skeletal system ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group M ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 72 41 0 21 48 6 402 M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS <5 0 0 <5 0 - 0 0 0 0 0 M03CA Dantrolene and derivatives <5 0 0 <5 0 - 0 0 0 0 0 M03CA01 dantrolene <5 0 0 <5 0 - 0 0 0 0 0 M04 ANTIGOUT PREPARATIONS 37 888 39 433 40 882 43 057 45 433 29 15 2 731 19 676 23 011 19 516 M04A ANTIGOUT PREPARATIONS 37 888 39 433 40 882 43 057 45 433 29 15 2 731 19 676 23 011 19 516 M04AA Preparations inhibiting uric acid production 34 952 36 397 37 670 39 470 41 647 29 <5 2 361 18 003 21 280 15 461 M04AA01 allopurinol 34 952 36 397 37 661 39 441 41 584 29 <5 2 351 17 974 21 256 13 894 M04AA03 febuxostat 0 0 9 33 75 29 0 12 34 29 1 567 M04AB Preparations increasing uric acid excretion 2 100 2 123 2 062 2 072 2 037 29 <5 127 922 987 2 313 M04AB01 probenecid 2 100 2 123 2 062 2 072 2 037 29 <5 127 922 987 2 313 M04AC Preparations with no effect on uric acid metabolism 2 373 2 597 3 070 3 688 4 202 23 11 457 1 924 1 810 1 742 M04AC01 colchicine 2 373 2 597 3 070 3 688 4 202 23 11 457 1 924 1 810 1 742 M05 DRUGS FOR TREATMENT OF BONE DISEASES 56 634 56 744 57 597 58 371 59 927 88 <5 675 21 602 37 646 71 565 M05B DRUGS AFFECTING BONE STRUCTURE AND MINER-ALIZATION 56 634 56 744 57 597 58 371 59 927 88 <5 675 21 602 37 646 71 565 M05BA Bisphosphonates 54 146 54 669 55 785 56 550 57 162 89 <5 630 20 768 35 760 53 316 M05BA01 etidronic acid 372 297 240 205 151 92 0 <5 21 129 111 M05BA02 clodronic acid 48 44 48 48 41 51 0 0 22 19 720 M05BA03 pamidronic acid 10 13 21 19 16 44 0 <5 7 8 76 M05BA04 alendronic acid 51 829 52 053 52 702 52 893 53 104 88 <5 548 18 984 33 568 38 175 M05BA06 ibandronic acid 704 704 696 668 653 93 0 <5 262 388 2 204 M05BA07 risedronic acid 1 405 1 214 1 097 948 832 93 0 6 302 524 2 112 M05BA08 zoledronic acid 221 835 1 584 2 329 2 903 88 0 78 1 426 1 399 9 919 M05BB Bisphosphonates, combi-nations 2 745 2 267 1 950 1 659 1 433 94 0 <5 298 1 131 2 748 M05BB01 etidronic acid and calcium, sequential 2 745 2 267 1 950 1 659 1 433 94 0 <5 298 1 131 2 748 M05BX Other drugs affecting bone structure and mineraliza-tion 0 0 27 398 1 847 78 0 41 653 1 153 15 501 M05BX04 denosumab 0 0 27 398 1 847 78 0 41 653 1 153 15 501 M09 OTHER DRUGS FOR DISOR-DERS OF THE MUSCULO-SKELETAL SYSTEM <5 <5 0 0 31 6 0 <5 17 13 301M09A OTHER DRUGS FOR DISOR-DERS OF THE MUSCULO-SKELETAL SYSTEM <5 <5 0 0 31 6 0 <5 17 13 301 M09AB Enzymes 0 0 0 0 31 6 0 <5 17 13 301 M09AB02 collagenase clostridium histolyticum 0 0 0 0 31 6 0 <5 17 13 301 M09AX Other drugs for disorders of the musculo-skeletal system <5 <5 0 0 0 - 0 0 0 0 0 M09AX01 hyaluronic acid <5 <5 0 0 0 - 0 0 0 0 0ATC group M ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group M ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NERVOUS SYSTEM 1 208 796 1 230 918 1 248 505 1 279 676 1 301 538 59 30 853 414 409 565 804 290 472 686 710 126 61 9 362 247 387 339 980 168 397 680 919 N02A OPIOIDS 484 768 487 517 491 941 500 644 513 389 56 5 207 169 147 228 467 110 568 398 383 N02AA Natural opium alkaloids 409 141 405 617 401 941 403 516 403 774 56 4 998 138 800 179 620 80 356 254 799 N02AA01 morphine 6 995 7 048 7 000 6 790 6 800 50 25 878 3 242 2 655 13 652 N02AA03 hydromorphone 53 41 40 48 68 47 0 13 40 15 5 584 N02AA05 oxycodone 14 983 16 910 19 067 20 444 22 927 53 16 3 543 10 647 8 721 78 829 N02AA08 dihydrocodeine 40 49 47 52 47 79 0 10 33 <5 277 N02AA55 oxycodone, combinations 5 228 1 001 1 831 2 869 55 0 276 1 221 1 372 9 124 N02AA59 codeine, combinations excl. psycholeptics 397 626 392 734 387 507 387 930 386 295 56 4 970 136 529 171 773 73 023 147 334 N02AB Phenylpiperidine deriva-tives 10 253 10 453 11 167 11 306 11 480 59 9 1 890 4 987 4 594 46 692 N02AB01 ketobemidone 3 738 3 731 3 994 3 972 3 988 54 <5 1 123 2 026 838 5 432 N02AB02 pethidine 1 377 1 340 1 343 1 243 1 198 61 0 351 662 185 1 923 N02AB03 fentanyl 5 657 5 857 6 331 6 583 6 764 62 8 512 2 556 3 688 39 336 N02AC Diphenylpropylamine derivatives 8 523 7 442 4 700 30 16 63 0 <5 <5 9 31 N02AC04 dextropropoxyphene 0 0 0 9 9 31 N02AC54 dextropropoxyphene, combi-nations excl. psycholeptics 8 523 7 442 4 700 22 0 - 0 0 0 0 0 N02AD Benzomorphan derivatives 49 45 41 35 30 50 0 <5 19 8 448 N02AD01 pentazocine 49 45 41 35 30 50 0 <5 19 8 448 N02AE Oripavine derivatives 10 244 12 080 13 189 14 009 15 226 71 <5 1 284 3 992 9 948 44 747 N02AE01 buprenorphine 10 244 12 080 13 189 14 009 15 226 71 <5 1 284 3 992 9 948 44 747 N02AG Opioids in combination with antispasmodics 1 819 1 729 1 840 1 776 1 957 58 <5 519 908 526 1 662 N02AG01 morphine and antispas-modics 218 218 263 310 383 52 <5 9 98 274 85 N02AG02 ketobemidone and antispas-modics 1 608 1 515 1 584 1 470 1 576 59 <5 510 811 253 1 577 N02AX Other opioids 106 796 114 947 127 986 138 495 155 275 58 249 44 768 71 570 38 688 50 006 N02AX02 tramadol 106 796 114 947 127 986 138 478 154 986 58 249 44 705 71 402 38 630 48 598 N02AX06 tapentadol 0 0 0 31 490 56 0 119 265 106 1 407 N02B OTHER ANALGESICS AND ANTIPYRETICS 255 894 281 468 305 897 337 952 362 751 64 3 081 86 224 162 270 111 176 69 053 N02BA Salicylic acid and deriva-tives 769 806 840 883 785 59 241 228 186 130 275 N02BA01 acetylsalicylic acid 768 802 836 879 779 58 N02BA11 0 <5 N02BB Pyrazolones 909 885 887 891 960 69 10 425 348 177 339 N02BB02 metamizole sodium 15 22 12 5 13 62 0 <5 7 5 23 N02BB51 phenazone, combinations excl. psycholeptics 894 863 875 886 947 69 10 424 341 172 315 N02BE Anilides 254 655 280 253 304 673 336 641 361 454 64 2 833 85 730 161 883 111 008 67 716 N02BE01 paracetamol 1)254 655 280 253 304 673 336 641 361 454 64 2 833 85 730 161 883 111 008 67 716 N02BG Other analgesics and antipyretics <5 <5 0 <5 723 N02BG07 flupirtine <5 <5 0 0 <5 100 0 0 1 N02BG08 ziconotide 0 0 0 <5 0 - 0 0 0 0 0 N02BG10 nabiximols 0 0 0 <5 67 46 0 19 43 5 722 N02C ANTIMIGRAINE PREPARATIONS 88 060 87 608 88 921 91 693 94 258 79 1 795 44 902 43 843 3 718 213 483 N02CA Ergot alkaloids 3 827 3 477 3 072 2 918 2 492 83 7 385 1 520 580 1 171 N02CA04 methysergide 8 6 6 9 7 43 0 0 <5 <5 17 N02CA52 ergotamine, combinations excl. psycholeptics 14 13 12 67 0 <5 6 <5 17 N02CA72 ergotamine, combinations with psycholeptics 3 808 3 458 3 053 2 895 2 473 83 7 383 1 510 573 1 137 N02CC Selective serotonin (5HT1) agonists 82 235 81 971 83 476 85 970 88 996 80 1 733 43 765 40 528 2 970 210 112 N02CC01 sumatriptan 35 885 40 472 41 843 43 349 45 173 77 1 538 24 215 18 004 1 416 85 697 N02CC02 naratriptan 1 515 1 497 1 501 1 581 1 651 87 8 697 871 75 4 843 N02CC03 zolmitriptan 14 983 14 223 14 230 14 481 14 776 82 124 6 645 7 444 563 32 761 N02CC04 rizatriptan 24 519 22 306 22 398 23 373 24 226 81 191 12 433 10 861 741 45 452 N02CC05 almotriptan 3 915 3 286 3 053 2 936 2 938 84 10 1 465 1 378 85 5 977 N02CC06 eletriptan 11 871 11 192 11 289 11 403 11 463 83 47 5 196 5 951 269 35 342 N02CC07 frovatriptan 12 19 6 5 7 86 0 <5 <5 0 40 N02CX Other antimigraine preparations 3 129 3 163 3 418 3 920 3 942 76 62 1 118 2 503 259 2 200 N02CX01 pizotifen 63 53 61 60 78 81 0 31 41 6 223 N02CX02 clonidine 3 067 3 111 3 357 3 861 3 867 76 62 1 088 2 464 253 1 978 N03 ANTIEPILEPTICS 97 238 100 382 103 954 108 555 113 208 56 3 499 35 703 52 641 21 365 391 699 N03A ANTIEPILEPTICS 97 238 100 382 103 954 108 555 113 208 56 3 499 35 703 52 641 21 365 391 699 N03AA Barbiturates and deriva-tives 2 959 2 844 2 700 2 544 2 419 52 14 239 1 317 849 1 817 N03AA02 phenobarbital 2 718 2 574 2 426 2 270 2 140 52 13 210 1 178 739 1 313 N03AA03 primidone 255 284 288 287 291 49 <5 29 144 117 505 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.2.14 ATC group N - Nervous system ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group N ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 218 2 051 1 938 1 796 42 19 206 1 018 553 857 N03AB02 phenytoin 2 332 2 217 2 051 1 937 1 796 42 19 206 1 018 553 857 N03AB05 fosphenytoin 0 <5 0 <5 0 - 0 0 0 0 0 N03AD Succinimide derivatives 116 139 149 173 182 65 91 70 18 <5 1 620 N03AD01 ethosuximide 116 139 149 173 182 65 91 70 18 <5 1 620 N03AE Benzodiazepine derivatives 13 927 13 713 13 528 13 006 12 531 54 169 3 445 6 472 2 445 6 154 N03AE01 clonazepam 13 927 13 713 13 528 13 006 12 531 54 169 3 445 6 472 2 445 6 154 N03AF Carboxamide derivatives 20 748 20 004 19 238 18 449 17 607 46 704 4 830 8 730 3 343 30 508 N03AF01 carbamazepine 18 586 17 750 16 830 15 931 14 986 47 339 3 788 7 834 3 025 13 979 N03AF02 oxcarbazepine 2 173 2 236 2 298 2 375 2 419 44 364 901 836 318 9 698 N03AF03 rufinamide 80 96 96 97 99 41 19 73 6 <5 2 247 N03AF04 eslicarbazepine 0 <5 205 213 232 55 <5 120 98 13 4 584 N03AG Fatty acid derivatives 13 320 13 867 14 184 14 347 14 644 45 1 617 5 825 5 951 1 251 31 858 N03AG01 valproic acid 13 227 13 786 14 111 14 279 14 576 45 1 597 5 805 5 924 1 250 31 000 N03AG03 aminobutyric acid 0 0 0 0 7 43 0 <5 <5 <5 3 N03AG04 vigabatrin 127 114 100 88 88 49 39 25 23 <5 620 N03AG06 tiagabine 15 12 11 13 10 50 0 <5 7 0 236 N03AX Other antiepileptics 57 604 61 469 66 054 71 880 77 686 59 1 869 26 029 35 321 14 467 318 884 N03AX03 sultiame 54 64 98 130 161 44 126 32 <5 0 1 016 N03AX09 lamotrigine 20 820 22 368 23 711 24 878 26 165 60 1 012 13 095 9 846 2 212 83 646 N03AX10 felbamate 24 25 23 21 21 29 0 18 <5 0 463 N03AX11 topiramate 3 051 3 039 3 060 3 047 3 121 70 228 1 713 1 063 117 11 050 N03AX12 gabapentin 14 682 20 412 24 447 26 611 28 872 60 53 6 263 14 991 7 565 42 940 N03AX14 levetiracetam 4 320 4 977 5 539 6 101 6 763 48 628 2 602 2 439 1 094 62 532 N03AX15 zonisamide 349 444 457 473 517 56 82 271 144 20 6 728 N03AX16 pregabalin 20 274 17 120 15 264 16 892 18 299 59 9 4 334 9 590 4 366 102 495 N03AX17 stiripentol 0 19 33 30 24 42 14 10 0 0 1 373 N03AX18 lacosamide 0 122 262 341 410 52 9 240 143 18 5 626 N03AX21 retigabine 0 0 0 18 138 57 <5 103 32 <5 1 017 N04 ANTI-PARKINSON DRUGS 17 191 17 238 17 787 18 178 18 634 50 14 1 556 8 106 8 958 127 394 N04A ANTICHOLINERGIC AGENTS 3 162 3 034 2 915 2 808 2 662 49 <5 593 1 660 405 1 525 N04AA Tertiary amines 3 104 2 991 2 880 2 773 2 631 49 <5 591 1 638 398 1 432 N04AA01 trihexyphenidyl 15 15 22 23 20 55 <5 7 8 <5 156 N04AA02 biperiden 3 085 2 971 2 854 2 747 2 607 49 <5 584 1 628 N04AB Ethers chemically close to antihistamines 65 48 40 38 36 64 0 <5 27 7 92N04AB02 orphenadrine (chloride) 65 48 40 38 36 64 0 <5 27 7 92 N04B DOPAMINERGIC AGENTS 14 096 14 267 14 940 15 436 16 033 51 10 971 6 476 8 576 125 869 N04BA Dopa and dopa derivatives 7 606 7 716 7 906 8 015 8 274 43 10 121 2 475 5 668 63 300 N04BA02 levodopa and decarboxylase inhibitor 6 995 7 051 7 180 7 277 7 557 44 10 113 2 173 5 261 46 818 N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor 1 448 1 395 1 413 36 0 17 619 777 16 482 N04BB Adamantane derivatives 111 114 114 123 139 57 0 41 86 12 511 N04BB01 amantadine 111 114 114 123 139 57 0 41 86 12 511 N04BC Dopamine agonists 8 542 8 784 9 442 9 976 10 374 53 0 837 5 229 4 308 42 492 N04BC01 12 N04BC04 ropinirole 1 842 2 316 2 665 2 667 2 675 45 0 164 1 456 1 055 16 045 N04BC05 pramipexole 6 236 6 258 6 501 6 946 7 343 57 0 684 3 620 3 039 16 758 N04BC06 cabergoline 514 322 209 177 142 49 0 7 46 89 541 N04BC07 apomorphine 18 19 18 21 19 37 0 0 6 13 2 724 N04BC09 rotigotine 393 427 517 541 528 43 0 12 282 234 6 413 N04BD Monoamine oxidase B inhibitors 2 571 2 862 3 184 3 339 3 518 37 0 45 1 741 1 732 18 329 N04BD01 selegiline 2 081 2 116 2 126 2 087 2 137 38 0 26 1 081 1 030 3 055 N04BD02 rasagiline 575 864 1 183 1 329 1 460 38 0 19 715 726 15 274 N04BX Other dopaminergic agents 287 230 192 152 160 47 0 <5 59 100 1 237 N04BX01 tolcapone 13 13 11 11 9 11 0 0 <5 7 80 N04BX02 entacapone 274 218 181 141 151 49 0 <5 57 93 1 158 N05 PSYCHOLEPTICS 611 554 616 964 614 376 618 313 615 272 63 9 316 139 901 278 452 187 603 582 512 N05A ANTIPSYCHOTICS 104 087 104 082 104 077 104 361 105 768 56 877 36 184 47 492 21 215 291 676 N05AA Phenothiazines with aliphatic side-chain 26 862 25 877 24 617 23 180 21 732 57 15 5 748 11 481 4 488 8 518 N05AA01 chlorpromazine 702 492 439 276 55 0 109 127 40 893 N05AA02 levomepromazine 26 247 25 435 24 212 22 826 21 481 57 15 5 649 11 368 4 7 N05AB Phenothiazines with piperazine structure 20 902 19 829 18 276 17 128 15 731 67 14 3 342 6 742 5 633 8 017 N05AB01 dixyrazine 76 54 32 <5 0 - 0 0 0 0 0 N05AB02 fluphenazine 59 27 22 20 15 53 0 0 7 8 29 N05AB03 perphenazine 5 993 5 736 5 423 5 084 4 717 58 <5 1 061 2 756 899 5 862 N05AB04 prochlorperazine 14 841 14 075 12 860 12 078 11 036 71 13 2 284 3 997 4 N05AB06 trifluoperazine N05AC Phenothiazines with piperidine structure 79 70 62 61 50 60 0 <5 19 171 N05AC01 2ATC group N ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group N ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 18 145 N05AC04 pipotiazine 24 N05AD Butyrophenone derivatives 4 735 4 473 4 277 4 089 4 003 54 7 384 1 432 2 180 1 333 N05AD01 haloperidol 4 725 4 466 4 270 4 082 3 994 54 7 382 1 428 2 177 1 322 N05AD03 melperone 10 7 6 6 6 50 0 8 N05AD08 <5 3 N05AE Indole derivatives 1 383 1 302 1 164 1 033 956 60 <5 470 446 38 12 786 N05AE03 sertindole 165 186 161 138 127 57 0 85 40 <5 1 281 N05AE04 ziprasidone 1 231 1 118 1 006 897 830 60 <5 386 406 36 11 505 N05AF Thioxanthene derivatives 24 515 24 245 23 752 22 935 22 479 55 29 7 594 11 271 3 585 10 732 N05AF01 flupentixol 5 381 5 006 4 918 4 621 4 468 66 0 1 144 2 290 1 034 2 423 N05AF03 chlorprothixene 16 666 17 012 16 658 16 269 16 030 53 27 6 060 7 818 2 125 5 984 N05AF05 zuclopenthixol 3 156 2 908 2 822 2 661 2 574 51 <5 624 1 468 480 2 325 N05AG Diphenylbutylpiperidine derivatives 165 142 135 139 127 35 <5 68 40 15 297 N05AG02 pimozide 133 116 118 117 110 39 <5 58 34 14 265 N05AG03 penfluridol 33 27 17 22 17 12 0 10 6 <5 32 N05AH Diazepines, oxazepines, thiazepines and oxepines 26 510 28 510 31 688 35 237 39 762 52 111 18 561 16 945 4 145 127 594 N05AH02 clozapine 2 185 2 299 2 362 2 398 2 455 37 0 1 190 1 186 79 9 374 N05AH03 olanzapine 15 960 16 068 15 799 15 754 15 987 48 29 6 406 7 383 2 169 57 110 N05AH04 quetiapine 9 547 11 509 15 094 18 864 23 280 56 86 12 064 9 122 2 008 60 227 N05AH05 asenapine 0 0 0 0 117 58 0 60 56 <5 883 N05AL Benzamides 589 580 548 527 566 44 <5 294 244 27 3 573 N05AL03 tiapride 7 5 <5 <5 41 N05AL05 amisulpride 582 575 541 520 559 44 0 291 242 26 3 532 N05AN Lithium 7 927 7 995 7 877 7 727 7 781 56 6 2 253 4 382 1 140 13 043 N05AN01 lithium 7 927 7 995 7 877 7 727 7 781 56 6 2 253 4 382 1 140 13 043 N05AX Other antipsychotics 10 930 11 446 12 299 12 804 13 142 48 737 5 958 4 411 2 036 105 611 N05AX07 prothipendyl 0 0 <5 0 4 N05AX08 risperidone 8 158 8 150 8 255 8 366 8 269 46 640 2 979 2 780 1 870 39 452 N05AX12 aripiprazole 3 055 3 625 4 379 4 744 4 898 52 131 2 975 1 620 172 54 838 N05AX13 paliperidone 0 0 0 37 511 40 <5 336 165 9 11 318 N05B ANXIOLYTICS 285 503 282 070 277 880 273 985 273 463 64 3 654 62 174 128 190 79 445 104 552 N05BA Benzodiazepine derivatives 265 344 261 074 255 446 250 055 249 237 65 3 230 53 097 118 673 74 237 90 685 N05BA01 diazepam 143 631 138 282 132 588 128 283 125 645 63 3 032 26 159 60 377 36 077 44 547 N05BA02 3 N05BA04 oxazepam 134 012 134 703 133 963 131 939 134 167 67 74 29 544 63 252 41 297 38 919N05BA06 lorazepam 18 20 21 30 31 55 <5 12 13 <5 55 N05BA08 bromazepam 5 7 5 6 7 71 0 0 <5 <5 26 N05BA09 clobazam 547 558 615 645 701 54 218 343 132 8 1 920 N05BA12 alprazolam 4 631 4 521 4 340 4 024 4 112 47 0 1 754 1 926 432 5 216 N05BB Diphenylmethane derivatives 27 294 28 280 30 163 31 960 32 244 62 425 11 264 13 383 7 172 9 153 N05BB01 hydroxyzine 27 294 28 280 30 163 31 960 32 244 62 425 11 264 13 383 7 172 9 153 N05BC Carbamates 9 10 6 7 6 83 0 0 0 6 12 N05BC01 meprobamate 9 10 6 7 6 83 0 0 0 6 12 N05BE Azaspirodecanedione derivatives 2 808 2 394 2 345 2 371 2 573 59 6 933 1 268 366 4 701 N05BE01 buspirone 2 808 2 394 2 345 2 371 2 573 59 6 933 1 268 366 4 701 N05C HYPNOTICS AND SEDA - TIVES 397 070 405 810 406 162 411 062 406 576 65 5 696 78 638 182 927 139 315 186 284 N05CA Barbiturates, plain <5 <5 <5 <5 barbital <5 <5 <5 <5 0 - 0 0 0 0 0 N05CD Benzodiazepine derivatives 46 685 44 520 41 807 39 255 34 045 60 856 6 087 13 464 13 638 17 507 N05CD01 flurazepam 22 20 17 16 16 50 0 0 8 8 48 N05CD02 nitrazepam 37 541 35 856 33 406 31 315 27 847 61 319 4 726 11 288 11 514 8 341 N05CD03 flunitrazepam 9 223 8 479 7 690 6 971 5 777 55 <5 888 2 499 2 386 3 680 N05CD04 estazolam <5 <5 0 0 0 - 0 0 0 0 0 N05CD05 triazolam 103 105 115 98 107 56 <5 35 38 33 99 N05CD08 midazolam 831 1 071 1 493 1 759 2 227 49 630 850 427 320 5 339 N05CF Benzodiazepine related drugs 346 261 351 044 349 542 352 287 354 874 66 71 59 640 166 040 129 123 133 824 N05CF01 zopiclone 306 246 308 363 305 048 306 107 306 040 66 55 47 411 142 379 116 195 116 108 N05CF02 zolpidem 51 245 53 835 55 244 56 956 61 025 66 17 15 263 29 156 16 589 17 716 N05CF03 zaleplon 5 7 <5 0 0 - 0 0 0 0 0 N05CH Melatonin receptor agonists 29 906 38 868 42 795 48 436 53 460 60 4 988 21 250 20 065 7 157 32 688 N05CH01 melatonin 29 906 38 868 42 795 48 436 53 460 60 4 988 21 250 20 065 7 157 32 688 N05CM Other hypnotics and sedatives 1 899 1 944 2 109 2 131 2 157 47 0 194 612 1 351 2 265 N05CM02 clomethiazole 1 843 1 870 2 048 2 057 1 991 46 0 168 556 1 267 2 091 N05CM05 scopolamine 57 77 65 75 89 42 0 <5 28 58 139 N05CM06 propiomazine 0 0 0 0 15 67 0 <5 10 <5 12 N05CM09 valerianae radix 0 0 0 0 65 75 0 19 20 26 23 N05CM11 bromides 0 0 0 <5 <5 100 0 <5 0 0 1 N06 PSYCHOANALEPTICS 319 757 325 942 333 134 341 017 348 615 63 11 056 117 387 145 022 75 150 551 430 N06A ANTIDEPRESSANTS 288 418 292 396 297 124 303 747 309 491 66 673 101 237 142 130 65 451 285 035ATC group N ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group N ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 60 237 61 908 63 098 64 671 72 98 16 079 34 469 14 025 25 378 N06AA02 imipramine 47 34 26 22 19 58 <5 0 8 8 74 N06AA04 clomipramine 3 455 3 276 3 080 2 907 2 709 70 13 457 1 558 681 2 187 N06AA05 opipramol 5 5 6 6 9 44 0 <5 <5 6 14 N06AA06 trimipramine 12 628 11 930 11 431 10 943 10 549 70 5 2 110 5 403 3 031 6 589 N06AA07 lofepramine 18 15 13 12 11 55 0 <5 7 <5 52 N06AA09 amitriptyline 38 809 40 585 43 086 45 318 47 756 72 73 13 066 25 969 8 648 14 018 N06AA10 nortriptyline 1 651 1 837 2 104 1 983 1 978 69 6 550 926 496 710 N06AA12 doxepin 3 580 3 348 3 017 2 749 2 495 70 0 162 1 026 1 307 1 732 N06AA21 N06AB Selective serotonin reuptake inhibitors 176 994 178 930 180 612 184 013 185 977 66 544 66 377 81 196 37 860 151 065 N06AB03 fluoxetine 8 827 9 010 9 289 9 634 10 545 75 196 6 053 3 608 688 15 334 N06AB04 citalopram 35 572 32 885 30 680 29 143 27 102 68 11 6 296 13 303 7 492 17 943 N06AB05 paroxetine 18 698 17 508 16 895 16 172 15 503 69 <5 3 257 8 480 3 764 14 810 N06AB06 sertraline 26 040 26 427 26 384 27 181 28 723 66 327 11 366 11 827 5 203 28 358 N06AB08 fluvoxamine 653 620 603 586 552 55 0 208 271 73 1 053 N06AB10 escitalopram 93 703 98 493 102 626 107 172 109 202 65 25 41 687 45 876 21 614 73 566 N06AF Monoamine oxidase inhibitors, non-selective 110 111 111 102 95 62 0 22 54 19 1 231 N06AF03 phenelzine 100 102 102 94 88 60 0 19 51 18 584 N06AF04 tranylcypromine 10 9 9 9 7 86 0 <5 <5 647 N06AG Monoamine oxidase A inhibitors 1 081 965 880 853 757 63 0 161 435 161 1 734 N06AG02 moclobemide 1 081 965 880 853 757 63 0 161 435 161 1 734 N06AX Other antidepressants 88 987 90 568 92 850 95 460 98 561 60 48 31 021 45 064 22 428 105 628 N06AX01 oxitriptan 187 244 261 308 292 82 10 149 124 9 356 N06AX02 tryptophan 11 5 <5 7 N06AX03 mianserin 32 133 31 289 30 307 29 477 28 065 62 12 6 604 13 325 8 6 N06AX06 nefazodone 48 43 42 36 36 47 0 <5 31 <5 278 N06AX11 mirtazapine 28 798 30 394 31 458 33 331 35 629 57 17 9 958 15 070 10 584 30 660 N06AX12 bupropion 3 892 5 978 7 641 8 808 10 186 59 <5 5 010 4 108 <5 78 N06AX16 venlafaxine 28 349 28 734 28 791 29 240 30 220 62 6 11 229 14 631 4 354 33 878 N06AX18 reboxetine 569 530 512 424 410 64 0 200 173 37 862 N06AX21 duloxetine 3 945 2 419 2 804 3 021 3 190 68 0 994 1 722 474 10 460 N06AX22 agomelatine 0 0 28 22 15 80 0 <5 11 <5 196N06AX25 Hyperici herba 0 0 <5 <5 5 N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS 25 207 27 837 30 080 31 221 32 973 38 10 527 19 403 2 897 146 193 589 N06BA Centrally acting sympathomimetics 24 862 27 490 29 711 30 821 32 575 37 10 519 19 186 2 761 109 192 970 N06BA01 amfetamine 221 269 303 336 382 48 23 255 90 14 4 591 N06BA02 dexamfetamine 857 1 024 1 167 1 285 1 473 43 80 1 008 364 21 18 472 N06BA04 methylphenidate 21 769 24 240 26 471 27 302 28 962 37 9 880 16 859 2 160 63 137 038 N06BA07 modafinil 288 291 329 349 366 62 15 218 119 14 4 061 N06BA09 atomoxetine 3 246 3 213 3 055 3 108 3 032 34 1 089 1 776 167 0 28 800 N06BA12 lisdexamfetamine 0 0 0 0 <5 100 0 <5 0 0 8 N06BC Xanthine derivatives 294 281 285 326 321 47 <5 187 105 27 167 N06BC01 caffeine 294 281 285 326 321 47 <5 187 105 27 167 N06BX Other psychostimulants and nootropics 57 75 102 86 87 41 6 37 34 10 452 N06BX03 piracetam 49 65 77 70 76 38 <5 30 34 10 249 N06BX13 idebenone 8 10 8 10 11 64 <5 7 0 0 203 N06BX17 adrafinil 0 0 18 6 0 - 0 0 0 0 0 N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION 0 0 0 0 <5 0 0 <5 0 0 0 N06CA Antidepressants in combi-nation with psycholeptics 0 0 0 0 <5 0 0 <5 0 0 0 N06CA02 melitracen and psycholeptics 0 0 0 0 <5 0 0 <5 0 0 0 N06D ANTI-DEMENTIA DRUGS 13 367 13 344 14 174 14 759 15 484 63 <5 89 1 440 13 953 72 806 N06DA Anticholinesterases 12 377 12 372 12 920 12 850 13 023 63 0 <5 1 217 11 804 52 083 N06DA02 donepezil 9 837 9 243 8 920 8 530 8 303 64 0 <5 731 7 571 24 535 N06DA03 rivastigmine 2 161 2 975 3 935 4 303 4 767 60 0 <5 486 4 280 24 876 N06DA04 galantamine 694 558 502 395 347 57 0 0 52 295 2 672 N06DX Other anti-dementia drugs 1 501 1 538 1 969 3 030 3 578 61 <5 87 382 3 107 20 723 N06DX01 memantine 1 501 1 538 1 816 2 837 3 445 61 0 <5 341 3 101 20 640 N06DX02 Ginkgo folium 0 0 153 193 133 77 <5 84 41 6 83 N07 OTHER NERVOUS SYSTEM DRUGS 42 733 46 042 47 182 48 455 45 068 49 9 16 489 26 054 2 516 280 914 N07A PARASYMPATHOMIMETICS 743 721 660 684 732 66 <5 113 371 246 2 381 N07AA Anticholinesterases 476 493 509 523 567 60 <5 104 248 213 1 166 N07AA02 pyridostigmine 476 492 505 519 565 60 <5 combinations 0 0 <5 <5 0 - 0 0 0 0 0 N07AB Choline esters 149 112 22 33 30 60 0 <5 23 6 55ATC group N ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group N ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 60 0 <5 23 6 55 N07AX Other parasympathomimetics 129 123 130 131 138 93 0 8 103 27 1 160 N07AX01 pilocarpine 129 123 130 131 138 93 0 8 103 27 1 160 N07B DRUGS USED IN ADDICTIVE DISORDERS 41 279 44 554 45 745 46 701 41 810 48 0 15 989 23 898 1 923 209 415 N07BA Drugs used in nicotine dependence 31 433 34 174 34 822 35 032 29 849 55 0 10 299 17 925 1 625 42 253 N07BA01 nicotine 1)770 769 906 1 000 915 53 0 131 528 256 623 N07BA03 varenicline 30 731 33 475 34 002 34 123 29 010 55 0 10 179 17 451 1 380 41 629 N07BB Drugs used in alcohol dependence 4 990 4 984 4 866 4 953 4 934 31 0 1 539 3 135 260 3 966 N07BB01 disulfiram 4 464 4 533 4 450 4 541 4 510 30 0 1 418 2 853 239 3 060 N07BB03 acamprosate 584 550 526 543 587 33 0 179 383 25 804 N07BB04 naltrexone 119 26 19 17 13 69 0 6 6 <5 102 N07BC Drugs used in opioid dependence 5 160 5 704 6 368 7 048 7 346 30 0 4 266 3 038 42 163 196 N07BC01 buprenorphine 2)1 719 1 981 2 133 2 270 2 624 30 0 1 688 933 <5 50 102 N07BC02 methadone2)2 952 3 140 3 337 3 636 3 629 32 0 1 794 1 797 38 88 613 N07BC51 buprenorphine, combinations2)1 156 1 194 1 562 1 759 1 851 26 0 1 359 491 PREPARATIONS 413 421 424 454 65 279 N07CA Antivertigo preparations 413 421 424 454 527 65 <5 312 115 1 279 N07CA01 betahistine 401 410 413 438 508 64 0 88 305 115 1 247 N07CA03 flunarizine 12 11 11 16 19 68 <5 9 7 0 32 N07X OTHER NERVOUS SYSTEM DRUGS 311 361 366 644 2 060 58 <5 305 1 514 237 67 839 N07XX Other nervous system drugs 311 361 366 644 2 060 58 <5 305 1 514 237 67 839 N07XX02 riluzole 253 286 278 294 297 34 0 18 160 119 7 627 N07XX04 sodium oxybate 28 33 49 58 63 54 <5 45 12 <5 4 896 N07XX05 amifampridine 0 0 0 0 <5 0 0 <5 0 0 927 N07XX06 tetrabenazine 30 42 37 35 40 50 0 8 24 8 647 N07XX07 fampridine 0 0 <5 257 1 318 107 53 742P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 89 343 86 714 88 743 92 296 94 797 63 3 329 42 623 37 887 10 958 33 814 P01 ANTIPROTOZOALS 86 259 83 638 85 626 88 926 91 338 63 2 150 41 076 37 327 10 785 31 870 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 53 345 54 583 55 588 57 290 57 887 66 576 24 745 24 117 8 449 6 502 P01AB Nitroimidazole derivatives 53 340 54 576 55 587 57 289 57 884 66 576 24 743 24 116 8 449 6 475 P01AB01 metronidazole 53 340 54 571 55 540 57 236 57 820 66 573 24 700 24 098 8 449 6 218 P01AB02 tinidazole 0 7 6 9 124 73 6 81 36 <5 251 P01AB03 ornidazole 0 0 46 73 9 78 0 5 <5 0 4 P01AB06 nimorazole 0 0 0 0 <5 0 0 0 <5 0 2 P01AC Dichloroacetamide deriva-tives 6 13 <5 33 5 <5 27 P01AC01 diloxanide 6 13 <5 11 12 33 <5 5 5 <5 27 P01AX Other agents against amoebiasis and other protozoal diseases <5 <5 <5 0 0 - 0 0 0 0 0 P01AX05 mepacrine <5 0 0 0 0 - 0 0 0 0 0 P01AX11 nitazoxanide <5 <5 <5 0 0 - 0 0 0 0 0 P01B ANTIMALARIALS 33 502 29 645 30 716 32 446 34 243 59 1 583 16 708 13 570 2 382 25 358 P01BA Aminoquinolines 7 804 5 421 5 684 5 912 6 122 82 43 1 669 3 415 995 3 497 P01BA01 chloroquine 2 630 40 21 17 21 71 0 6 11 <5 18 P01BA02 hydroxychloroquine 5 211 5 371 5 661 5 897 6 102 82 43 1 663 3 405 991 3 480 P01BA03 primaquine 17 12 <5 0 0 - 0 0 0 0 0 P01BB Biguanides 21 153 19 494 20 468 21 918 23 860 53 1 078 12 694 9 042 1 046 19 905 P01BB01 proguanil 62 22 11 7 <5 100 0 0 <5 0 1 P01BB51 proguanil, combinations 21 096 19 476 20 459 21 913 23 859 53 1 078 12 694 9 041 1 046 19 904 P01BC Methanolquinolines 5 056 5 044 4 802 4 841 4 457 59 469 2 471 1 173 344 1 954 P01BC01 quinine 595 629 569 473 440 65 0 21 197 222 267 P01BC02 mefloquine 4 463 4 415 4 235 4 368 4 018 58 469 2 450 977 122 1 687 P01BD Diaminopyrimidines <5 5 <5 0 0 - 0 0 0 0 0 P01BD01 pyrimethamine <5 5 <5 0 0 - 0 0 0 0 0 P01BE Artemisinin and deriva-tives, plain 0 0 0 0 <5 100 0 <5 0 0 1 P01BE03 artesunate 0 0 0 0 <5 100 0 <5 0 0 1 P01BF Artemisinin and deriva-tives, combinations 0 0 <5 0 0 0 <5 <5 <5 100 0 0 <5 0 2 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2) The figures only include methadone dispensed according to prescription from the pharmacies. Patients may also receive this drug dispensed according to special arrangements in the health regions.ATC group N ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.15 ATC group P - Antiparasitic products, insecticides and repellents ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 0 10 P02 ANTHELMINTICS 2 008 2 047 2 107 2 224 2 269 57 1 020 811 351 87 1 414 P02B ANTITREMATODALS 16 19 26 41 44 45 5 23 12 <5 115 P02BA Quinoline derivatives and related substances 16 19 26 41 44 45 5 23 12 <5 115 P02BA01 praziquantel 16 19 26 41 44 45 5 23 12 <5 115 P02C ANTINEMATODAL AGENTS 1 985 2 016 2 068 2 171 2 223 57 1 014 785 342 82 1 292 P02CA Benzimidazole derivatives 1 853 1 870 1 900 2 004 2 038 56 955 701 309 73 1 180 P02CA01 mebendazole 1 835 1 847 1 877 1 960 1 974 56 941 666 295 72 376 P02CA03 albendazole 18 24 23 45 70 60 14 38 16 <5 804 P02CF Avermectines 43 47 62 58 77 52 12 38 21 6 94 P02CF01 ivermectin 43 47 62 58 77 52 12 38 21 6 94 P02CX Other antinematodals 103 114 120 119 123 71 49 53 16 5 18 P02CX01 pyrvinium 103 114 120 119 123 71 49 53 16 5 18 P02D ANTICESTODALS 10 18 18 26 12 42 <5 7 <5 <5 7 P02DA Salicylic acid derivatives 10 18 18 26 12 42 <5 7 <5 <5 7 P02DA01 niclosamide 10 18 7 P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES REPELLENTS 1 216 1 157 1 176 1 297 1 354 52 173 835 252 94 530 P03A ECTOPARASITICIDES, INCL. SCABICIDES 1 216 1 157 1 176 1 297 1 354 52 173 835 252 94 530 P03AC Pyrethrines, incl. synthetic compounds 1 126 1 085 1 093 1 222 1 278 51 160 798 233 87 507 P03AC04 permethrin 1)1 126 1 085 1 093 1 222 1 278 51 160 798 233 87 507 P03AX Other ectoparasiticides, incl. scabicides 97 77 86 82 84 67 14 41 21 8 23 P03AX01 benzyl benzoate 1)36 18 24 <5 <5 6 P03AX03 malathion1)61 59 62 54 63 73 10 30 17 6 17R RESPIRATORY SYSTEM 1 151 928 1 183 767 1 183 735 1 223 490 1 234 841 56 169 146 451 770 445 061 168 864 1 448 923 R01 NASAL PREPARATIONS 333 006 348 415 353 908 364 669 375 789 57 32 354 176 737 135 634 31 064 113 282 R01A DECONGESTANTS AND OTHER NASAL PREPARA - TIONS FOR TOPICAL USE 278 007 294 861 297 143 307 141 315 476 55 30 954 143 622 112 782 28 118 107 107 R01AA Sympathomimetics, plain 4 204 3 803 4 017 3 672 3 521 53 1 003 1 334 837 347 258 R01AA05 oxymetazoline 1)1 734 1 550 1 802 1 781 1 740 54 691 621 331 97 113 R01AA07 xylometazoline1)2 483 2 264 2 233 1 899 1 790 51 315 714 510 251 146 R01AB Sympathomimetics, combinations excl. corticosteroids 1 124 514 602 603 54 11 187 165 103 86 R01AB06 xylometazoline 1)1 124 514 602 603 466 54 165 103 86 R01AC Antiallergic agents, excl. corticosteroids 44 711 44 853 39 407 40 956 39 373 55 10 402 18 752 8 678 1 541 10 628 R01AC01 acid 1)10 718 10 197 8 772 8 705 7 926 59 1 735 3 731 2 084 376 2 111 R01AC02 levocabastine1)34 025 34 686 30 659 32 377 31 513 54 8 733 15 028 6 586 1 166 8 472 R01AC03 azelastine1)261 227 198 127 151 55 20 81 41 9 46 R01AD Corticosteroids 234 552 252 559 259 097 267 954 278 023 55 20 701 126 404 104 650 26 268 95 659 R01AD01 beclometasone 2 228 1 943 11 <5 0 - 0 0 0 0 0 R01AD04 flunisolide 4 133 2 634 11 9 10 60 0 0 7 <5 16 R01AD05 budesonide 43 762 39 753 34 996 32 644 31 182 56 1 849 12 163 13 647 3 523 11 314 R01AD08 fluticasone 32 446 27 939 24 352 22 518 21 902 55 975 8 073 10 046 2 808 9 214 R01AD09 mometasone 142 288 143 465 141 114 144 414 150 797 55 9 967 68 048 57 740 15 042 52 700 R01AD11 triamcinolone 13 593 11 025 9 687 8 713 7 886 57 394 3 253 3 371 868 3 174 R01AD12 fluticasone furoate 3 945 38 322 60 417 70 241 77 223 55 8 111 39 800 24 291 5 021 19 241 R01AX Other nasal preparations 459 572 630 728 816 53 56 210 253 297 475 R01AX03 ipratropium bromide 264 302 355 422 467 50 <5 50 164 252 366 R01AX06 mupirocin 195 270 276 306 349 58 55 160 89 45 108 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 75 926 75 490 81 771 83 161 88 517 67 1 816 48 518 33 865 4 318 6 175 R01BA Sympathomimetics 75 926 75 490 81 771 83 161 88 517 67 1 816 48 518 33 865 4 318 6 175 R01BA01 phenylpropanolamine 75 926 75 490 81 771 83 161 88 517 67 1 816 48 518 33 865 4 318 6 175 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 397 839 419 368 423 205 418 109 418 777 54 87 973 108 738 148 215 73 851 1 094 637 R03A ADRENERGICS, INHALANTS 309 382 328 514 335 492 347 921 353 699 54 59 251 98 941 131 898 63 609 703 188 R03AA Alpha- and beta-adrenore - ceptor agonists 185 181 209 246 230 35 200 17 7 6 220 R03AA01 epinephrine 185 181 209 246 230 35 200 17 7 6 220 R03AC Selective beta-2-adrenore - ceptor agonists 230 012 244 327 249 080 258 858 263 993 54 56 212 75 627 90 209 41 945 142 844 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group P ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.16 ATC group R - Respiratory system ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 198 277 208 540 215 094 54 54 499 61 549 68 518 30 528 76 681 R03AC03 terbutaline 39 227 38 318 35 556 34 151 32 110 57 1 656 12 091 13 280 5 083 12 333 R03AC04 fenoterol 23 17 17 16 12 42 0 0 11 <5 65 R03AC12 salmeterol 10 847 10 555 10 563 9 699 9 189 55 215 1 017 4 377 3 580 15 951 R03AC13 formoterol 17 310 16 879 16 627 15 456 14 418 55 296 3 039 7 048 4 035 21 468 R03AC18 indacaterol 0 0 713 4 814 7 446 46 0 173 3 959 3 314 16 346 R03AK Adrenergics and other drugs for obstructive airway diseases 155 451 164 536 168 450 175 117 178 056 55 10 285 48 000 79 357 40 414 560 123 R03AK04 salbutamol and other drugs for obstructive airway diseases <5 <5 <5 0 0 - 0 0 0 0 0 R03AK06 salmeterol and other drugs for obstructive airway diseases 86 941 90 149 90 997 94 190 95 766 55 8 381 23 175 40 755 23 455 323 552 R03AK07 formoterol and other drugs for obstructive airway diseases 71 382 77 502 80 699 84 168 85 605 56 2 006 25 673 40 171 17 755 236 572 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS 134 223 140 443 146 450 149 797 152 252 51 42 757 21 502 50 901 37 092 258 064 R03BA Glucocorticoids 85 762 88 434 91 633 92 760 93 478 51 42 485 18 589 22 612 9 792 81 339 R03BA01 beclometasone 4 825 4 729 4 380 4 075 4 014 55 807 977 1 533 697 3 388 R03BA02 budesonide 26 377 25 860 25 066 23 194 21 246 57 2 604 5 627 8 566 4 449 27 457 R03BA05 fluticasone 56 192 59 302 62 013 64 095 63 451 47 39 590 10 157 9 874 3 830 43 009 R03BA07 mometasone <5 <5 <5 0 544 54 50 229 211 54 486 R03BA08 ciclesonide 0 0 1 874 3 476 6 094 58 412 1 951 2 830 901 6 999 R03BB Anticholinergics 53 722 57 032 60 133 62 625 64 392 52 686 3 504 30 783 29 419 176 473 R03BB01 ipratropium bromide 41 832 39 555 38 289 35 884 32 150 56 685 2 945 14 335 14 185 30 527 R03BB04 tiotropium bromide 16 714 22 767 27 429 32 809 39 680 49 <5 685 19 889 19 104 145 947 R03BC Antiallergic agents, excl. corticosteroids 539 521 454 252 R03BC01 cromoglicic acid 539 521 454 430 383 66 27 139 179 38 252 R03C ADRENERGICS FOR SYSTEMIC USE 67 040 68 733 63 272 40 582 33 046 49 24 952 3 297 3 489 1 308 4 470 R03CA Alpha- and beta-adrenore - ceptor agonists 53 610 55 608 49 364 23 993 17 151 50 12 150 2 161 2 160 680 2 662 R03CA02 ephedrine 53 610 55 608 49 364 23 993 17 151 50 12 150 2 161 2 160 680 2 662 R03CC Selective beta-2-adrenore - ceptor agonists 16 509 16 104 16 917 17 886 16 770 48 13 642 1 147 1 352 629 1 808 R03CC02 salbutamol 5 091 4 877 4 731 4 844 4 265 46 3 549 280 309 127 306 R03CC03 terbutaline 11 420 11 149 12 109 12 968 12 440 49 10 233 842 936 429 1 258 R03CC12 bambuterol 227 238 245 210 219 58 0 30 114 75 245R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 39 324 40 012 41 123 42 178 42 233 56 8 826 10 623 16 153 6 631 128 915 R03DA Xanthines 5 938 5 287 4 785 4 300 3 855 59 5 228 1 900 1 722 2 782 R03DA02 choline theophyllinate 12 8 10 6 8 100 0 <5 7 0 33 R03DA04 theophylline 5 916 5 272 4 768 4 288 3 843 59 5 224 1 892 1 722 2 692 R03DA05 aminophylline 29 26 19 19 14 57 0 <5 10 <5 57 R03DC Leukotriene receptor antagonists 34 436 35 710 37 220 38 267 38 493 56 8 817 10 452 14 415 4 809 102 858 R03DC01 zafirlukast 28 25 22 22 21 62 0 <5 12 7 194 R03DC03 montelukast 34 409 35 686 37 199 38 245 38 473 56 8 817 10 450 14 404 4 802 102 664 R03DX Other systemic drugs for obstructive airway diseases 44 53 145 751 1 058 49 10 105 534 409 23 275 R03DX05 omalizumab 44 53 84 133 175 55 10 97 66 <5 20 507 R03DX07 roflumilast 0 0 61 620 885 47 0 9 469 407 2 767 R05 COUGH AND COLD PREPARATIONS 373 471 385 148 382 371 422 433 412 291 59 31 876 136 634 167 947 75 834 71 178 R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS 126 488 133 512 135 840 147 156 135 543 58 6 848 30 721 57 135 40 839 32 532 R05CA Expectorants 3 135 3 334 3 671 4 351 3 817 55 1 608 873 849 487 274 R05CA10 combinations 1)3 135 3 334 3 671 4 351 3 817 55 1 608 873 849 487 274 R05CB Mucolytics 123 898 130 752 132 821 143 557 132 373 58 5 318 29 990 56 522 40 543 32 258 R05CB01 acetylcysteine1)119 891 126 968 128 953 139 329 128 617 58 3 931 29 241 55 597 39 848 25 155 R05CB02 bromhexine1)4 836 4 561 4 658 4 974 4 452 54 1 388 855 1 188 1 021 676 R05CB12 tiopronin <5 5 5 8 R05CB13 dornase alfa ( desoxyribonuclease) 110 109 118 128 130 51 42 80 8 0 6 418 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 255 435 258 842 254 586 283 928 280 472 60 23 070 102 962 115 180 39 260 33 894 R05DA Opium alkaloids and derivatives 255 434 258 842 254 586 283 928 280 472 60 23 070 102 962 115 180 39 260 33 894 R05DA01 ethylmorphine 246 451 249 476 245 677 274 413 271 143 60 22 669 99 845 110 994 37 635 31 129 R05DA03 hydrocodone 570 581 592 592 543 62 <5 94 297 151 184 R05DA04 codeine 7 660 7 715 7 203 7 752 7 699 64 110 2 816 3 571 1 202 1 671 R05DA07 noscapine 1)1 561 1 763 1 880 1 952 530 269 149 R05DA09 dextromethorphan 0 R05DA20 combinations 2 881 3 036 2 836 2 918 2 978 62 31 867 1 491 589 761 R05DB Other cough suppressants <5 0 0 0 0 - 0 0 0 0 0 R05DB05 pentoxyverine <5 0 0 0 0 - 0 0 0 0 0 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group R ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group R ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 37 584 41 525 41 844 48 192 49 132 61 3 395 18 489 20 097 7 151 4 752 R05FA Opium derivatives and expectorants 37 584 41 525 41 844 48 192 49 132 61 3 395 18 489 20 097 7 151 4 752 R05FA02 opium derivatives and expectorants 37 584 41 525 41 844 48 192 49 132 61 3 395 18 489 20 097 7 151 4 752 R06 ANTIHISTAMINES FOR SYSTEMIC USE 514 755 519 116 511 537 529 217 543 430 58 72 424 224 888 191 959 54 159 167 923 R06A ANTIHISTAMINES FOR SYSTEMIC USE 514 755 519 116 511 537 529 217 543 430 58 72 424 224 888 191 959 54 159 167 923 R06AA Aminoalkyl ethers 18 18 15 14 23 52 8 6 31 R06AA02 diphenhydramine R06AA04 clemastine 14 14 14 14 17 59 <5 6 5 5 28 R06AB Substituted alkylamines 40 313 35 818 25 263 22 719 20 206 67 4 566 7 452 5 534 2 654 5 868 R06AB02 dexchlorpheniramine 40 313 35 818 25 263 22 719 20 206 67 4 566 7 452 5 534 2 654 5 868 R06AD Phenothiazine derivatives 62 532 62 798 64 453 65 875 65 863 62 3 973 23 263 28 737 9 890 35 046 R06AD01 alimemazine 55 908 56 465 57 913 59 728 59 976 62 3 910 21 003 26 163 8 900 32 267 R06AD02 promethazine 7 311 6 991 7 154 6 719 6 447 67 69 2 480 2 849 1 049 2 768 R06AD03 thiethylperazine 8 <5 0 <5 11 R06AE Piperazine derivatives 272 062 294 720 285 404 293 955 285 294 58 40 389 113 759 101 056 30 090 57 878 R06AE03 cyclizine 1)276 655 737 759 726 69 13 221 316 176 278 R06AE05 meclozine1)2 094 1 956 2 031 2 165 2 227 88 77 1 640 317 193 202 R06AE07 cetirizine1)269 004 291 604 282 294 290 730 282 094 58 40 298 111 811 100 286 29 699 56 880 R06AE09 levocetirizine 1 040 844 703 661 609 62 16 265 263 65 518 R06AX Other antihistamines for systemic use 180 177 164 938 169 564 178 145 206 015 58 27 655 94 797 68 802 14 761 69 100 R06AX02 cyproheptadine 61 59 40 17 23 61 7 8 5 <5 15 R06AX13 loratadine 1)74 765 92 307 83 864 82 823 71 330 60 4 422 33 534 26 676 6 698 17 651 R06AX17 ketotifen 5 <5 7 0 5 <5 <5 14 R06AX22 ebastine1)23 548 11 035 10 315 10 432 9 815 65 166 4 430 4 339 880 8 747 R06AX26 fexofenadine 11 575 24 496 27 017 30 412 29 310 62 794 15 322 10 824 2 370 9 606 R06AX27 desloratadine 81 363 48 971 55 048 60 505 103 310 56 22 750 45 559 29 682 5 319 33 067 R07 OTHER RESPIRATORY SYSTEM PRODUCTS 0 0 0 0 <5 50 0 <5 0 0 1 903 R07A OTHER RESPIRATORY SYSTEM PRODUCTS 0 0 0 0 <5 50 0 <5 0 0 1 903 R07AX Other respiratory system products 0 0 0 0 <5 50 0 <5 0 0 1 903 R07AX02 ivacaftor 0 0 0 0 <5 50 0 <5 0 0 1 903S SENSORY ORGANS 596 101 596 290 609 467 617 742 614 238 57 112 776 177 918 192 459 131 085 302 360 S01 OPHTHALMOLOGICALS 525 644 526 629 538 818 549 815 543 836 57 99 861 156 004 166 156 121 815 287 430 S01A ANTIINFECTIVES 262 875 250 367 269 034 266 933 258 814 56 71 421 75 690 74 191 37 512 47 176 S01AA Antibiotics 260 246 247 638 266 185 264 028 255 819 56 71 253 74 615 73 060 36 891 45 738 S01AA01 chloramphenicol 192 708 182 292 197 212 200 731 195 118 55 46 730 59 178 59 547 1 763 1 702 1 597 1 242 59 105 419 450 268 145 S01AA12 tobramycin 2 455 2 332 2 302 2 322 2 014 60 277 576 707 454 189 S01AA13 fusidic acid 79 306 75 838 82 810 75 325 70 028 57 29 458 17 227 15 236 8 107 6 332 S01AA26 azithromycin 0 0 0 0 2 738 61 835 830 751 322 272 S01AA30 combinations of different antibiotics 4 917 4 936 5 105 5 269 4 330 59 220 980 1 662 1 468 592 S01AD Antivirals 3 080 3 249 3 266 3 171 3 395 56 122 1 020 1 392 861 836 S01AD01 idoxuridine 0 <5 0 0 0 - 0 0 0 0 0 S01AD02 trifluridine <5 0 0 0 0 - 0 0 0 0 0 S01AD03 aciclovir 3 079 3 248 3 266 3 171 3 395 56 122 1 020 1 392 861 836 S01AE Fluoroquinolones 1 923 1 982 2 138 2 327 2 459 54 174 964 869 452 583 S01AE03 ciprofloxacin 1 923 1 982 2 138 2 327 2 459 54 174 964 869 452 583 S01AX 0 0 0 <5 0 2 S01B ANTIINFLAMMATORY AGENTS 42 882 44 119 45 945 46 769 49 765 58 1 675 9 028 18 520 20 542 15 378 S01BA Corticosteroids, plain 30 231 30 111 30 638 31 478 33 466 57 1 618 8 044 13 497 10 307 10 610 S01BA01 dexamethasone 17 332 18 319 18 993 20 148 20 457 55 500 4 547 8 782 6 628 7 184 S01BA04 prednisolone 15 017 12 418 11 840 10 925 13 558 59 1 068 4 069 5 363 3 058 2 192 S01BA07 fluorometholone 15 17 16 12 12 58 0 <5 8 <5 10 S01BA09 clobetasone 22 18 16 56 <5 <5 9 <5 59 S01BA13 rimexolone 2 151 4 177 4 351 4 414 4 284 57 189 1 127 1 586 1 382 1 164 S01BB Corticosteroids and mydriatics Antiinflammatory agents, non-steroids 14 254 15 618 17 141 17 568 18 705 58 69 1 311 5 915 11 410 4 767 S01BC03 diclofenac 14 254 15 618 15 814 11 689 7 404 57 54 1 048 2 425 3 877 1 476 S01BC10 nepafenac 0 0 1 528 6 095 10 279 58 11 244 3 155 6 869 2 985 S01BC11 bromfenac 0 0 0 0 1 366 60 5 40 458 863 306 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group R ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.17 ATC group S - Sensory organs ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 COMBINATION 57 374 56 226 56 906 57 674 57 726 58 1 125 8 988 20 689 26 924 10 824 S01CA Corticosteroids and anti-infectives in combination 57 374 56 226 56 906 57 674 57 726 58 1 125 8 988 20 689 26 924 10 824 S01CA01 dexamethasone and antiin-fectives 57 374 56 226 56 906 57 674 57 726 58 1 125 8 988 20 689 26 924 10 824 S01E ANTIGLAUCOMA PREPARA - TIONS AND MIOTICS 68 239 68 940 70 039 70 786 71 349 57 187 2 112 21 488 47 562 136 473 S01EA Sympathomimetics in glaucoma therapy1) 3 953 3 992 4 077 4 222 4 439 53 7 170 1 169 3 093 3 991 S01EA01 epinephrine dipivefrine 217 122 9 <5 0 - 0 0 0 0 0 S01EA03 apraclonidine 91 97 115 122 145 52 <5 17 56 71 83 S01EA05 brimonidine 3 706 3 838 3 983 4 122 4 344 53 6 159 1 131 3 048 3 905 S01EB Parasympathomimetics 1 498 1 433 1 291 1 254 1 177 60 <5 61 314 800 1 044 S01EB01 pilocarpine 1 496 1 431 1 289 1 253 1 176 60 <5 61 040 S01EB02 S01EC Carbonic anhydrase inhibitors 9 488 9 634 10 040 10 322 10 634 57 103 729 2 770 7 032 12 449 S01EC01 acetazolamide 1 597 1 531 1 699 1 828 1 920 53 50 572 669 629 1 056 S01EC03 dorzolamide 2 783 2 660 2 503 2 393 2 340 58 12 43 542 1 743 2 882 S01EC04 brinzolamide 5 415 5 811 6 195 6 452 6 753 57 46 126 1 660 4 921 8 511 S01EC05 methazolamide <5 0 0 0 0 - 0 0 0 0 0 S01ED Beta blocking agents 1)47 883 48 377 48 841 49 028 49 427 56 127 1 178 14 898 33 224 72 490 S01ED01 timolol 23 313 22 977 22 326 21 731 21 575 57 99 536 7 287 13 653 22 510 S01ED02 betaxolol 2 233 2 012 1 778 1 587 1 433 65 <5 14 335 1 081 964 S01ED51 timolol, combinations 24 676 25 922 27 060 27 984 28 598 55 32 702 8 025 19 839 49 016 S01EE Prostaglandin analogues1)35 402 36 048 36 697 37 171 37 030 58 14 652 10 412 25 952 46 500 S01EE01 latanoprost 29 658 28 946 27 890 26 156 24 215 58 5 352 6 328 17 530 20 507 S01EE03 bimatoprost 1 814 1 807 1 867 1 871 2 055 58 <5 61 612 1 381 3 220 S01EE04 travoprost 4 469 4 844 5 035 6 464 7 190 55 <5 123 2 127 4 938 10 849 S01EE05 tafluprost 0 1 654 3 068 4 029 4 997 63 7 137 1 805 3 048 11 924 S01F MYDRIATICS AND CYCLOPLEGICS 4 744 4 899 5 066 5 041 5 301 46 477 1 270 2 354 1 200 995 S01FA Anticholinergics 4 737 4 891 5 062 5 038 5 295 46 477 1 267 2 352 1 199 989 S01FA01 atropine 2 750 2 670 2 549 2 323 2 318 47 416 477 935 490 476 S01FA04 cyclopentolate 2 034 2 277 2 546 2 746 3 057 45 57 823 1 453 724 485 S01FA06 tropicamide 164 157 189 164 140 56 10 51 63 16 29S01FB Sympathomimetics excl. antiglaucoma preparations 48 39 29 35 33 39 0 15 15 <5 5 S01FB01 phenylephrine 48 39 29 35 33 39 0 15 15 <5 5 S01G DECONGESTANTS AND ANTIALLERGICS 164 724 172 049 158 625 167 530 163 297 58 29 102 73 198 48 775 12 222 47 041 S01GA Sympathomimetics used as decongestants 23 730 23 098 20 728 21 288 20 269 60 2 415 9 165 6 902 1 787 6 023 S01GA51 naphazoline, combinations 11 11 <5 1 S01GA52 tetryzoline, combinations 23 719 23 089 20 725 21 283 20 266 60 2 414 9 165 6 901 1 786 6 022 S01GX Other antiallergics 144 671 152 775 141 091 149 662 146 376 58 27 320 65 543 42 870 10 643 41 018 S01GX01 cromoglicic acid 1)24 839 25 305 22 551 23 401 22 526 61 3 348 9 764 7 549 1 865 5 698 S01GX02 levocabastine1)73 171 77 301 70 567 75 499 73 730 57 14 686 33 142 20 955 4 947 18 750 S01GX04 nedocromil 1 982 2 018 1 777 1 702 1 442 58 171 731 449 91 291 S01GX05 lodoxamide1)339 35 0 0 0 - 0 0 0 0 0 S01GX06 emedastine 546 490 379 384 374 63 67 129 135 43 128 S01GX07 azelastine 755 691 580 553 528 56 74 231 162 61 151 S01GX08 ketotifen1)16 912 17 926 16 305 17 279 16 678 59 2 970 7 422 4 961 1 325 6 367 S01GX09 olopatadine 30 752 34 046 32 856 35 349 35 400 57 7 051 15 768 9 927 2 654 9 633 S01X OTHER OPHTHALMOLOGICALS 6 859 18 266 26 371 34 504 40 527 76 305 3 967 17 429 18 826 29 519 S01XA Other ophthalmologicals 6 859 18 266 26 371 34 504 40 527 76 305 3 967 17 429 18 826 29 519 S01XA03 sodium chloride, hypertonic 16 20 15 17 10 30 0 <5 <5 6 32 S01XA18 ciclosporin 27 41 70 112 252 61 10 72 131 39 2 635 S01XA20 artificial tears and other indifferent preparations 1)6 823 18 234 26 329 34 451 40 435 76 296 3 942 17 386 18 811 26 853 S02 OTOLOGICALS 13 048 14 496 14 933 20 226 18 667 54 3 446 4 974 7 220 3 027 3 578 S02A ANTIINFECTIVES 7 097 7 037 7 346 10 565 9 559 48 3 241 2 722 2 623 973 1 711 S02AA Antiinfectives 7 097 7 037 7 346 10 565 9 559 48 3 241 2 722 2 623 973 1 711 S02AA01 chloramphenicol 202 123 75 75 17 41 <5 5 <5 <5 19 S02AA15 ciprofloxacin 6 923 6 937 7 290 10 501 9 545 48 3 238 2 718 2 620 969 1 691 S02B CORTICOSTEROIDS 6 139 7 724 7 847 10 185 9 535 60 233 2 424 4 787 2 091 1 851 S02BA Corticosteroids 6 139 7 724 7 847 10 185 9 535 60 233 2 424 4 787 2 091 1 851 S02BA07 betamethasone 6 139 7 724 7 847 10 185 9 535 60 233 2 424 4 787 2 091 1 851 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 58 70 66 104 91 49 <5 20 42 26 16 S02CA Corticosteroids and anti-infectives in combination 58 70 66 104 91 49 <5 20 42 26 16 S02CA02 flumetasone and antiinfectives 58 70 66 104 91 49 <5 20 42 26 16 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group S ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 ATC group S ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales 318 75 322 77 041 68 909 73 148 54 13 607 21 755 26 744 11 042 11 352 S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBI-NATION 78 318 75 322 77 041 68 909 73 148 54 13 607 21 755 26 744 11 042 11 352 S03CA Corticosteroids and antiin-fectives in combination 78 318 75 322 77 041 68 909 73 148 54 13 607 21 755 26 744 11 042 11 352 S03CA01 dexamethasone and antiin-fectives 18 919 15 356 14 416 24 937 11 210 55 1 109 3 071 4 868 2 162 1 390 S03CA04 hydrocortisone and antiin-fectives 62 532 62 503 65 038 47 812 64 324 54 12 714 19 350 22 909 9 351 9 962V VARIOUS 11 571 13 317 15 898 18 600 21 769 50 3 026 7 406 7 228 4 109 77 662 V01 ALLERGENS 4 962 6 170 7 289 8 273 8 880 46 1 691 5 582 1 573 34 41 735 V01A ALLERGENS 4 962 6 170 7 289 8 273 8 880 46 1 691 5 582 1 573 34 41 735 V01AA Allergen extracts 4 962 6 170 7 289 8 273 8 880 46 1 691 5 582 1 573 34 41 735 V01AA02 grass pollen 3 056 4 021 5 033 5 758 6 295 44 1 065 4 278 939 13 23 719 V01AA03 house dust mites 284 301 349 426 487 47 121 292 72 <5 2 785 V01AA05 tree pollen 3 104 3 705 4 150 4 670 4 839 49 933 2 970 917 19 11 218 V01AA07 insects 206 185 183 181 156 53 20 50 78 8 660 V01AA10 flowers 54 90 108 141 149 63 10 91 48 0 715 V01AA11 animals 201 217 288 382 421 52 103 227 91 0 2 638ATC group S ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 2.18 ATC group V - Various ATC level2008 2009 2010 2011 2012 2012 2012 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 juli)/ Population in Norway 2008-2012 (as of 1st July) Y ear 2008 2009 2010 2011 2012 Population 4 768 077 4 829 800 4 888 946 4 953 217 5 018 415 Folkemengde etter alder i 2012 (per 1. juli)/ Population by age in 2012 (as of 1st July) Age groups <15 15-44 45-69 70 Population 893 338 Kjemisk (klassifikasjonssystem for Chemical (classification medicines) DDD Definert d\u00f8gndose Defined Daily Doses samarbeid FHI Folkehelseinstituttet GP General Practitioner ICD -10 International Classification of Diseases version 10 ICPC International Classification of Primary Care MA Markedsf\u00f8ringstillatelse Marketing Authorisation NIPH Norwegian Institute of Public Health NMD Norsk Medisinaldepot Norwegian Medicinal Depot (wholesaler) NOK Norske kroner NorPD Reseptregisteret Anti-Inflammatory Drug OTC Reseptfritt Over The Counter, non prescription drugs SPC Summary of Product Characteristics SSB Statistisk sentralbyr\u00e5 Statistics definerte befolkningsutvalget. Definitions PrevalenceUsers (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 inhabitants (%) in the defined population sample. Incidence (new users) Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population sample. Reseptregisteret per mars 2013 / List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2013 2013: Bakken LB, Ranhoff AH, Hunskaar S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013; [Epub KJ, Midthjell K, et al. Does diabetes have a protective effect on migraine? Epidemiology S, et al. Antidepressants to cancer patients during the last year of life - a population-based study. Psychooncology 2013;22:506-14. Engeland S, Vollset SE, et al. Effects of preconceptional paternal drug expo - sure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population-based databases. British Journal of Gjelstad S, Dalen children the burden of broad-spectrum antibi- otics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections Norway. Grytli HH, Fagerland of b-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or P . Systematic screening with information and home sampling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial. BMC Infectious Diseases 2013;13:Article number 30. Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? Social Science and Medicine 2013;81:42-52. Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record-linkage study. Eur J Clin Pharmacol Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. Addiction 2013;108:367-76. Nordeng H, Lupattelli A, Rom\u00f8ren M, Koren G. after gestational to Obstet rics Gynecology psychological - tors of and z-hypnotic use severe pain]. Tidsskrift for den OM, Svendsen K, Skurtveit S, Borchgrevink PC. Laxative prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. Supportive Care in Cancer 2013;21:67-73. Stene LE, Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population-based cohort study. Journal of Women's Health 2013;22:250-8. Stephansson O, Kieler H, Haglund B, Artama Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309:48-54. Welle-Strand Bjark\u00f8 L, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: A National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug and Alcohol Dependence 2013;127:200-6. 2012: Berge LI, Riise T, Fasmer OB, Lund A, Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti-diabetic agents. Diabet Med. May]. Tidsskr Nor Laegeforen. 2012 ;132:1084-8. legemidler 1975-2010. [Patterns in Norway, 1975 - 2010] Tidsskr Nor Laegeforen In Norwegian. Bramness JG, Furu Skurtveit S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Clin Pharmacol Therap 2012;91:438-41. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. Addiction. 2012;107:967-72. Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, S\u00f8g\u00e5rd AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21:297-304. Devold HM, S\u00f8gaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporosis International 2012;24:1225-33. Fasmer OB, switching to methadone: A pharmacoepidemiological study from a national prescription database. Palliative Medicine 2012;26:804-12. Fredheim OM, Moksnes K, Opoid switching to methadone: a pharmacoepidemiological study from a national prescription database. Palliat Med 2012;26;804-812. Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. Pharma- coepidemiology and Drug Safety 2012;21:881-5. Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self-poisoning: a longitudinal study. J Clin Psychiatry. 2012;73:e548-54. Bratlid T, Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: A nation- wide prescription database study. Scandinavian Journal of Public Health 2012;40:704-11. Hjellvik V, Mahic M, Tverdal A. Utdanning S, Comorbidities in an asthma population 8-29 years old: A study from the Norwegian Prescription Database. Pharmacoepidemiology and Drug Safety 2012;21:1045-52. Kieler H, Artama M, Engeland A, Ericsson O, Furu Gissler M, N\u00f8rgaard M, Nielsen RB, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B. Selective serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hyper - tension of the newborn: population based cohort study from the five Nordic countries BMJ. 2012 Jan 12;344:d8012. doi: 10.1136/bmj.d8012. Kjome RL, Roraas T, AG, Sandberg differences in sales of glucometer strips and antidiabetics. Tidsskr Nor Laegeforen 2012;132:1453-7. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012;68: 311-9. Kvaale MK, Grave M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004-2008. Journal of Holmen J. The HUNT study: Participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Medical Research Methodology 2012;12:Article number 143. Lillemoen Hunsk\u00e5r S, 2004 - 08. Tidsskr Nor Laegeforen 2012;132:1856-60.Mellbye A, Svendsen K, Borchgrevink PC, Skurtveit S, Fredheim OMS. Concomitant medication among persistent pain. Acta Anaesthesiologica Scandinavica 2012;56:1267-76. Neutel CI, Skurtveit is the point of guidelines? Benzodiazepine and z-hypnotic use by an S. Generic substitution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49-59. Engeland A, Bj\u00f8rge S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157-63. Espnes MG, Bj\u00f8rge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011;20:243-8. Fasmer OB, Riise in opioid main- therapy: High validity of mother-reported use of antiasth-matics among children: a comparison with a prescription 2011;64:878-84. Nor Laegeforen 2011;131:461-3. In Godman B, Sakshaug Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121-9. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi prescribing in findings and future implications. Frontiers Pharmacology 2011. Gjelstad S, Straand J, Dalen I, Fetveit A, Str\u00f8m H, Lindb\u00e6k M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? J Antimicrob Chemother 2011;66:2425-33. Hancock P , Nystad W, London SJ. Oral contraceptive pill use before preg- nancy and respiratory outcomes in early childhood. Pediatr Allergy Immunol 2011;22:528-36. Handal M, Engeland A, of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Pharmacol 2011;67:953-60. Harman C, Reid M, Thomas KV.In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. Environ Sci Technol. 2011;45:5676-82. Hartz I, Bramness JG, Skurtveit S. Prescription of antidepressants to patients on opioid maintenance therapy - a Tverdal A, Str\u00f8m H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. Epidemiology 2011;22:418-21. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway - explained by hormone therapy or mammographic screening? International Journal of Cancer S, Nafstad P , Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. Pharmacoepidemiol Drug Saf 2011;20:370-7. Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Acta Scand Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95:51-9. Landmark CJ, Larsson 2011;131:800-1. In Norwegian.Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199-206. Neutel CI, Skurtveit S, Berg C. Benzodiazepine and transdermal buprenorphine - long-term use drugs. Acta Anaesthesiol Scand. 2012;56:88-94. Nordfj\u00e6rn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiaz- epine and z-hypnotic users. Addictive Behaviors 2012;37:1151-7. Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? European Journal of Clinical Pharmacology 2012;68:1085-94. Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Borchgrevink PC, Fredheim OMS. Reimbursement Nor Laegeforen 2012;132:2489-93. Romoren M, Lindbaek M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population- based register study from Norway. British Journal of Clinical Pharmacology 2012;74:1053-62. R\u00f8nning PA, Helseth E, Meling TR, population-based study on the effect of temozolomide in the treat - ment of glioblastoma multiforme. Neuro-Oncology 2012;14:1178-84.Selmer R, Blix HS, Landmark K, Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use--a 4-year follow-up Nordstr\u00f6m Hartz I. Mental distress and subsequent use of psychotropic drugs among adolescents - a prospective register linkage study. J Adolescent Health 2012;50:578-87. Steffenak AKM, Wilde-Larsson G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. Clinical Epidemiology 2012;4:225-31. Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012 Apr 5;2(2):e000614. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: A nationwide population-based study with focus on gender differences. BMC Medicine 2012;10:Article 148. Differential patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain 2012;16:359-69. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012;41:196-201. Von Soest T, Bramness JG, Pedersen W, Wichstr\u00f8m The relationship between socio-economic status and antidepres- sant prescription: A longitudinal survey and register study of young adults. Epidemiology and Psychiatric Sciences 2012;21:87-95. \u00c5svold BO, Vatten LJ, Midthjell K, Bj\u00f8ro T. Serum TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the 2012;97:93-9. M, Tverdal A. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365 117 men and women. J Antimicrob Chemother 2011;66:2159-67. Bramness JG, Sexton JA. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. BMC of antipsychotic medication: a Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodi- azepines users. Soc Sci Med 2010;70:921-5. Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population-based cohort study of 16 000 individuals. Scand J Public Health 2010;38:465-73. Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235-42. Hunskaar S, E, Lur\u00e5s H. Competition in general practice: prescriptions to the elderly in a list patient system. J Health Econ. 2010;29:751-64 K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. Eur J Clin Pharmacol M, CJ. Psychiatric comorbidity in patients Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort. Diabetes Technol Ther 2010;12:701-5. Korn\u00f8r H, Pedersen W, In Skurtveit K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids- a follow-up study of 17 074 men and women. Pain Med 2010;11:805-14. Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. Ann Epidemiol drugs: use and co-treatment with potentially interacting medications Eur S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or i Sogn og Fjordane [Use of lithium in the Norwegian counties Oslo and Sogn og Fjordane]. Tidsskr Nor Engeland Furu K. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 - a prescription database study. J Affect Disord 2009; Bramness JG, Skurtveit S, Neutel I, M\u00f8rland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? Pharmacoepidemiol Drug Saf 2009;18:492-6. Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord 2009;118:224-8. Devold H, Molden of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Brit J Clin Pharmacol 2009;67:234-41. Engeland Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Prescription of codeine for non-malignant pain in Norway- a pharmacoepidemiological study Langballe EM, of anti-dementia drugs with psychotropic drugs in Norway--a population-based study. Pharmacoepidemiol Saf. Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults - a population-based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90-8. Log T, Hartz I, Tverdal A, Furu K, Skurtveit S. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. Scand J Pain 2011;2:36-44. Mahic M, Skurtveit S, Selmer R, R\u00f8nning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimimab in Norway 2005-2009. Pharmacoepidemiol Drug Saf. 2011;20:457-63. Neubert A, Hsia Y, de Jong-van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, N\u00f8rgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. Br J Clin Phar - macol. P , Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain ADHD OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the Norwegian J pharmacol. \u00d8. A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. J Affective Disorders 2011;129:198-204. 2010: Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. Pharm World Sci. 2010;32:752-8. Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs - a population based study. Pharmacoepidemiol Drug Saf 2010;19:273-9. Andersen JB, Engeland A, Owe JF, Gilhus NE. requiring pyridostigmine treatment in a national popula- tion cohort. Eur J analgetika [Use of need for other pain-relieving drugs]. Tidsskr Nor Laegeforen 2010;130:1463-6. In Norwegian. Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. Drugs: Education, Prevention, and Bramness Engeland A, Skurtveit S. (Lyrica) help patients reduce their use of benzodi- azepines? A comparison with gabapentin using the Norwegian Clin Devold HE, Falch JA, S\u00f8gaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 - a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:299-306. Fredheim OM, Skurtveit . Increasing use of opoids from 2004 to 2007 - Pharmacoepidemio - logical data from a complete national prescription database in Norway. Eur J Pain 2010;14:289-294. Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen \u00d8, Borchgrevink P . Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. Pediatric Anesthesia 2010;20:537-544. Furu K, Skurtveit Almarsdottir AB, S\u00f8rensen HT. The Nordic Countries as cohort S, Furu K. Prescription druguse among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. register - basert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] A, J, B. an arctic population: the Troms\u00f8 Study. BMC Health Serv Res 2008;8:117. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; Neutel CI, M\u00f8rland J. Road traffic accident risk related to prescrip - tions of the of antipsychotic medication: linking population-based prescription database to the HUNT study. Pharmacoepidemiol Drug Saf 2008;17:372-7. Litleskare I, Blix H, in Tidsskr opioider til norske kreftpasienter cancer in Laegeforen Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later - a follow-up study of 13 390 men and women aged 40-42 years. Pharmacoepidemiol Drug Saf 2008;17:926-933. Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:714-17. Str\u00f8m H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. Nor J Epidemiol 2008;18:191-94. 2007: Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. J Antimicrob Chemother 2007;59:1161-6. Blix f\u00e6rre forskrivninger? [The use of antidepressants amongst children and adolescents - did the warnings lead to fewer prescriptions?] Tidsskr Nor Laegeforen 2007;127:2653-5. In Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. pharmacoepidemiological Br Clin Pharmacol 2007;64: 210-8. H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007;90:203-9. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. The risk of road traffic accidents after prescriptions of carisoprodol. Accid Anal Prev 2007;39:1050-5. Engeland A, Skurtveit S, M\u00f8rland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. Ann Epidemiol A, Nafstad P . Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription Bramness and potential abuse of anticholinergic antiparkinson drugs in Norway: a , between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of Eur of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal orphenadrine. J Clin Pharmacol 2009;68:238-42. Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320-6. Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nation- wide administrative register. Nor J Epidemiol 2009;19:169-172. Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addictive drugs in Norway - use among disability pensioners. Nor J Epidemiol 2009;19:209-218. Hauge Aavitsland P . Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Bramness Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database SR, Ruths S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database Pharmacoepidemiol Drug Saf 2009;18:572-8. Landmark CJ, Larsson P , Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population- based study of prescriptions. Epilepsy Res 2009; 87: 31-9. Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Pharmacol 2009;67:355-62. Skurtveit S, Furu K, Introduction of low dose transdermal buprenorphine - did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Eur J Pain 2009;13:949-53. Skurtveit Skrivarhaug T, M\u00f8rland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy - a population-based cohort study Pharmacoepidemiol Drug Saf 2009;18:737-42. Winther Legemiddelshopping av vanedannende medikamenter addictive Skurtveit S. Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185-90. Berg A, Furu Norwegian. Bramness JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of cariso - prodol (Somadril\u00ae) in Europe. Nor J Epidemiol 2008;18:167-72.Bramness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074-5.Bramness JG , Skurtveit S, Neutel CI, M\u00f8rland J, Engeland A. Minor increase in risk of road traffic accidents after prescrip - tions of T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. Scand J Prim Health Care S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81. Torkildsen O, Grytten N, Myhr av flunitrazepam etter 1999. [Changes in the sale and use of flunitrazepam in Norway, 1999 - 2004]. Tidsskr Nor Laegeforen J, Dalen I, Rognstad S, Lindback M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155]. N, Hausken T, P . A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. BMC Straand S, Brekke M, Dalen I. A cluster-randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. diabetes mellitus? [How and who receiving medication for diabetes mellitus?] Tidsskr Nor Laegeforen 2006;126:768-70. Prescription An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53-56. 2001: Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. Nor J Epide - miol 2001;11:55-60. Utgitt av Nasjonalt folkehelseinstitutt Institute Health Bestilling/Order: E-mail:publikasjon@fhi.noTelephone: +47 21 07 "}